Document:

Exhibit 10.1

EMPLOYMENT
AGREEMENT 

THIS EMPLOYMENT AGREEMENT
(“Agreement”), dated effective as of August 17, 2015, is
among Krispy Kreme Doughnut Corporation, a North Carolina corporation
(“KKDC”), Krispy Kreme Doughnuts, Inc., a North Carolina
corporation (the “Company” and, together
with KKDC, the “Companies”), and Thomas
Kuharcik (the “Executive”). 

The parties hereto agree as
follows: 

ARTICLE 1 

DEFINITIONS 

SECTION 1.01. Definitions. For purposes
of this Agreement, in addition to other terms defined herein, the following
terms have the meanings set forth below: 

“Base Salary” has the meaning set forth in Section 4.01. 

“Board” means the Board of Directors of the Company. 

“Cause” shall mean (a) the Executive’s failure or refusal to perform the
Executive’s lawful and proper duties, to the extent material, hereunder (other
than as a result of total or partial incapacity due to physical or mental
illness or a court or governmental order), (b) the Executive’s conviction of or
plea of nolo
contendere to any felony (other
than a traffic infraction), (c) an act or acts on the Executive’s part
constituting fraud, theft or embezzlement or that otherwise constitutes a felony
under the laws of the United States or any state thereof which results or was
intended to result directly or indirectly in gain or personal enrichment by the
Executive at the expense of the Companies, or (d) the Executive’s
insubordination to the Companies’ most senior executive officer or willful
violation of any material provision of the code of ethics of the Companies
applicable to the Executive or the Executive’s willful breach of a material term
of the Agreement (as determined by the Board or the Committee). In the case of
any item described in the previous sentence, the Executive shall be given
written notice of the alleged act or omission constituting Cause, which notice
shall set forth in reasonable detail the reason or reasons that the Board
believes the Executive is to be terminated for Cause, including any act or
omission that is the basis for the decision to terminate the Executive. In the
case of an act or omission described in clause (a) or (d) of the definition of
Cause, (i) if reasonably capable of being cured, the Executive shall be given
thirty (30) days from the date of such notice to effect a cure of such alleged
act or omission constituting “Cause” which, upon such cure to the reasonable
satisfaction of the Board, shall no longer constitute a basis for Cause, and
(ii) the Executive shall be given an opportunity to make a presentation to the
Board (accompanied by counsel or other representative, if the Executive so
desires) at a meeting of the Board held promptly following such thirty (30)-day
cure period if the Board intends to determine that no cure has occurred. At or
following such meeting, the Board shall determine whether or not to terminate the Executive for “Cause” and shall
notify the Executive in writing of its determination and the effective date of
such termination (which date may be no earlier than the date of the
aforementioned Board meeting). For purposes of this Agreement, no act or failure
to act shall be considered “willful” unless it is done, or omitted to be done,
by Executive in bad faith or without a reasonable belief that Executive’s action
or omission was in the best interests of KKDC or the Company. 

“Change in Control” means any of the following events: 

(a) the
acquisition by any Person of “beneficial ownership” (within the meaning of Rule
13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of the
combined voting power of the Company’s then outstanding voting securities;
provided, however, that a Change in
Control shall not be deemed to occur solely because fifty percent (50%) or more
of the combined voting power of the Company’s then outstanding securities is
acquired by (i) a trustee or other fiduciary holding securities under one or
more employee benefit plans maintained by the Company or any of its
Subsidiaries, or (ii) any Person, which, immediately prior to such acquisition,
is owned directly or indirectly by the shareholders of the Company in the same
proportion as their ownership of stock in the Company immediately prior to such
acquisition; 

(b) the
consummation of (i) a merger or consolidation involving the Company if the
shareholders of the Company, immediately before such merger or consolidation do
not, as a result of such merger or consolidation, own, directly or indirectly,
more than fifty percent (50%) of the combined voting power of the then
outstanding voting securities of the corporation resulting from such merger or
consolidation in substantially the same proportion as their ownership of the
combined voting power of the voting securities of the Company outstanding
immediately before such merger or consolidation, or (ii) a sale or other
disposition of all or substantially all of the assets of the Company other than
to a Person which is owned directly or indirectly by the shareholders of the
Company in the same proportion as their ownership of stock in the Company;

(c) a
change in the composition of the Board such that the individuals who, as of the
Effective Date, constitute the Board (such Board shall be hereinafter referred
to as the “Incumbent
Board”) cease for any reason to
constitute at least a majority of the Board; provided, however, for purposes of this definition, that any
individual who becomes a member of the Board subsequent to the Effective Date
whose election, or nomination for election by the Company’s shareholders, was
approved by a vote of at least a majority of those individuals who are members
of the Board and who were also members of the Incumbent Board (or deemed to be
such pursuant to this proviso) shall be considered as though such individual
were a member of the Incumbent Board; provided further, however, that any such
individual whose initial assumption of office occurs as a result of either an
actual or threatened election contest, or other actual or threatened
solicitation of proxies or consents by or on behalf of a Person other than the
Board, shall not be so considered as a member of the Incumbent Board; or

(d) the
approval by shareholders of the Company of a complete liquidation or dissolution
of the Company;

provided, however, that, if and to
the extent required under Section 409A of the Code or any regulations and
guidelines promulgated thereunder (collectively, “Section 409A”), an event will be treated as a “Change in
Control” for purposes of this Agreement only if it is also a “change in control
event” (as defined in Treas. Reg. Section 1.409A-3(i)(5)) with respect to the
Company. 

2 

“Code” means the Internal Revenue Code of 1986, as amended, and any related
regulations or other guidance. 

“Committee” means the Compensation Committee of the Board of Directors of the
Company. 

“Confidential Information” means information that is not generally known to
the public and that was or is used, developed or obtained by the Company or its
Subsidiaries in connection with the business of the Company and its Subsidiaries
and which constitutes trade secrets or information which they have attempted to
protect, which may include, but is not limited to, trade “know-how”, customer
information, supplier information, cost and pricing information, marketing and
sales techniques, strategies and programs, computer programs and software and
financial information. It shall not include information (a) required to be
disclosed by court or administrative order; (b) lawfully obtainable from other
sources or which is in the public domain through no fault of the Executive; or
(c) the disclosure of which is consented to in writing by the Company.

“Date of Termination” has the meaning set forth in Section 5.07.

“Effective Date” has the meaning set forth in Section 2.01.

“Employment Period” has the meaning set forth in Section 2.01.

“Exchange Act” means the Securities Exchange Act of 1934, as
amended. 

“Good Reason” shall mean the occurrence of any of the following without the
Executive’s consent: (a) a reduction in the Executive’s Base Salary or a
material reduction in the Executive’s annual target bonus opportunity (other
than a reduction in bonus opportunities that applies to the executive officers
of the Company generally; and for the avoidance of doubt, a failure to attain
performance or other objectives, as determined in the discretion of the Board
and/or Committee, shall not, alone, constitute Good Reason), (b) the Executive
is no longer the most senior supply chain operations (i) both the Company and
KKDC or (ii) in the event of a merger, consolidation or other business
combination involving the Company, the successor to the Company’s business or
assets or (iii) if all or substantially all of the voting stock of the Company
is held by another company, such company, (c) the assignment to the Executive of
any duties or responsibilities materially inconsistent with the Executive’s
status under clause (b) of this sentence or his failure at any time to report
directly to the Chief Executive Officer or to the most senior executive officer
of the applicable company described in clause (b), (d) any failure by the
Companies to maintain the Executive’s principal place of employment and the
executive offices of the Companies within 25 miles of the Winston-Salem, North
Carolina area, (e) any material breach by the Companies of this Agreement, or
(f) the term of the Employment Period ending as a result of the Companies giving
the Executive notice of nonextension of the term of this Agreement in accordance
with Section 5.01 solely at either the end of the initial term or the end of the first, second or third one-year extensions
of the term under Section 5.01 (but, for the avoidance of doubt, not at the end
of any further extension of the term); provided, however, that for any of the foregoing to constitute Good Reason, the Executive
must provide written notification of his intention to resign within sixty (60)
days after the Executive knows or has reason to know of the occurrence of any
such event, and the Companies shall have thirty (30) days (ten (10) days in the
case of a material breach related to payment of any amounts due hereunder) from
the date of receipt of such notice to effect a cure of the condition
constituting Good Reason, and, upon cure thereof by the Companies, such event
shall no longer constitute Good Reason. 

3 

“Notice of Termination” has the meaning set forth in Section 5.06.

“Permanent Disability” means the Executive becomes permanently disabled
within the meaning of the long-term disability plan of the Companies applicable
to the Executive, and the Executive commences to receive benefits under such
plan. 

“Person” means an individual, a partnership, a corporation, a limited liability
company, an association, a joint stock company, an estate, a trust, a joint
venture, an unincorporated organization or a governmental entity or any
department, agency or political subdivision thereof. 

“Reimbursable Expenses” has the meaning set forth in Section 4.04.

“Securities Act” means the Securities Act of 1933, as amended.

“Subsidiary” or “Subsidiaries” means, with
respect to any Person, any corporation, partnership, limited liability company,
association or other business entity of which (a) if a corporation, 50 percent
(50%) or more of the total voting power of shares of stock entitled (without
regard to the occurrence of any contingency) to vote in the election of
directors, managers or trustees thereof is at the time owned or controlled,
directly or indirectly, by that Person or one or more of the other Subsidiaries
of that Person or combination thereof; or (b) if a partnership, limited
liability company, association or other business entity, 50 percent (50%) or
more of the partnership or other similar ownership interests thereof are at the
time owned or controlled, directly or indirectly, by any Person or one or more
Subsidiaries of that Person or a combination thereof. For purposes of this
definition, a Person or Persons will be deemed to have a 50 percent (50%) or
more ownership interest in a partnership, limited liability company, association
or other business entity if such Person or Persons are allocated 50 percent
(50%) or more of partnership, limited liability company, association or other
business entity gains or losses or control the managing director or member or
general partner of such partnership, limited liability company, association or
other business entity. 

ARTICLE 2 

EMPLOYMENT 

SECTION 2.01. Employment. The Companies
shall employ the Executive, and the Executive shall accept employment with the
Companies, upon the terms and conditions set forth in this Agreement for the
period beginning on August 17, 2015 (the “Effective Date”) and
ending as provided in Section 5.01 (the
“Employment Period”). It is acknowledged that the Executive may
begin service to the Companies prior to the date of this Agreement, with
continued service contingent upon the preparation of this Agreement in a form
mutually acceptable to both the Executive and the Companies. 

4 

ARTICLE 3 

POSITION AND DUTIES

SECTION 3.01. Position and Duties.
During the Employment Period, the Executive shall serve as Senior Vice President – Supply Chain Operations of the Company reporting directly to the Chief Executive
Officer or most senior executive officer of the Company, and shall be the
Company’s most senior supply chain operations officer. During the Employment
Period, the Executive also shall serve as Senior Vice President – Supply Chain
Operations of KKDC and shall be KKDC’s most senior supply chain operations
officer. The Executive shall have such responsibilities, powers and duties as
may from time to time be prescribed by the Board, the Chief Executive Officer,
or the most senior executive officer of the Companies; provided that such responsibilities, powers and duties are substantially
consistent with those customarily assigned to individuals serving in such
position at comparable companies or as may be reasonably required for the proper
conduct of the business of the Companies. During the Employment Period, the
Executive shall devote substantially all of his working time and efforts, which
shall be conducted on a full-time basis, to the business and affairs of the
Company and its Subsidiaries. The Executive shall not directly or indirectly
render any services of a business, commercial or professional nature to any
other person or organization not related to the business of the Company or its
Subsidiaries, whether for compensation or otherwise, without the prior approval
of the Board; provided, however, the Executive may serve on the board of
directors of one for-profit corporation with the prior approval of the Board,
which will not be unreasonably withheld, and the Executive may serve as a
director of not-for-profit organizations or engage in other charitable, civic or
educational activities, so long as the activities described in this proviso do
not interfere with the Executive’s performance of his duties hereunder or result
in any conflict of interest with the Companies.

ARTICLE 4 

BASE SALARY AND BENEFITS

SECTION 4.01. Base Salary. During the
Employment Period, the Executive will receive base salary from the Companies
equal to $335,000 per annum (the “Base Salary”). The Base Salary will be payable in accordance with the normal payroll
practices of the Companies. Annually during the Employment Period, the Company
shall review with the Executive his job performance and compensation, and if
deemed appropriate by the Board or the Committee, in their discretion, the
Executive’s Base Salary may be increased but not decreased. After any such
increase, the term “Base Salary” as used in this Agreement will thereafter refer
to the increased amount. 

SECTION 4.02. Bonuses. As soon as
practicable following the Effective Date, Executive shall be paid a signing
bonus in the amount of One Hundred Thousand Dollars ($100,000), which shall be subject to applicable withholdings. In
addition to Base Salary and the signing bonus described herein, the Executive
shall be eligible to be considered for an annual bonus, and the Executive’s
annual target bonus shall be equal to 50% of Base Salary. Such annual bonus
shall be prorated for Fiscal Year 2016. The Committee and/or the Board shall set
targets with respect to and otherwise determine the Executive’s bonus in
accordance with the Company’s then current incentive plans.

5 

SECTION 4.03. Benefits. During the
Employment Period, the Executive shall be entitled to participate in all
employee benefit, perquisite and fringe (if any) benefit plans and arrangements
made available by the Companies to their executives and key management employees
upon the terms and subject to the conditions set forth in the applicable plan or
arrangement. Such benefits shall include medical, life and disability insurance
provided in accordance with the policies of the Companies. The Executive shall
be entitled to four (4) weeks of paid vacation annually during the Employment
Period. 

SECTION 4.04. Expenses; Relocation. The
Companies shall reimburse the Executive for all reasonable expenses incurred by
him in the course of performing his duties under this Agreement which are
consistent with the Companies’ policies in effect from time to time with respect
to travel, entertainment and other business expenses (“Reimbursable Expenses”), subject to the Companies’ requirements with
respect to reporting and documentation of expenses and the provisions of Section
13.14. The Executive shall reside in the Winston-Salem, North Carolina community
on a full-time basis commencing on or before the sixth month anniversary of the
Effective Date. The Executive shall be eligible to receive relocation benefits
in accordance with the Companies’ relocation policies for executive officers,
and, without limiting the foregoing, the Companies shall reimburse the Executive
for all reasonable relocation expenses incurred by him in relocating his
immediate family’s household items to the Winston-Salem, North Carolina area,
subject to compliance with the Companies’ relocation reimbursement policies for
executive officers and the Companies’ requirements with respect to reporting and
documentation of such expenses.

SECTION 4.05. Restricted Stock Units. The Company shall grant to the Executive restricted stock units (the
“Restricted Stock
Units”) for such number of shares
of the Company’s common stock as may be determined based on an aggregate award
fair value of $300,000, as calculated on or as close in time as practicable to
the grant date. The grant date for the Restricted Stock Units shall be
determined by the Committee and shall occur on or as soon as practicable after
August 17, 2015. The Restricted Stock Units shall vest, provided that the
Executive’s employment continues through the applicable vesting dates, in four
equal annual installments, beginning on August 17, 2016 and continuing on each
of the following three year anniversaries of such date (except as otherwise
provided herein). The Restricted Stock Units (including the distribution of any
shares of the Company’s common stock issuable pursuant thereto) shall be subject
to the terms of the Krispy Kreme Doughnuts, Inc. 2012 Stock Incentive Plan, as
it may be amended, or its successor plan (the “Stock Plan”), and a Restricted Stock Unit Agreement in a form acceptable to the
Committee, which shall include the terms provided herein. For the avoidance of
doubt, the Restricted Stock Units granted pursuant to this Section 4.05 shall
fully vest upon: the Executive’s death or disability (as set forth in the
Restricted Stock Unit Agreement), the Executive’s termination for Good Reason or
without Cause (as set forth in Section 5.03 of this Agreement), or the
Executive’s termination for Good Reason or without Cause following a Change in Control (as set forth in Section 5.09 of this
Agreement). The Executive agrees and acknowledges that the future grant of
equity awards, if any, and the terms of any such equity awards shall be subject
to the sole discretion of the Compensation Committee of the Board.

6 

SECTION 4.06. Compliance with Compensation and Equity Policies. The Executive agrees to comply with the Company’s
Stock Ownership and Equity Retention Policy and Compensation Recovery Policy,
each as in effect from time to time, with respect to annual or long-term
incentive or other compensation, as applicable, including the compensation
provided pursuant to this Agreement. The terms of the Company’s Stock Ownership
and Equity Retention Policy and Compensation Recovery Policy, each as in effect
from time to time, are hereby incorporated by reference into this Agreement.

ARTICLE 5 

TERM AND TERMINATION

SECTION 5.01. Term. The Employment
Period will terminate on the third anniversary of the Effective Date (unless
sooner terminated as hereinafter provided); provided, however, that the Employment Period will be automatically
extended for successive one-year periods following the original term ending on
the third anniversary of the Effective Date, until either the Companies, on the
one hand, or the Executive, on the other hand, at least one hundred eighty (180)
days prior to the expiration of the original term or any extended term, shall
give written notice to the other of their intention not to so extend the
Employment Period. 

SECTION 5.02. Termination Due to Death or Permanent Disability. If the Employment Period shall be terminated due
to death or Permanent Disability of the Executive, the Executive (or his estate
or legal representative) shall be entitled solely to the following: (a) Base
Salary through the Date of Termination (paid on the Companies’ normal payroll
payment date); and (b) medical benefits as provided in Section 5.05 below. The
Executive’s entitlements under any other benefit plan or program shall be as
determined thereunder. In addition, promptly following any such termination, the
Executive (or his estate or legal representative) shall be reimbursed for all
Reimbursable Expenses incurred by the Executive prior to such termination in
accordance with Section 4.04 and Section 13.14 herein. 

7 

SECTION 5.03. Termination for Good Reason or Without Cause. Except as otherwise set forth in Section 5.09
below, if the Employment Period shall be terminated (a) by the Executive for
Good Reason, or (b) by the Companies not for Cause, provided in either case that
the Executive has executed, on or before the date that is fifty (50) days
following the date of his termination of employment, an irrevocable (except to
the extent required by law to be revocable) general release of claims similar to
the form attached hereto as Exhibit A, and does not revoke such release prior to
the end of the seven (7) day statutory revocation period, the Executive shall be
entitled solely to the following: (i) Base Salary through the Date of
Termination, paid on the Companies’ normal payroll payment date; (ii) an amount
equal to one times the Base Salary, provided that, the Executive shall be
entitled to any unpaid amounts only if the Executive has not breached and does
not breach the provisions of Sections 6.01, 7.01, 8.01 or Article 9 below; (iii)
a bonus for the year of termination of employment equal to the Executive’s
actual annual bonus for such year pro rated for the number of full months
during the bonus year prior to such termination of employment, to be paid,
subject to Section 13.14 below (including but not limited to any delay in
payment due to application of the Delay Period), seventy-five (75) days after
the end of the fiscal year during which the bonus was eligible to be earned;
(iv) medical benefits as provided in Section 5.05 below. The Executive’s
entitlements under any other benefit plan or program shall be as determined
thereunder, except that duplicative severance benefits shall not be payable
under any other plan or program. Amounts described in clause (ii) above will be
paid, subject to Section 13.14 below (including, but not limited to, any delay
in payment due to application of the Delay Period), in twelve (12) equal monthly
installments, the first two (2) of which shall be paid on the date that is two
(2) months following the Date of Termination and the next ten (10) of which will
be paid in ten (10) equal monthly installments commencing on the date that is
three (3) months following the Date of Termination and continuing on each of the
next nine (9) monthly anniversaries of the Date of Termination. In addition, the
Executive shall be reimbursed for all Reimbursable Expenses incurred by the
Executive prior to such termination in accordance with Section 4.04 and Section
13.14 herein. For the purposes of this Agreement, the actual annual bonus shall
be determined by the Committee. In addition, the provisions of clause (iv)
above, shall apply to any involuntary termination of Executive’s employment by
the Company without Cause or voluntary termination by Executive for Good Reason
occurring on or after the expiration of the Employment Period under Section 5.01
following any Company notice to Executive that the Employment Period will not be
automatically so extended (and for the avoidance of doubt, this sentence and
related provisions of this Agreement shall survive any such expiration of the
Employment Period). 

SECTION 5.04. Termination for Cause or Other Than Good Reason. If the Employment Period shall be terminated (a)
by the Companies for Cause, or (b) as a result of the Executive’s resignation or
leaving of his employment other than for Good Reason, the Executive shall be
entitled to receive solely Base Salary through the Date of Termination (paid on
the Companies’ normal payroll payment date) and reimbursement of all
Reimbursable Expenses incurred by the Executive prior to such termination (in
accordance with Section 4.04 and Section 13.14 herein). The Executive’s rights
under the benefit plans and programs shall be as determined thereunder. A
voluntary resignation by the Executive shall not be deemed to be a breach of
this Agreement. 

SECTION 5.05. Benefits. If the
Employment Period is terminated as a result of a termination of employment as
specified in Section 5.02, 5.03 or 5.09, the Executive and his covered
dependents shall be entitled to continue to participate in the Companies’
medical (including prescription coverage) and dental plans (the “Company Health
Care Plan”) for up to eighteen (18) months following the date his employment is
terminated (the “Continuation
Coverage Period”). The Executive
shall pay the entire premium charged for the coverage of the Executive and his
covered dependents under the Company Health Care Plan. The premium required for
the continuation coverage provided pursuant to this Section 5.05 shall be equal
to the premium required by the continuation of coverage requirements of Section
4980B of the Code and Part 6 of Title I of the Employee Retirement Income
Security Act of 1974, as amended (“COBRA”), for such continuation coverage. During the
Continuation Coverage Period, the Company shall reimburse the Executive for the difference between the
monthly premium amount actually paid by the Executive pursuant to this Section
5.05 and the monthly premium amount paid by active employees for the same level
of coverage under the Company Health Care Plan. Such reimbursement shall be
paid to the Executive on or before the 20th day of the month immediately
following the month in which the Executive timely remits the required premium
payment. The right to reimbursement and the coverage provided pursuant to this
Section 5.05 shall terminate prior to the end of the Continuation Coverage
Period if the Executive is eligible to receive benefits under another
employer-provided or group plan (which plan may be the plan of his new employer
or his spouse’s employer) substantially comparable to the benefits provided by
the Company Health Care Plan. Furthermore, in the event of the Executive’s
Permanent Disability, insurance benefits will continue under the Companies’ long
term disability plan in accordance with its terms. 

8 

SECTION 5.06. Notice of Termination. Any
termination by the Companies for Permanent Disability or Cause or without Cause
or by the Executive with or without Good Reason shall be communicated by written
Notice of Termination to the other party hereto. For purposes of this Agreement,
a “Notice of
Termination” shall mean a notice
which shall indicate the specific termination provision in this Agreement relied
upon and shall set forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of employment under the provision
indicated. 

SECTION 5.07. Date of Termination.
“Date of
Termination” shall mean (a) if
the Employment Period is terminated as a result of a Permanent Disability, five
(5) days after a Notice of Termination is given, (b) if the Employment Period is
terminated as a result of his death, on the date of his death, (c) if the
Employment Period terminates due to expiration of the term of this Agreement,
the date the term expires, and (d) if the Employment Period is terminated for
any other reason, the later of the date of the Notice of Termination and the end
of any applicable correction period. 

SECTION 5.08. No
Duty to Mitigate. The Executive
shall have no duty to seek new employment or other duty to mitigate following a
termination of employment as described in this Article 5, and no compensation or
benefits described in this Article 5 shall be subject to reduction or offset on
account of any subsequent compensation, other than as provided in Section 5.05.

9 

SECTION 5.09. Termination for Good Reason or Without Cause Following a Change in
Control. If the Employment Period
shall be terminated within two years after a Change in Control (a) by the
Executive for Good Reason or (b) by the Companies not for Cause, then the
Executive’s compensation and benefits upon termination shall be governed by this
Section 5.09 instead of the provisions of Section 5.03 above, and, provided the
Executive has executed, on or before the date that is fifty (50) days following
the date of his termination of employment, an irrevocable (except to the extent
required by law to be revocable) general release of claims similar to the form
attached hereto as Exhibit A, and does not revoke such release prior to the end
of the seven (7) day statutory revocation period, the Executive shall be
entitled solely to the following: (i) Base Salary and accrued unused vacation
through the Date of Termination, paid on the Companies’ normal payroll payment
date; (ii) an amount equal to two times the sum of his Base Salary and his
target annual bonus for the year of termination, provided that, the Executive
shall be entitled to any unpaid amounts only if the Executive has not breached
and does not breach the provisions of Sections 6.01, 7.01 or 8.01 or Article 9
below; (iii) a bonus for the year of termination of employment equal to the
Executive’s target annual bonus for such year pro rated for the number of full
months during the bonus year prior to such termination of employment; (iv) notwithstanding anything to the contrary in any equity award
agreement, the Restricted Stock Units granted under Section 4.05 herein shall
fully vest and the Restricted Stock Units shall be settled immediately (provided
that (A) all other equity awards granted to the Executive pursuant to Section
4.06 or otherwise shall instead be subject to the terms of the Stock Plan and
applicable award agreement(s), and (B) with respect to the Restricted Stock
Units granted under Section 4.05 herein, such equity awards shall be subject to
the terms of the Stock Plan and applicable award agreement if the benefits
provided pursuant to such instruments in the event of a Change in Control are
more favorable to the Executive); and (v) medical benefits as provided in
Section 5.05. The Executive’s entitlements under any other benefit plan or
program shall be as determined thereunder, except that duplicative severance
benefits shall not be payable under any other plan or program. In addition,
promptly following any such termination, the Executive shall be reimbursed for
all Reimbursable Expenses incurred by the Executive prior to such termination
(in accordance with Section 13.14). The amounts due under clauses (ii) and
(iii) of this Section 5.09 shall be paid, subject to Section 13.14 below, sixty
(60) days following such termination of employment. In addition, the provisions
of clause (iv), above, shall apply to any involuntary termination of Executive’s
employment by the Company without Cause or voluntary termination by Executive
for Good Reason occurring on or after expiration of the Employment Period under
Section 5.01 following any Company notice to Executive that the Employment
Period will not be automatically so extended (and for the avoidance of doubt,
this sentence and related provisions of this Agreement shall survive any such
expiration of the Employment Period). 

SECTION 5.10. Separation From Service. Notwithstanding any provision of this Agreement to the contrary, for
purposes of Section 5.03 and Section 5.09, the Executive will be deemed to have
terminated his employment on the date of his “separation from service” (within
the meaning of Treas. Reg. Section 1.409A-1(h)) with the Companies, the
Employment Period will be deemed to have ended on the date of his “separation
from service” with the Companies, and the Date of Termination will be deemed to
be the date of his “separation from service” with the Companies if and to the
extent required under Section 409A. Further, to the extent required under
Section 409A, references to “termination of employment” or words of similar
import shall be deemed to refer to, and shall be defined in accordance with, a
“separation from service” as defined under Section 409A. 

ARTICLE 6 

CONFIDENTIAL INFORMATION

SECTION 6.01. Nondisclosure and Nonuse of Confidential Information;
Nondisparagement. The Executive
will not disclose or use at any time during or after the Employment Period any
Confidential Information of which the Executive is or becomes aware, whether or
not such information is developed by him, except to the extent he reasonably
believes that such disclosure or use is directly related to and appropriate in
connection with the Executive’s performance of duties assigned to the Executive
pursuant to this Agreement. Under all circumstances and at all times, the
Executive will take all appropriate steps to safeguard Confidential Information
in his possession and to protect it against disclosure, misuse, espionage, loss
and theft. The Executive also agrees to execute and comply with such other
confidentiality agreements or provisions as required of executive officers of
the Company. The Executive further agrees that, during the Employment Period and
thereafter, the Executive shall not make any disparaging remarks, or any remarks that could reasonably be construed as
disparaging, regarding the Companies, or its or their officers, directors,
employees, shareholders, representatives, agents, businesses or practices.

10 

ARTICLE 7 

INTELLECTUAL PROPERTY

SECTION 7.01. Ownership of Intellectual Property. In the event that the Executive as part of his
activities on behalf of the Companies generates, authors or contributes to any
invention, design, new development, device, product, method of process (whether
or not patentable or reduced to practice or comprising Confidential
Information), any copyrightable work (whether or not comprising Confidential
Information) or any other form of Confidential Information relating directly or
indirectly to the business of the Company or its Subsidiaries as now or
hereafter conducted (collectively, “Intellectual Property”),
the Executive acknowledges that such Intellectual Property is the sole and
exclusive property of the Company and its Subsidiaries and hereby assigns all
right, title and interest in and to such Intellectual Property to the Company or
its designated Subsidiary. Any copyrightable work prepared in whole or in part
by the Executive during the Employment Period will be deemed “a work made for
hire” under Section 201(b) of the Copyright Act of 1976, as amended, and the
Company or its designated Subsidiary will own all of the rights comprised in the
copyright therein. The Executive will promptly and fully disclose all
Intellectual Property and will cooperate with the Companies to protect their
interests in and rights to such Intellectual Property (including providing
reasonable assistance in securing patent protection and copyright registrations
and executing all documents as reasonably requested by the Companies, whether
such requests occur prior to or after termination of the Executive’s employment
hereunder). 

ARTICLE 8 

DELIVERY OF MATERIALS UPON
TERMINATION OF EMPLOYMENT 

SECTION 8.01. Delivery of Materials upon Termination of Employment. As requested by the Companies from time to time,
and upon the termination of the Executive’s employment with the Companies for
any reason, the Executive will promptly deliver to the Companies all property of
the Company or its Subsidiaries, including, without limitation, all copies and
embodiments, in whatever form or medium, of all Confidential Information in the
Executive’s possession or within his control (including, but not limited to,
written records, notes, photographs, manuals, notebooks, documentation, program
listings, flow charts, magnetic media, disks, diskettes, tapes and all other
materials containing any Confidential Information) irrespective of the location
or form of such material and, if requested by the Companies, will provide the
Companies with written confirmation that to the best of his knowledge all such
materials have been delivered to the Companies or destroyed. 

11 

ARTICLE 9 

NON-COMPETITION AND
NONSOLICITATION 

 SECTION 9.01.
Noncompetition. The Executive acknowledges that, during his
employment with the Companies, he will become familiar with trade secrets and
other Confidential Information concerning the Company and its Subsidiaries and
his services will be of special, unique and extraordinary value to the
Companies. In addition, the Executive hereby agrees that at any time during the
Noncompetition Period (as defined below), he will not directly or indirectly
own, manage, control, participate in, consult with, become employed by or
otherwise render services in an executive or senior management capacity to, or
as a director of, to any business listed on Exhibit B hereto in the Territory.
During the Noncompetition Period, the Company shall have the right to, in good
faith and upon ninety (90) day advance written notice, add other entities which
are in substantial competition with the Companies to the list of businesses on
Exhibit B, subject to the consent of the Executive which shall not be
unreasonably withheld. It shall not be considered a violation of this Section
9.01 for the Executive to be a passive owner of not more than 2% of the
outstanding stock of any class of any corporation which is publicly traded, so
long as the Executive has no active participation in the business of such
corporation. 

SECTION 9.02. Nonsolicitation. The
Executive hereby agrees that (a) during the Nonsolicitation Period (as defined
below), the Executive will not, directly or indirectly through another Person,
induce or attempt to induce any employee of the Company or its Subsidiaries to
leave the employ of the Company or its Subsidiaries, or in any way interfere
with the relationship between the Company or its Subsidiaries and any person
employed by them at any time during such Nonsolicitation Period, and (b) during
the Nonsolicitation Period, the Executive will not induce or attempt to induce
any customer, supplier, client or other business relation of the Company or its
Subsidiaries to cease doing business with or reduce the volume of business done
with the Company or its Subsidiaries. 

SECTION 9.03. Definitions. It is agreed
that the “Territory,” for purposes
of this Article 9, shall mean: 

(a) The
entire United States and any other country where the Company or any of its
Subsidiaries, joint venturers, franchisees or affiliates has operated a retail
facility at which the Companies’ products have been sold at any time in the
one-year period ending on the last day of the Executive’s employment with the
Companies; 

(b) In the
event that the preceding clause shall be determined by judicial action to define
too broad a territory to be enforceable, then “Territory” shall mean the entire
United States; 

(c) In the
event that the preceding clauses shall be determined by judicial action to
define too broad a territory to be enforceable, then “Territory” shall mean the
states in the United States where the Company or any of its Subsidiaries, joint
venturers, franchisees or affiliates has operated a retail facility at which the
Companies’ products have been sold at any time in the one-year period ending on
the last day of Executive’s employment with the Companies; 

(d) In the
event that the preceding clauses shall be determined by judicial action to
define too broad a territory to be enforceable, then “Territory” shall mean the
area that includes all of the areas that are
within a 50-mile radius of any retail store location in the United States at
which the Companies’ products have been sold at any time in the one-year period
ending on the last day of the Executive’s employment with the Companies; and

12 

(e) In the
event that the preceding clauses shall be determined by judicial action to
define too broad a territory to be enforceable, then “Territory” shall mean the
entire state of North Carolina. 

It is also agreed that
“Noncompetition
Period,” for purposes hereof,
shall mean: 

(a) The
Employment Period and a period ending one year after the Date of Termination;
and 

(b) In the
event that the preceding clause shall be determined by judicial action to define
too long a period to be enforceable, “Noncompetition Period” shall mean the
Employment Period and a period ending six months after the Date of Termination.

It is also agreed that
“Nonsolicitation
Period,” for purposes hereof,
shall mean: 

(a) The
Employment Period and a period ending two years after the Date of Termination;

(b) In the
event that the preceding clause shall be determined by judicial action to define
too long a period to be enforceable, “Nonsolicitation Period” shall mean the
Employment Period and a period ending eighteen months after the Date of
Termination; 

(c) In the
event that the preceding clauses shall be determined by judicial action to
define too long a period to be enforceable, “Nonsolicitation Period” shall mean
the Employment Period and a period ending one year after the Date of
Termination; and 

(d) In the
event that the preceding clauses shall be determined by judicial action to
define too long a period to be enforceable, “Nonsolicitation Period” shall mean
the Employment Period and a period ending six months after the Date of
Termination. 

ARTICLE 10 

EQUITABLE RELIEF

SECTION 10.01. Equitable Relief. The
Executive acknowledges that (a) the covenants contained herein are reasonable,
(b) the Executive’s services are unique, and (c) a breach or threatened breach
by him of any of his covenants and agreements with the Companies contained in
Sections 6.01, 7.01, 8.01 or Article 9 could cause irreparable harm to the
Companies for which they would have no adequate remedy at law. Accordingly, and
in addition to any remedies which the Companies may have at law, in the event of
an actual or threatened breach by the Executive of his covenants and agreements
contained in Sections 6.01, 7.01, 8.01 or Article 9, the Companies shall have
the absolute right to apply to any court of competent jurisdiction for such
injunctive or other equitable relief, without the necessity to post bond, as
such court may deem necessary or appropriate in the circumstances. Further, in
the event that any provision contained in Sections 6.01, 7.01, 8.01 or Article 9 shall be declared by a court of competent
jurisdiction to be overbroad as written, the Executive specifically agrees that
the court should modify such provision in order to make it enforceable, and that
the court should view each such provision as severable and enforce those
severable provisions deemed reasonable by such court.

13 

ARTICLE 11 

EXECUTIVE REPRESENTATION
AND INDEMNIFICATION 

SECTION 11.01. Executive Representation.
The Executive hereby represents and warrants to the Companies that (a) the
execution, delivery and performance of this Agreement by the Executive does not
and will not conflict with, breach, violate or cause a default under any
contract, agreement, instrument, order, judgment or decree to which the
Executive is a party or by which he is bound, (b) the Executive is not a party
to or bound by any employment agreement, noncompetition agreement or
confidentiality agreement with any other Person, and (c) upon the execution and
delivery of this Agreement by the Companies, this Agreement will be the valid
and binding obligation of the Executive, enforceable in accordance with its
terms. Notwithstanding Section 11.02 below, in the event that any action is
brought against the Executive involving any breach of any employment agreement,
noncompetition agreement or confidentiality agreement with any other Person, the
Executive shall bear his own costs incurred in defending such action, including
but not limited to court fees, arbitration costs, mediation costs, attorneys’
fees and disbursements. 

SECTION 11.02. General Indemnification.
The Companies, jointly and severally, agree that if the Executive is made a
party, or is threatened to be made a party, to any action, suit or proceeding,
whether civil, criminal, administrative or investigative (each, a
“Proceeding”), by reason of the fact that he is or was a
director, officer or employee of the Company or any of its Subsidiaries or is or
was serving at the request of the Company or any of its Subsidiaries as a
director, officer, member, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, including service with
respect to employee benefit plans, whether or not the basis of such Proceeding
is the Executive’s alleged action in an official capacity while serving as a
director, officer, member, employee or agent, the Executive shall be indemnified
and held harmless by the Companies to the fullest extent permitted or authorized
by applicable law and their bylaws, against all cost, expense, liability and
loss (including, without limitation, advancement of attorneys’ and other fees
and expenses) reasonably incurred or suffered by the Executive in connection
therewith. The Company agrees to use its best efforts to maintain a directors’
and officers’ liability insurance policy covering the Executive during the
Employment Period and for at least four years thereafter to the extent available
on commercially reasonable terms. 

14 

ARTICLE 12 

LIMITATION ON CERTAIN
PAYMENTS CONTINGENT ON CHANGE IN CONTROL 

SECTION 12.01. Limitation on Certain Payments Contingent on Change in Control.

(a) Anything in this Agreement to the contrary notwithstanding, in the event
it shall be determined that (i) any payment, award, benefit or distribution (or
any acceleration of any payment, award, benefit or distribution) by the
Companies (or any of their affiliated entities) or any entity which effectuates
a Change in Control (or any of its affiliated entities) to or for the benefit of
the Executive (whether pursuant to the terms of this Agreement or otherwise)
(the “Payments”) would be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), and (ii) the
reduction of the amounts payable to the Executive under this Agreement to the
maximum amount that could be paid to the Executive without giving rise to the
Excise Tax (the “Safe Harbor
Cap”) would provide the Executive
with a greater after-tax amount than if such amounts were not reduced, then the
amounts payable to the Executive under this Agreement shall be reduced (but not
below zero) to the Safe Harbor Cap. Unless the Companies and the Executive agree
otherwise (in a manner intended to comply with Code Section 409A), the reduction
of the amounts payable hereunder, if applicable, shall be made to the extent
necessary in the following order: (i) first, any such Payments
that became fully vested prior to the Change in Control and that pursuant to
paragraph (b) of Treas. Reg. § 1.280G-1, Q/A 24, are treated as contingent
compensation payments solely by reason of the acceleration of their originally
scheduled dates of payment will be reduced, by cancellation of the acceleration
of their vesting; (ii) second, any severance
payments or benefits, performance-based cash or equity incentive awards, or
other contingent compensation payments the full amounts of which are treated as
contingent on the Change in Control pursuant to paragraph (a) of Treas. Reg. §
1.280G-1, Q/A 24, will be reduced; and (iii) third, any cash or equity incentive awards, or nonqualified deferred
compensation amounts, that vest solely based on the Executive’s continued
service with the Companies, and that pursuant to paragraph (c) of Treas. Reg. §
1.280G-1, Q/A 24, are treated as contingent on the Change in Control because
they become vested as a result of the Change in Control, will be reduced, first
by cancellation of any acceleration of their originally scheduled dates of
payment (if payment with respect to such items is not treated as automatically
occurring upon the vesting of such items for purposes of Section 280G of the
Code) and then, if necessary, by canceling the acceleration of their vesting. In
each case, the amounts of the contingent compensation payments will be reduced
in the inverse order of their originally scheduled dates of payment or vesting,
as applicable, and will be so reduced only to the extent necessary to achieve
the required reduction. For purposes of reducing the Payments to the Safe Harbor
Cap, only amounts payable under this Agreement (and no other Payments) shall be
reduced. If the reduction of the amounts payable hereunder would not result in a
greater after-tax result to the Executive, no amounts payable under this
Agreement shall be reduced pursuant to this provision. 

(b) All
determinations required to be made under this Section 12.01 shall be made by the
public accounting firm that is retained by the Companies as of the date
immediately prior to the Change in Control (the “Accounting Firm”), which shall provide detailed supporting
calculations both to the Companies and the Executive within fifteen (15)
business days of the receipt of notice from the Companies or the Executive that
there has been a Payment, or such earlier time as is requested by the Companies.
Notwithstanding the foregoing, in the event (i) the Board shall determine prior
to the Change in Control that the Accounting Firm is precluded from performing
such services under applicable auditor independence rules or (ii) the Audit
Committee of the Board determines that it does not want the Accounting Firm to
perform such services because of auditor independence concerns or (iii) the
Accounting Firm is serving as accountant or auditor for the person(s) effecting
the Change in Control, the Board shall appoint another nationally recognized public accounting firm to make the
determinations required hereunder (which accounting firm shall then be referred
to as the Accounting Firm hereunder). All fees, costs and expenses (including,
but not limited to, the costs of retaining experts) of the Accounting Firm shall
be borne by the Companies. If payments are reduced to the Safe Harbor Cap or the
Accounting Firm determines that no Excise Tax is payable by the Executive
without a reduction in payments, the Accounting Firm shall provide a written
opinion to the Executive to such effect, that the Executive is not required to
report any Excise Tax on the Executive’s federal income tax
return, and that the failure to report the Excise Tax, if any, on the
Executive’s applicable federal income tax return will not result in the
imposition of a negligence or similar penalty. The determination by the
Accounting Firm shall be binding upon the Companies and the Executive (except as
provided in Section 12.01(c) below). 

15 

(c) If it
is established pursuant to a final determination of a court or an Internal
Revenue Service (the “IRS”) proceeding, which
has been finally and conclusively resolved, that Payments have been made to, or
provided for the benefit of, the Executive by the Companies, which are in excess
of the limitations provided in this Section 12.01 (referred to hereinafter as an
“Excess Payment”), the Executive shall repay the Excess Payment
to the Companies on demand, together with interest on the Excess Payment at the
applicable federal rate (as defined in Section 1274(d) of the Code) from the
date of the Executive’s receipt of such Excess Payment until the date of such
repayment. As a result of the uncertainty in the application of Section 4999 of
the Code at the time of the determination, it is possible that Payments which
will not have been made by the Companies should have been made (an
“Underpayment”), consistent with the calculations required to
be made under this Section 12.01. In the event that it is determined (i) by the
Accounting Firm, the Companies (which shall include the position taken by the
Companies, or together with their consolidated group, on their federal income
tax returns) or the IRS or (ii) pursuant to a determination by a court, that an
Underpayment has occurred, the Companies shall pay an amount equal to such
Underpayment to the Executive within ten (10) days of such determination
together with interest on such amount at the applicable federal rate from the
date such amount would have been paid to the Executive until the date of
payment. The Executive shall cooperate, to the extent the
Executive’s expenses are reimbursed by the Companies, with any
reasonable requests by the Companies in connection with any contests or disputes
with the IRS in connection with the Excise Tax or the determination of the
Excess Payment. Notwithstanding the foregoing, in the event that amounts payable
under this Agreement were reduced pursuant to Section 12.01(a) and the value of
stock options is subsequently re-determined by the Accounting Firm within the
context of Treasury Regulation §1.280G-1 Q/A 33 that reduces the value of the
Payments attributable to such options, the Companies shall promptly pay to the
Executive any amounts payable under this Agreement that were not previously paid
solely as a result of Section 12.01(a), subject to the Safe Harbor Cap.

ARTICLE 13 

MISCELLANEOUS 

SECTION 13.01. Binding Arbitration. The
parties agree that, except as provided in Articles 9 and 10 above, any disputes
under this Agreement shall be settled exclusively by arbitration conducted in
Winston-Salem, North Carolina. Except to the extent inconsistent with this
Agreement, such arbitration shall be conducted in accordance with the National
Rules for the Resolution of Employment
Disputes of the American Arbitration Association then in effect at the time of
the arbitration and otherwise in accordance with principles which would be
applied by a court of law or equity. The arbitrator shall be acceptable to both
the Companies and the Executive. If the parties cannot agree on an acceptable
arbitrator, the dispute shall be decided by a panel of three arbitrators, one
appointed by each of the parties and the third appointed by the other two
arbitrators or if the two arbitrators do not agree, appointed by the American
Arbitration Association. The costs of arbitration incurred by the Executive (or
his beneficiaries) will be borne by the Companies (including, without
limitation, reasonable attorneys’ fees and other reasonable charges of counsel)
(a) if the arbitration occurs prior to a Change in Control, if the Executive
prevails on a majority of the material issues in the dispute, and (b) if the
arbitration occurs after a Change in Control, if the Executive prevails on at
least one material issue in the dispute. Judgment upon the final award rendered
by such arbitrator(s) may be entered in any court having jurisdiction thereof.

16 

Following the final
determination of the dispute in which, based on the outcome of the dispute, the
Executive is, in accordance with this Section 13.01, entitled to have his costs
borne by the Companies, the Companies shall pay all such reasonable costs within
ten (10) days following written demand therefor (supported by documentation of
such costs) by the Executive, and the Executive shall make such written demand
within sixty (60) days following the final determination of the dispute;
provided, however, that such payment
shall be made no later than on or prior to the end of the calendar year
following the calendar year in which the costs are incurred. Notwithstanding the
foregoing, in the event a final determination of the dispute has not been made
by December 20 of the year following the calendar year in which the costs are
incurred, the Companies shall, within ten (10) days after such December 20,
reimburse such reasonable costs (supported by documentation of such costs)
incurred in the prior taxable year; provided, however, that the Executive shall return such amounts to the Companies within
ten (10) business days following the final determination if (i) in the case of
an arbitration prior to a Change in Control, the Executive does not prevail on a
majority of the material issues in the dispute, or (ii) in the case of an
arbitration after a Change in Control, the Executive does not prevail on at
least one material issue in the dispute. The amount of any costs eligible for
payment under this Section 13.01 during a calendar year will not affect the
amount of any costs eligible for payment under this Section 13.01 in any other
taxable year. 

SECTION 13.02. Consent to Amendments; No Waivers. The provisions of this Agreement may be amended or waived only by a
written agreement executed and delivered by the Companies and the Executive.
Notwithstanding the foregoing, the Companies shall have unilateral authority to
amend this Agreement (without Executive consent) to the extent necessary to
comply with applicable laws, rules or regulations (including but not limited to
Section 409A) or changes to applicable laws, rules or regulations. No other
course of dealing between the parties to this Agreement or any delay in
exercising any rights hereunder will operate as a waiver of any rights of any
such parties. 

SECTION 13.03. Successors and Assigns.
All covenants and agreements contained in this Agreement by or on behalf of any
of the parties hereto will bind and inure to the benefit of the respective
successors, assigns, heirs, executors and estates of the parties hereto whether
so expressed or not, provided that the Executive may not assign his rights or
delegate his obligations under this Agreement without the written consent of the
Companies (other than to his estate or heirs) and the Company may assign this Agreement only to a successor to
all or substantially all of the assets of the Company. 

17 

SECTION 13.04. Severability. Whenever
possible, each provision of this Agreement will be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Agreement is held to be prohibited by or invalid under applicable law, such
provision will be ineffective only to the extent of such prohibition or
invalidity, without invalidating the remainder of this Agreement. 

SECTION 13.05. Counterparts. This
Agreement may be executed simultaneously in two or more counterparts, any one of
which need not contain the signatures of more than one party, but all of which
counterparts taken together will constitute one and the same agreement.

SECTION 13.06. Descriptive Headings. The
descriptive headings of this Agreement are inserted for convenience only and do
not constitute a part of this Agreement. 

SECTION 13.07. Notices. All notices,
demands or other communications to be given or delivered under or by reason of
the provisions of this Agreement will be in writing and will be deemed to have
been given when delivered personally to the recipient, two (2) business days
after the date when sent to the recipient by reputable express courier service
(charges prepaid) or four (4) business days after the date when mailed to the
recipient by certified or registered mail, return receipt requested and postage
prepaid. Such notices, demands and other communications will be sent to the
Executive and to the Companies at the addresses set forth below. 

	       	If to
      the Executive:	       	To
      the last address delivered to the Companies
			 	by
      the Executive in the manner set forth herein.
		 
		If to
      the Companies:		Krispy Kreme Doughnuts, Inc.
				Krispy Kreme Doughnut Corporation
				Suite 500
				370
      Knollwood Street
				Winston-Salem, NC 27103
				Attn: Senior Vice President-Human
Resources

or to such other address or
to the attention of such other person as the recipient party has specified by
prior written notice to the sending party. 

SECTION 13.08. Withholding. The Companies
may withhold from any amounts payable under this Agreement such federal, state,
local or foreign taxes as shall be required to be withheld pursuant to any
applicable law or regulation. 

SECTION 13.09. No
Third-Party Beneficiary. This
Agreement will not confer any rights or remedies upon any person other than the
Companies, the Executive and their respective heirs, executors, successors and
assigns. 

SECTION 13.10. Entire Agreement. This
Agreement (including any other documents referred to herein) constitutes the
entire agreement among the parties and supersedes any prior understandings, agreements or representations by
or among the parties, written or oral, that may related in any way to the
subject matter hereof. 

18 

SECTION 13.11. Construction. The language
used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rule of strict construction will be
applied against any party. Any reference to any federal, state, local or foreign
statute or law will be deemed also to refer to all rules and regulations
promulgated thereunder, unless the context requires otherwise. 

SECTION 13.12. Survival. Sections 6.01,
7.01, 8.01 and Articles 1, 5, 9, 10, 11, 12 and 13 will survive and continue in
full force in accordance with their terms notwithstanding any termination of the
Employment Period, and the Agreement shall otherwise remain in full force to the
extent necessary to enforce any rights and obligations arising hereunder during
the Employment Period. 

SECTION 13.13. GOVERNING LAW. ALL
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY AND INTERPRETATION OF THIS
AGREEMENT WILL BE GOVERNED BY THE INTERNAL LAW OF NORTH CAROLINA, WITHOUT REGARD
TO PRINCIPLES OF CONFLICT OF LAWS. 

SECTION 13.14. Section 409A. It is
intended that this Agreement will comply with Section 409A, to the extent the
Agreement is subject thereto, and the Agreement shall be interpreted on a basis
consistent with such intent. If an amendment of this Agreement is necessary in
order for it to comply with Section 409A, the parties hereto will negotiate in
good faith to amend the Agreement in a manner that preserves the original intent
of the parties to the extent reasonably possible. Notwithstanding any provision
to the contrary in this Agreement, if the Executive is deemed on the date of his
“separation from service” (within the meaning of Treas. Reg. Section 1.409A-1(h)) to be a “specified employee” (within the meaning of Treas. Reg. Section
1.409A-1(i)), then with regard to any payment that is required to be delayed
pursuant to Section 409A(a)(2)(B) of the Code, the portion, if any, of such
payment so required to be delayed shall not be made prior to the earlier of (i)
the expiration of the six (6)-month period measured from the date of his
“separation from service”, or (ii) the date of his death (the “Delay Period”). Upon the expiration of the Delay Period, all
payments delayed pursuant to this Section shall be paid to the Executive in a
lump sum, and any remaining payments shall be made as provided in the Agreement
and in a manner in accordance with Section 409A. The Companies shall not have
any obligation to indemnify or otherwise protect the Executive from any
obligation to pay any taxes pursuant to Section 409A. In the event that this
Agreement or any compensation payable hereunder shall be deemed not to comply
with (or be exempt from) Section 409A, then neither the Companies, the Board,
the Board of Directors of KKDC, nor its or their designees or agents, shall be
liable to the Executive or other persons for actions, decisions or
determinations made in good faith. 

19 

With respect to any
reimbursement or in-kind benefit arrangements of the Companies and their
subsidiaries that constitute deferred compensation for purposes of Section 409A,
except as otherwise permitted by Section 409A, the following conditions shall be
applicable: (a) the amount eligible for reimbursement, or in-kind benefits
provided, under any such arrangement in one calendar year may not affect the
amount eligible for reimbursement, or in-kind benefits to be provided,
under such arrangement in any other calendar year (except that the health and
dental plans may impose a limit on the amount that may be reimbursed or paid),
(b) any reimbursement must be made on or before the last day of the calendar
year following the calendar year in which the expense was incurred, and (c) the
right to reimbursement or in-kind benefits is not subject to liquidation or
exchange for another benefit. Whenever a payment under this Agreement specifies
a payment period with reference to a number of days (e.g., “payment shall be
made within thirty (30) days after termination of employment”), the actual date
of payment within the specified period shall be within the sole discretion of
the Companies. Whenever payments under this Agreement are to be made in
installments, each such installment shall be deemed to be a separate payment for
purposes of Section 409A. Any reimbursement by the Company pursuant to Section
12.01(c) herein shall be made to the Executive not later than the end of the
Executive’s taxable year following the taxable year in which he remits the
related taxes. 

SECTION 13.15. Representations of the Companies. The Companies represent and warrant that (a) the execution, delivery and
performance of this Agreement by the Companies has been fully and validly
authorized by all necessary corporate action, (b) the officer(s) signing this
Agreement on behalf of the Companies is duly authorized to do so, (c) the
execution, delivery and performance of this Agreement does not violate any
applicable law, regulation, order, judgment or decree or any agreement, plan or
corporate governance document to which the Companies are a party or by which
they are bound, and (d) upon execution and delivery of this Agreement by the
parties hereto, it will be a valid and binding obligation of the Companies
enforceable against the Companies and their successors and assigns in accordance
with its terms, except to the extent that enforceability may be limited by
applicable bankruptcy, insolvency or similar laws affecting the enforcement of
creditors’ rights generally. 

[remainder of page left
intentionally blank] 

20 

IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date and year first above
written. 

		KRISPY KREME
      DOUGHNUTS, INC.
		 
		 
		By:      
    	/s/ Tony Thompson
			Tony
      Thompson
			Chief Executive
      Officer
		 
		 
	 	KRISPY KREME
      DOUGHNUT CORPORATION
		 
		 
		By:	/s/ Cathleen D. Allred
			Cathleen D.
      Allred
			Senior Vice President Human Resources
			and
      Organizational Development
		 
		 
		EXECUTIVE
		 
		 
		/s/ Thomas Kuharcik
		Thomas
      Kuharcik

21 

Exhibit
A 

MUTUAL
RELEASE 

This mutual release (this
“Release”) is entered into as of this ____ day of ______,
_____ (the “Release
Date”) among Krispy Kreme
Doughnut Corporation, a North Carolina corporation (“KKDC”), Krispy Kreme
Doughnuts, Inc., a North Carolina corporation (the “Company” and, together with KKDC, the “Companies”) and Thomas
Kuharcik (the “Executive”). 

1. Reference is hereby made to the employment agreement dated as of
[_________], 2015 (the “Employment Agreement”) by the parties hereto setting forth the
agreements among the parties regarding the termination of the employment
relationship between the Executive and the Companies. Capitalized terms used but
not defined herein have the meanings ascribed to them in the Employment
Agreement. 

2. The
Executive, for himself, his spouse, heirs, executors, administrators, successors
and assigns, hereby releases and discharges the Companies and its respective
direct and indirect parents and subsidiaries, and other affiliated companies,
and each of their respective past and present officers, directors, agents and
employees, from any and all actions, causes of action, claims, demands,
grievances and complaints, known and unknown, which the Executive or his spouse,
heirs, executors, administrators, successors or assigns ever had or may have at
any time through the Release Date. The Executive acknowledges and agrees that
this Release is intended to and does cover, but is not limited to, (i) any claim
of employment discrimination of any kind whether based on a federal, state or
local statute or court decision, including the Age Discrimination in Employment
Act with appropriate notice and rescission periods observed; and (ii) any claim,
whether statutory, common law or otherwise, arising out of the terms or
conditions of the Executive’s employment at the Companies and/or the Executive’s
separation from the Companies. The enumeration of specific rights, claims and
causes of action being released shall not be construed to limit the general
scope of this Release. It is the intent of the parties that by this Release the
Executive is giving up all rights, claims and causes of action occurring prior
to the Release Date, whether or not any damage or injury therefrom has yet
occurred. The Executive accepts the risk of loss with respect to both
undiscovered claims and with respect to claims for any harm hereafter suffered
arising out of conduct, statements, performance or decisions occurring before
the Release Date. 

It is understood that the
Executive has been advised to consult with an attorney prior to executing this
Release; that he in fact has consulted a knowledgeable, competent attorney
regarding this Release; that he may, before executing this Release, consider
this Release for a period of twenty-one (21) calendar days; and that the
consideration he receives for this Release is in addition to amounts to which he
was already entitled. If the Executive is signing this Release prior to the
expiration of such twenty-one (21)-day period, the Executive is waiving his
right to review the Release for such full twenty-one (21)-day period prior to
signing it. It is further understood that the Executive may revoke this Release
within seven calendar days from the date of execution hereof. If the Executive
revokes this Release within such seven (7)-day period, no severance benefit will
be payable to him under the Employment Agreement and he shall return to the
Company any such payment received prior to that date. 

3. The
Companies hereby release and discharge the Executive, his spouse, heirs,
executors, administrators, successors and assigns, from any and all actions,
causes of actions, claims, demands, grievances and complaints, known and
unknown, which the Companies ever had or may have at any time through the
Release Date. The Companies acknowledge and agree that this Release is intended
to and does cover, but is not limited to, (i) any claim, whether statutory,
common law or otherwise, arising out of the terms or conditions of the
Executive’s employment at or service to the Companies and/or the Executive’s
separation from the Companies, and (ii) any claim for attorneys’ fees, costs,
disbursements or other like expenses. The enumeration of specific rights, claims
and causes of action being released shall not be construed to limit the general
scope of this Release. It is the intent of the parties that by this Release the
Companies are giving up all of their respective rights, claims and causes of
action occurring prior to the Release Date, whether or not any damage or injury
therefrom has yet occurred. The Companies accept the risk of loss with respect
to both undiscovered claims and with respect to claims for any harm hereafter
suffered arising out of conduct, statements, performance or decisions occurring
before the Release Date. 

4. This
Release shall in no event (i) apply to any claim by either the Executive or the
Companies arising from any breach by
the other party of its obligations under the Employment Agreement occurring on
or after the Release Date, (ii) waive the Executive’s claim with respect to
compensation or benefits earned or accrued prior to the Release Date to the
extent such claim survives termination of the Executive’s employment under the
terms of the Employment Agreement, (iii) waive the Executive’s right to
indemnification under the charters and by-laws of the Companies, or (iv) waive
the Executive’s rights as a shareholder. 

5. This
Mutual Release shall be effective as of the Release Date and only if executed by
both parties. 

6. All
questions concerning the construction, validity and interpretation of this
Mutual Release will be governed by
the internal law of North Carolina, without regard to principles of conflict of
laws. 

2 

IN WITNESS WHEREOF, each
party hereto, intending to be legally bound, has executed this Mutual Release on
the date indicated above. 

		KRISPY KREME DOUGHNUTS, INC.
		 
		 
		By:       	
			Tony
      Thompson
			Chief Executive Officer
		 
		 
	 	KRISPY KREME DOUGHNUT CORPORATION
		 
		 
		By:	
			Cathleen D. Allred
			Senior Vice President Human Resources
			and
      Organizational Development
		 
		 
		EXECUTIVE
		 
		            
			
			Thomas
      Kuharcik

3 

Exhibit
B 

The following businesses,
together with their Subsidiaries, Affiliates and successors in interest, are the
businesses for purposes of Section 9.01 hereof: 

	             
      	Dunkin Brands Inc.
		Tim Hortons, Inc.
		George Weston Limited
		Flowers Foods, Inc.
		McKee Foods Corporation
		Starbucks
		Dewey’s Bakery
		Salem Baking Company
		Dawn Food Products, Inc.
	 	CSM Baking Products
		Bimbo Bakeries USA, Inc.
		Hostess Brands, LLC
		Panera Bread Company
		Sysco Corp

And any other business that
derives more than fifty percent (50%) of its revenues from the indirect or
direct sale of coffee, doughnuts and/or bakery or sweet goods.Exhibit 10.1

 

 

Portions of this
exhibit have been omitted pursuant to a request for confidential

treatment pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b).

The omitted portions, marked by [***], have been separately filed with the Securities and Exchange Commission.

 

 

 

AMENDED AND RESTATED

EXCLUSIVE LICENSE AND SUPPLY AGREEMENT

 

by and between

 

PFIZER INC.

 

and

 

PROTALIX LTD. 

 

October 12, 2015

 

     

     

    

 

TABLE OF CONTENTS

	 	 	Page
	 	 	 
	Section 1.	DEFINITIONS	1
	 	 	 
	Section 2.	[INTENTIONALLY OMITTED]	12
	 	 	 
	Section 3.	LICENSE	12
	 	 	 
	3.1	Exclusive License	12
	 	 	 
	3.2	Other License Provisions	13
	 	 	 
	3.4	Sublicensing and Subcontracting	13
	 	 	 
	3.5	Improvements	14
	 	 	 
	3.6.	No Implied License; Brazil Activities	14
	 	 	 
	Section 4.	REGULATORY APPROVALS AND MARKETING	15
	 	 	 
	4.1	Regulatory Affairs	15
	 	 	 
	4.2	Commercialization and Pricing	21
	 	 	 
	4.3	Protalix Trademarks	22
	 	 	 
	4.4	Pfizer Trademarks	22
	 	 	 
	4.5	Use of Names	24
	 	 	 
	4.6	Access to Information	25
	 	 	 
	4.7	Transition Assistance	25
	 	 	 
	4.8	Records	26
	 	 	 
	Section 5.	MANUFACTURE AND SUPPLY.	26
	 	 	 
	5.1	Supply Chain Committee	26
	 	 	 
	5.2	Capacity	27
	 	 	 
	5.3	Development Supply of Drug Substance	28
	 	 	 
	5.4	Commercial Supply of Drug Substance	28
	 	 	 
	5.5	Supply Term	28
	 	 	 
	5.6	Forecasting and Ordering	29
	 	 	 
	5.7	Pricing and Invoicing	30
	 	 	 
	5.8	Shipping and Delivery	30
	 	 	 
	5.9	Compliance; Quality Control Obligations	31
	 	 	 
	5.10	Certificate of Analysis; Acceptance and Returns	31
	 	 	 
	5.11	Product Specification and Manufacturing Changes	33

 

    	 	ii	 

     

    

  

	5.12	Change Control	33
	 	 	 
	5.13	Practices	33
	 	 	 
	5.14	Pest Control	33
	 	 	 
	5.15	Records and Audits	33
	 	 	 
	5.16	Quality Assurance	34
	 	 	 
	5.17	Technical Support	34
	 	 	 
	5.18	Technical Assistance; Facility Access	34
	 	 	 
	5.19	Other Assistance by Pfizer	34
	 	 	 
	5.20	Master Cell Bank	35
	 	 	 
	5.23	Manufacturing Transition Assistance	35
	 	 	 
	Section 6.	FINANCIAL PROVISIONS	35
	 	 	 
	6.1	Second Amendment Effective Date Payment	35
	 	 	 
	6.2	Deferred Payment	36
	 	 	 
	6.3	Payments With Respect to Commercialization in Israel	36
	 	 	 
	6.4	Payments With Respect to Commercialization in Brazil	36
	 	 	 
	6.5	Release of Payment Obligations	36
	 	 	 
	Section 7.	ACCOUNTING AND PROCEDURES FOR PAYMENT	36
	 	 	 
	7.1	Currency	36
	 	 	 
	7.2	Method of Payments	36
	 	 	 
	7.3	Tax Matters	37
	 	 	 
	Section 8.	PATENTS AND INFRINGEMENT	38
	 	 	 
	8.1	Filing and Prosecution	38
	 	 	 
	8.2	Correspondence	38
	 	 	 
	8.3	Maintenance	39
	 	 	 
	8.4	Notices and Encumbrances	39
	 	 	 
	8.5	Patent Term Extensions	40
	 	 	 
	8.6	Third Party Infringement	40
	 	 	 
	8.7	Paragraph IV Notices	41
	 	 	 
	8.8	Other Actions by a Third Party	41
	 	 	 
	8.9	Compensation to Inventors	42
	 	 	 
	8.10	Patent Marking	42
	 	 	 
	8.11	In-Licensed Patents	42

 

    	 	iii	 

     

    

  

	Section 9.	CONFIDENTIALITY; PUBLICATION	42
	 	 	 
	9.1	Confidential Information	42
	 	 	 
	9.2	Permitted Disclosure of Confidential Information	42
	 	 	 
	9.3	Publication	44
	 	 	 
	9.4	Publicity	44
	 	 	 
	9.5	Filing, Registration or Notification of the Agreement	45
	 	 	 
	Section 10.	REPRESENTATIONS, WARRANTIES AND COVENANTS	46
	 	 	 
	10.1	Protalix Representations, Warranties and Covenants	46
	 	 	 
	10.2	Manufacturing Representations, Warranties and Covenants	50
	 	 	 
	10.3	Environmental Representations, Warranties and Covenants	52
	 	 	 
	10.4	Pfizer Representations, Warranties and Covenants	53
	 	 	 
	10.5	Disclaimer of Warranty	54
	 	 	 
	Section 11.	ADDITIONAL COVENANTS	54
	 	 	 
	11.1	Restrictions on Transfers and Liens	54
	 	 	 
	11.2	Third Party Licenses and Agreements	55
	 	 	 
	11.3	Compliance with Laws	55
	 	 	 
	11.4	Coordination outside the Territory	55
	 	 	 
	11.5	Protalix Non-Compete	55
	 	 	 
	11.6	Limitation on Non-Compete Restrictions	55
	 	 	 
	Section 12.	[Reserved.]	55
	 	 	 
	Section 13.	TERM	55
	 	 	 
	Section 14.	TERMINATION	56
	 	 	 
	14.1	Pfizer Termination Right for Convenience	56
	 	 	 
	14.2	Pfizer Termination Right for Breach	56
	 	 	 
	14.3	Protalix Right of Termination	56
	 	 	 
	14.4	Continuing and Accrued Obligations and Surviving Provisions	56
	 	 	 
	14.5	Effects of Termination or Expiration	57
	 	 	 
	14.6	Bankruptcy	57
	 	 	 
	Section 15.	INDEMNIFICATION AND INSURANCE	58
	 	 	 
	15.1	Indemnification	58
	 	 	 
	15.2	Losses	59

 

    	 	iv	 

     

    

  

	15.3	Defense Procedures; Procedures for Third Party Claims	60
	 	 	 
	15.4	Disclaimer of Liability for Consequential Damages	60
	 	 	 
	15.5	Sole Remedy	61
	 	 	 
	15.6	Insurance Requirements	61
	 	 	 
	Section 16.	[RESERVED.]	63
	 	 	 
	Section 17.	GOVERNING  LAW AND JURISDICTION	63
	 	 	 
	17.1	Governing Law	63
	 	 	 
	17.2	Jurisdiction	64
	 	 	 
	Section 18.	MISCELLANEOUS	64
	 	 	 
	18.1	Force Majeure	64
	 	 	 
	18.2	Severability	64
	 	 	 
	18.3	Waivers	64
	 	 	 
	18.4	Entire Agreements; Amendments	65
	 	 	 
	18.5	Survival	65
	 	 	 
	18.6	Assignment; Binding Effect	65
	 	 	 
	18.7	Divestiture	66
	 	 	 
	18.8	Independent Contractor	66
	 	 	 
	18.9	Notices	66
	 	 	 
	18.10	Third Party Beneficiaries	67
	 	 	 
	18.11	Binding Effect	67
	 	 	 
	18.12	Performance by Affiliates	67
	 	 	 
	18.13	Corporate Integrity Agreement	68
	 	 	 
	18.14	Counterparts	68
	 	 	 
	18.15	Headings	68
	 	 	 
	18.16	Equitable Remedies	68

 

EXHIBITS

 

		·	EXHIBIT A – AMINO ACID SEQUENCE FOR DRUG SUBSTANCE

		·	EXHIBIT B – PROTALIX PATENT RIGHTS

		·	EXHIBIT C – THIRD PARTY LICENSES

		·	EXHIBIT D – BRAZIL Uplyso Trademarks

		·	EXHIBIT E – IMPORTATION AUTHORIZATION

 

    	 	v	 

     

    

  

		·	EXHIBIT F – TRANSITION PLAN 

		·	Exhibit g – PERSISTENT FAILURE
TO SUPPLY promissory note

		·	EXHIBIT H – PROTALIX PAYMENT PROMISSORY NOTE

		·	EXHIBIT I – PRESS RELEASE

		·	EXHIBIT J – [***] LETTER AGREEMENT COMPLIANCE CERTIFICATE

		·	EXHIBIT K – cOMPLIANCE CERTIFICATE

		·	exhibit l – Audit Completion CertificatION

 

APPENDICES

 

Appendix 4.1(g) – Regulatory Approvals for the Licensed Product
in the Field in the Territory

 

Appendix 7.2(a) – Protalix Account Information

 

Appendix 7.2(b) – Pfizer Account Information

 

Appendix 10.1(t) – Pfizer’s Anti-Bribery and Anti-Corruption
Principles

 

[***] Redacted pursuant to confidential treatment request.

 

 

    	 	vi	 

     

    

 

AMENDED AND RESTATED EXCLUSIVE
LICENSE AND SUPPLY AGREEMENT

 

This Amended and Restated Exclusive License
and Supply Agreement (this “Agreement”) dated as of October 12, 2015 (the “Second Amendment Effective
Date”) between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located
at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel (“Protalix”), and Pfizer Inc., a Delaware
corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. (“Pfizer”).

 

WHEREAS, Protalix and Pfizer are parties to
that certain Exclusive License and Supply Agreement (the “Original Agreement”) dated November 30, 2009, pursuant
to which Protalix provided Pfizer with an exclusive license in all countries of the world other than Israel to certain patents,
patent applications, technology, know how and scientific and technical information relating to an enzyme replacement therapy for
the treatment of Gaucher Disease;

 

WHEREAS, Protalix and Pfizer amended the Original
Agreement pursuant to the Amendment to the Exclusive License and Supply Agreement (the “First Amendment” and,
the Original Agreement as amended by the First Amendment, the “Amended Agreement”) dated June 18, 2013 (the
“Amendment Effective Date”) pursuant to which the parties amended the territory and other terms with respect
to Brazil; and

 

WHEREAS, Protalix and Pfizer wish to further
amend and also restate in its entirety the Amended Agreement (including, for the avoidance of doubt, the First Amendment) to modify
the territory and make such other changes as set forth herein, with the effect that the Original Agreement and First Amendment
shall be superseded hereby.

 

NOW, THEREFORE, in consideration of the mutual
covenants and agreements provided herein, Protalix and Pfizer hereby agree that the Amended Agreement is hereby amended
and restated in its entirety to read as follows:

 

Section
1.             DEFINITIONS

 

For purposes of this Agreement, the following
definitions shall be applicable:

 

1.1          “Affiliate”
means any entity directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but
only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative
meanings, “controlled by”, “controlling” and “under common control with”) means (a) possession,
direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership
of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of at least 50% of the voting
securities or other ownership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other
comparable equity interests of an entity, it being understood and agreed that for purposes of clause (a), neither ownership of
voting securities or other ownership interests of an entity nor membership or representation on (if less than half of the members
of) an entity’s board of directors shall, by themselves, be presumed to constitute the power to direct or cause direction
of the management or policies of such entity. With respect to the grant of license rights by Protalix to Pfizer under Section
3, “Affiliate” shall exclude any Third Party that becomes an Affiliate due to such Third Party’s acquisition
of Protalix.

 

     

     

    

  

1.2          “Allocation
Percentage” shall have the meaning assigned to it in Section 5.2(c).

 

1.3          “Amended
Agreement” shall have the meaning assigned to it in the Recitals.

 

1.4          “Amendment
Effective Date” shall have the meaning assigned to it in the Recitals.

 

1.5          [***]

 

1.6          “Brazil
Activities” shall have the meaning assigned to it in Section 3.6(b).

 

1.7          “Brazil
Uplyso Trademark” means the trademark “UPLYSOTM” registered in Brazil, as set forth in Exhibit D,
as such Exhibit D may be updated by mutual agreement of the parties within thirty (30) days following the Second Amendment
Effective Date.

 

1.8          “Business
Associates” shall have the meaning assigned to it in Appendix 10.1(t).

 

1.9          “Business
Day” means a day other than a Saturday, Sunday, or bank or other public holiday in New York, New York.

 

1.10        “Capacity
Cap” shall have the meaning assigned to it in Section 5.2(c).

 

1.11        “Capacity
Expansion Project” shall have the meaning assigned to it in Section 5.2(b).

 

1.12        “Change
of Control” means any transaction or series of related transactions that would occasion: (a) any share exchange, re-capitalization,
business combination, consolidation, merger, or other transaction or series of transactions resulting in the exchange of the outstanding
shares of a party, unless the stockholders of a party that exist immediately prior to the closing date of such transaction (or
series of related transactions) hold, after the closing date, more than fifty percent (50%) of the voting securities or other similar
interest of the surviving entity in such transaction computed on a fully diluted basis; (b) a sale, lease, or other transfer of
all or substantially all of the stock or assets of a party; (c) any tender offer or exchange offer for fifty percent (50%) or more
of the outstanding voting securities or other similar interest of a party or the filing of a registration statement under the United
States Securities Act of 1933, as amended, in connection therewith; or (d) any Person or group acting in concert having acquired
beneficial ownership or the right to acquire beneficial ownership of fifty percent (50%) or more of the outstanding voting securities
or similar interest of a party.

 

1.13        “Commercialization”
means, with respect to a product or compound (including any Compound, Licensed Product, Drug Substance or Competing Product), any
activities directed to and including marketing, promoting, distributing, offering for sale and selling such product or compound,
importing such product or compound (to the extent applicable) and conducting [***]. When used as a verb, “Commercialize”
means to engage in Commercialization.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	2	 

     

    

  

1.14        “Commercially
Reasonable Efforts” means, with respect to the efforts to be expended by a party with respect to the objective that is
the subject of such efforts, reasonable, good faith efforts and resources to accomplish such objective that such party would normally
use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the Development
or Commercialization of the Licensed Product in the Territory by Pfizer, such efforts shall be similar to those efforts and resources
consistent with the usual practice of Pfizer in pursuing the Development or Commercialization of drug products owned by it or to
which it otherwise has rights that are of similar market potential as a Licensed Product in the Territory, taking into account
all relevant factors, including the orphan drug status (if any) of the Licensed Product and other regulatory matters, safety and
efficacy matters, product labeling or anticipated labeling, pricing, present and future market potential, past performance of the
Licensed Product, past performance of Pfizer’s own drug products that are of similar market potential (taking into account
that the Licensed Product is intended for the treatment of a rare disease), financial return [***], medical and clinical considerations,
present and future regulatory environment and competitive market conditions, all as measured by the facts and circumstances at
the time such efforts are due. It is anticipated that the level of effort constituting Commercially Reasonable Efforts may change
over time.

 

1.15        “Competing
Product” means [***]

 

1.16        “Compliance
Questionnaire” shall have the meaning assigned to it in Section 10.1(s).

 

1.17        “Compound”
means (a) prGCD and (b) any analogs, derivatives and variants thereof.

 

1.18        “Confidential
Information” means the Protalix Confidential Information or the Pfizer Confidential Information, as applicable.

 

1.19        “Control”
or “Controlled” means, with respect to any compound, material, information, or intellectual property right,
that a party owns or has a license to use, commercialize, manufacture, market, distribute or sell, and has the ability to grant
to the other party access and/or a license or a sublicense (as applicable under this Agreement) to such compound, material, information,
or intellectual property right as provided for herein without violating (a) the terms of any agreement or other arrangements
with any Third Party existing before or after the Second Amendment Effective Date or (b) any law or governmental regulation applicable
to such license or sublicense.

 

1.20        “Country”
means any generally recognized sovereign entity.

 

1.21        “Court”
shall have the meaning assigned to it in Section 17.2.

 

1.22        “Development”
or “Develop” means conducting pre-clinical studies and clinical trials, collecting, validating and analyzing
pre-clinical and clinical trial data, preparing and submitting regulatory filings, obtaining Regulatory Approvals, and regulatory
affairs related to the foregoing. When used as a verb, “Develop” means to engage in Development. For clarity, Development
does not include Phase 4 Trials or any of the foregoing in connection therewith.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	3	 

     

    

  

1.23        “Divestiture”
shall have the meaning assigned to it in Section 18.7.

 

1.24        “Drug
Substance” means the Compound component of a pharmaceutical drug product.

 

1.25        “Early
Access Program” means any program to provide patients with the Licensed Product prior to Regulatory Approval and prior
to Launch in any Country in the Territory. Early Access Programs include treatment INDs / protocols in the United States, named
patient programs in the EU and compassionate use programs in other Countries in the Territory.

 

1.26        “Effective
Date” means the date of the Original Agreement.

 

1.27        “EMEA”
means the European Agency for the Evaluation of Medicinal Products or any successor agency thereto.

 

1.28        “Environmental
Laws” means all applicable Laws relating to (a) safety (including occupational health and safety); conservation, preservation
or protection of human health, drinking water, natural resources, biota and the environment; (b) the generation, use, storage,
handling, treatment, transportation or disposal of Hazardous Materials or Waste, (c) Releases and threatened Releases of Hazardous
Materials, or (d) chemical classification and labeling.

 

1.29        “Environmental
Permits” shall have the meaning assigned to it in Section 10.3(a)(ii).

 

1.30        “European
Union” or “EU” means the Countries that are members of the European Union as of the Effective Date
or that become members of the European Union thereafter.

 

1.31        “Expansion
Costs” shall have the meaning assigned to in Section 5.2(b).

 

1.32        “Facility”
means, as applicable, a party’s Manufacturing facility and such other facilities used by such party (or its Affiliates) in
the Manufacture or storage of (a) Drug Substance, (b) Licensed Product or (c) materials utilized in the Manufacture of Drug Substance
or Licensed Product.

 

1.33        “Failure
to Supply” shall have the meaning assigned to it in Section 5.21(a).

 

1.34        “FCPA”
shall have the meaning assigned to it in Appendix 10.1(t).

 

1.35        “FDA”
means the United States Food and Drug Administration or any successor agency thereto.

 

1.36        “FDCA”
means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder.

 

1.37        “Field”
means enzyme replacement therapy for the treatment of Gaucher Disease.

 

    	 	4	 

     

    

  

1.38        “Fill/Finish”
means (a) formulating the Licensed Product using Drug Substance and other excipients, (b) filling the Licensed Product into vials,
(c) lyophilization of the Drug Substance for incorporation into the Licensed Product, and (d) testing, including ongoing stability
testing, and release of the Licensed Product. For the avoidance of doubt, Fill/Finish shall not include any activities included
in the definition of Labeling and Packaging.

 

1.39        “Fiocruz”
means Fundação Oswaldo Cruz, an agency of the Brazilian Ministry of Health organized under the Laws of Brazil.

 

1.40        “First
Amendment” shall have the meaning assigned to it in the Recitals.

 

1.41        “Force
Majeure Event” shall have the meaning assigned to it in Section 18.1.

 

1.42        “Forecast”
shall have the meaning assigned to it in Section 5.6(a).

 

1.43        “FTE
Rate” means [***] per full time equivalent person engaged in scientific, regulatory, process development, manufacturing
or other similar work, consisting of [***] hours per year of such qualified work.

 

1.44        “GAAP”
means United States generally accepted accounting principles consistently applied.

 

1.45        “Good
Manufacturing Practices” or “GMP” means all applicable Good Manufacturing Practices including, (i)
the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the
quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals
and guidelines of good manufacturing practice, (ii) the principles detailed in the U.S. Current Good Manufacturing Practices, 21
C.F.R. Sections 210, 211, 601 and 610, (iii) the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing
Practice for Medicinal Products, (iv) the principles detailed in the ICH Q7A guidelines, and (v) the equivalent Laws in any relevant
Country, each as may be amended and applicable from time to time.

 

1.46        “Government
Official” shall have the meaning assigned to it in Section 10.1(r).

 

1.47        “Governmental
Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city
or other political subdivision.

 

1.48        “Hazardous
Materials” means any and all materials (including substances, chemicals compounds, mixtures, products, byproducts, biologic
agents, living or genetically modified materials, wastes, pollutants and contaminants), that are (a) (i) listed, classified, characterized
or regulated pursuant to Environmental Laws; (ii) identified or classified as “hazardous”, “dangerous”,
“toxic”, “pollutant”, “contaminant”, “waste”, “irritant”, “corrosive”,
“flammable”, “radioactive”, “reactive”, “carcinogenic”, “mutagenic”,
“bioaccumulative”, or “persistent” in the environment; or (iii) in quantity or concentration capable of
causing harm or injury to human health, natural resources or the environment, if Released or resulting in human exposure; or (b)
petroleum products and their derivatives, asbestos-containing material, lead-based paint, polychlorinated biphenyls, urea formaldehyde,
or viral, bacterial or fungal material.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	5	 

     

    

  

1.49        “Improvement
Notice” shall have the meaning assigned to in Section 3.5.

 

1.50        “Increased
Capacity Cap” shall have the meaning assigned to it in Section 5.2(b).

 

1.51        “IND”
means an investigational new drug application filed with the FDA in accordance with the FDCA with respect to a drug product or
an analogous application or filing with any Regulatory Authority outside of the United States (including any supra-national agency
such as the European Union) for the purpose of commencing clinical development of a drug product in such jurisdiction.

 

1.52        “Indemnified
Party” shall have the meaning assigned to it in Section 15.3(a).

 

1.53        “Indemnifying
Party” shall have the meaning assigned to it in Section 15.3(a).

 

1.54        “Initial
Forecast” shall have the meaning assigned to it in Section 5.6(a).

 

1.55        “Inventories”
shall have the meaning assigned to it in Section 4.2(c).

 

1.56        “Israel
Grant” shall have the meaning assigned to it in Section 10.1(i).

 

1.57        “IU”
shall have the meaning assigned to it in Section 5.7(a).

 

1.58        “Labeling
and Packaging” means the final product labeling and packaging of the Licensed Product (whether in commercial or clinical
packaging presentation), including materials to be inserted such as patient inserts, patient medication guides, professional inserts
and any other written, printed or graphic materials accompanying the Licensed Product.

 

1.59        “Launch”
means the first shipment of a Licensed Product in commercial quantities for commercial sale by Pfizer, its Affiliates or its Sublicensees
to a Third Party in a Country in the Territory after receipt by Pfizer of the first Regulatory Approval (and, in any Country in
which Price Approval is necessary or relevant for a majority of the population to obtain access to drug products, Price Approval)
for such Licensed Product in such Country.

 

1.60        “Laws”
means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or
ordinances of any Governmental Authority, and common law or other legal requirements of any kind, whether currently in existence
or hereafter promulgated, enacted, adopted or amended.

 

1.61        “Licensed
Product” means any finished dosage form of a drug product that contains Drug Substance (excluding any Oral Formulation)
and either: (a) the manufacture, sale, offer for sale, importation, or use of such drug product (i) would, absent the license granted
by Protalix to Pfizer herein, infringe at least one Valid Claim of a Protalix Patent Right, or (ii) embodies, incorporates or uses
Protalix Technology; or (b) such drug product is supplied by Protalix to Pfizer under this Agreement (or is manufactured using
Drug Substance supplied by Protalix to Pfizer under this Agreement) or is manufactured by Pfizer or a Third Party (or is manufactured
using Drug Substance manufactured by Pfizer or a Third Party).

 

1.62        “Long
Range Forecast” shall have the meaning assigned to it in Section 5.6(b).

 

    	 	6	 

     

    

  

1.63        “Losses”
shall have the meaning assigned to it in Section 15.2.

 

1.64        “Manufacture”
or “Manufacturing” means all activities related to the manufacturing of the Drug Substance or Licensed Product,
and/or any ingredient thereof, including manufacturing for clinical use or commercial sale, in-process and finished product testing,
Fill/Finish, Labeling and Packaging, release of product, quality assurance activities related to manufacturing and release of product
and ongoing stability tests and regulatory activities related to any of the foregoing.

 

1.65        “Manufacturing
Certificate of Analysis” shall have the meaning assigned to it in Section 5.10(a)(i).

 

1.66        “Manufacturing
Transition Plan” shall have the meaning assigned to it in Section 5.23.

 

1.67        “Minimum Delivery Requirements”
shall have the meaning assigned to it in Section 5.21(a).

 

1.68        “Minimum
Shelf Life” shall have the meaning assigned to it in Section 5.8(b).

 

1.69        “NDA”
means a New Drug Application filed with the FDA in accordance with the FDCA with respect to a drug product or an analogous application
or filing with any Regulatory Authority outside of the United States (including any supra-national agency such as the European
Union) for the purpose of obtaining approval to market and sell a drug product in such jurisdiction.

 

1.70       
“Notice of Non-Conformance” shall have the meaning assigned to it in Section 5.10(a)(ii).

 

1.71        “Oral
Formulation” means an oral formulation of a drug product for the treatment of Gaucher Disease which contains any Compound
as the active pharmaceutical ingredient.

 

1.72        “Original
Agreement” shall have the meaning assigned to it in the Recitals.

 

1.73        “Outside
of the Scope Product” shall have the meaning assigned to it in Section 8.2.

 

1.74        “Patent
Application” means any application for a Patent.

 

1.75        “Patent Challenge”
has the meaning assigned to it in Section 3.7(a).

 

1.76        “Patent
Rights” means Patents and Patent Applications.

 

1.77        “Patents”
means issued patents, whether domestic or foreign, including all continuations, continuations-in-part, divisions, provisionals
and renewals, and letters of patent granted with respect to any of the foregoing, patents of addition, supplementary protection
certificates, registration or confirmation patents and all reissues, re-examination and extensions thereof.

 

    	 	7	 

     

    

  

1.78        “Persistent
Failure to Supply” shall have the meaning assigned to it in Section 5.21(b).

 

1.79        “Person”
means an individual, corporation, partnership, company, joint venture, unincorporated organization, limited liability company or
partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any Governmental
Authority.

 

1.80        “Pfizer
Confidential Information” means all information relating to the Compound or Licensed Product, as well as any other information
regarding the business and operations of Pfizer, that is or has been disclosed (whether orally or in writing) by Pfizer to Protalix
or its Affiliates to the extent that such information is not: (a) as of the date of disclosure known to Protalix or its Affiliates;
or (b) disclosed in published literature, or otherwise generally known to the public through no breach by or Protalix; of this
Agreement or (c) obtained by Protalix or its Affiliates from a Third Party free from any obligation of confidentiality to Pfizer;
or (d) independently developed by Protalix or its Affiliates without use of the Pfizer Confidential Information; or (e) in the
good faith judgment of Protalix, after consultation with legal counsel, is required to be disclosed under Law; provided that,
in the case of (e), Protalix provides Pfizer prior notice (to the extent practicable) of such disclosure and agrees to cooperate,
at the request and sole expense of Pfizer, with Pfizer’s efforts to preserve the confidentiality of such information.

 

1.81        “Pfizer
Improvements” has the meaning assigned to it in Section 3.6(d).

 

1.82        “Pfizer
Payment” has the meaning assigned to it in Section 6.1.

 

1.83        “Phase
4 Trial” means a clinical trial for the Licensed Product that is initiated in a Country after receipt of Regulatory Approval
for the Licensed Product in such Country and is principally intended to support the marketing and Commercialization of the Licensed
Product, including investigator initiated trials and clinical experience trials. “prGCD” means a plant cell
expressed recombinant human Glucocerebrosidase enzyme having the sequence set forth in Exhibit A to this Agreement.

 

1.84        “Presentation”
means [***].

 

1.85        “Price”
means the price Pfizer pays to Protalix per IU of Drug Substance manufactured for and shipped to Pfizer.

 

1.86        “Price
Approval” means, in any Country where a Governmental Authority authorizes reimbursement for, or approves or determines
pricing for, drug products, receipt (or, if required to make such authorization, approval or determination effective, publication)
of such reimbursement authorization or pricing approval or determination (as the case may be).

 

1.87        “Product
Mark” shall have the meaning assigned to in Section 4.4(b).

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	8	 

     

    

  

1.88        “Product
Specifications” means those Manufacturing, performance, quality - control release, and Fill/Finish specifications for
Drug Substance or Licensed Product in the Territory, which are initially as set forth in the applicable Regulatory Approval for
a Licensed Product, as such specifications may be amended from time to time pursuant to the terms of this Agreement.

 

1.89        “Proposed Transaction”
shall have the meaning assigned to it in Section 11.7.

 

1.90        “Protalix
Confidential Information” [***]

 

1.91        “Protalix
Improvement” means any necessary or useful improvement, change, or modification to the Drug Substance, Licensed Product
or Protalix Technology which may be developed, created, or acquired by Protalix after the Effective Date and before termination
of this Agreement, including new or improved methods of Manufacturing, means of delivery (other than an Oral Formulation), dosage,
formulation (other than an Oral Formulation), and analysis. To the extent an improvement, change or modification to prGCD also
constitutes an analog, derivative or variant of prGCD, such improvement, change or modification shall be deemed to be a Compound
and not a Protalix Improvement.

 

1.92        “Protalix
Patent Rights” [***]

 

1.93        “Protalix
Payment” has the meaning assigned to it in Section 6.2.

 

1.94        “Protalix
System Patent Rights” means Protalix Patent Rights that relate primarily to the System.

 

1.95        “Protalix
Technology” means any Technology owned or otherwise Controlled by Protalix or any of its Affiliates as of the Second
Amendment Effective Date or at any time during the Term that is necessary or useful for the Development, Manufacture, use or Commercialization
of Compound, Drug Substance or a drug product that contains Drug Substance, including the System.

 

1.96        “Protalix Withholding Tax
Action” has the meaning assigned to in Section 7.3(c)(iii).

 

1.97        “Purchase
Order” shall have the meaning assigned to it in Section 5.6(a).

 

1.98        “Quality
Agreement” means the Quality Agreement entered into between Protalix and Pfizer, dated January 4, 2011, with respect
to the Drug Substance being Manufactured by Protalix [***] in the Territory.

 

1.99        “Redacted
Agreement” shall have the meaning assigned to it in Section 9.5.

 

1.100      “Regulatory Approval”
means any and all approvals, with respect to any Country, or authorizations (other than Price Approvals) of a Regulatory Authority,
that are necessary for the commercial Manufacture, distribution, use, marketing or sale of a drug product in such Country.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	9	 

     

    

  

1.101      “Regulatory Authority”
means, in respect of a particular Country or jurisdiction, the Governmental Authority having responsibility for granting Regulatory
Approvals in such Country or jurisdiction.

 

1.102      “Regulatory Exclusivity”
means any rights or protections which are recognized, afforded or granted by a Regulatory Authority in any Country or region of
the Territory, in association with the Regulatory Approval of a Licensed Product, providing such Licensed Product: (a) a period
of marketing exclusivity, during which the Regulatory Authority recognizing, affording or granting such marketing exclusivity will
refrain from either reviewing or approving a marketing authorization application or similar regulatory submission, submitted by
a party other than Pfizer, its Affiliates or Sublicensees seeking to market a drug product in which the Drug Substance is the primary
ingredient, or during which such an application or submission may be reviewed or approved by a Regulatory Authority, but the product
may not be placed on the market or (b) a period of data exclusivity, during which a party, other than Pfizer, its Affiliates or
Sublicensees, seeking to market a drug product in which the Drug Substance is the primary ingredient, is precluded from either
referencing or relying upon a Licensed Product’s clinical dossier or relying on previous findings of safety or effectiveness
with respect to a Licensed Product to support the submission, review or approval of a marketing authorization application or similar
regulatory submission before the applicable Regulatory Authority. Regulatory Exclusivity shall include rights conferred in the
United States pursuant to the Hatch-Waxman Act or the FDA Modernization Act of 1997 or in the European Union/European Economic
Area pursuant to Section 10.1 of Directive 2001/EC/83 or section 14.11 of Regulation (EC) No. 726/2004.

 

1.103      “Release” means
any release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, leaching or migration into
the indoor or outdoor environment, including the uncontrolled presence or the movement of Hazardous Materials through the ambient
air, soil, subsurface water, groundwater, wetlands, lands or subsurface strata.

 

1.104      “Released Obligations”
has the meaning assigned to it in Section 6.5.

 

1.105      “Resulting Companies”
shall have the meaning assigned to it in Section 18.7(a).

 

1.106      “Second Amendment Effective
Date” shall have the meaning assigned to it in the Recitals.

 

1.107      “Sublicense” means
the grant by Pfizer of a sublicense under, or an agreement of Pfizer not to assert, any of the rights licensed by Protalix to Pfizer
pursuant to Section 3.1.

 

1.108      “Sublicensee” means
a Third Party to whom Pfizer has granted a Sublicense.

 

1.109      “Supply Term” shall
have the meaning assigned to it in Section 5.5.

 

1.110      “System” means Protalix’s
proprietary protein expression system, ProCellExTM.

 

1.111      “Technology” means
proprietary materials, technology, data, results and non-public technical, scientific and clinical information, in any tangible
or intangible form, including know-how, expertise, trade secrets, practices, techniques, methods, processes, developments, specifications,
formulations, formulae, including any intellectual property rights embodying any of the foregoing, but excluding any Patent Rights.

 

    	 	10	 

     

    

  

1.112      “Technology Transfer Agreement”
means the Technology Transfer and Supply Agreement between Protalix and Fiocruz, dated June 18, 2013.

 

1.113      “Term” shall have
the meaning assigned to it in Section 13.

 

1.114      “Territory” means
the entire world, excluding Brazil.

 

1.115      “Third Party” means
any Person other than Pfizer, Protalix, or any of their respective Affiliates.

 

1.116      “Third Party Claim”
shall have the meaning assigned to it in Section 15.3.

 

1.117      “Third Party License”
means each license agreement between Protalix and a Third Party set forth on Exhibit C pursuant to which or from which Protalix
licenses Protalix Patent Rights or Protalix Technology.

 

1.118      “Transition Manager”
shall have the meaning assigned to it in Section 4.7(a).

 

1.119      “Transition Period”
shall have the meaning assigned to it in Section 4.7(a).

 

1.120      “Transition Plan”
shall have the meaning assigned to it in Section 4.7(b).

 

1.121      “Transition Team”
shall have the meaning assigned to it in Section 4.7(a).

 

1.122      “Unmatured Note”
shall have the meaning assigned to it in Section 5.21(b)(i).

 

1.123      “Uplyso
Trademarks” means the trademark “UPLYSOTM” in certain countries in the world.

 

1.124      “Valid Claim” means
(a) a claim of an issued and unexpired Patent (including the term of any patent term extension, supplemental protection certificate,
renewal or other extension) which has not been held unpatentable, invalid or unenforceable in a final decision of a court or other
Governmental Authority of competent jurisdiction from which no appeal may be or has been taken, and which has not been admitted
to be invalid or unenforceable through reissue, re-examination or disclaimer; or (b) a claim of a Patent Application, which claim
has been pending less than five (5) years from the original priority date of such claim in a given jurisdiction, unless or until
such claim thereafter issues as a claim of an issued Patent (from and after which time the same shall be deemed a Valid Claim subject
to paragraph (a) above).

 

1.125      [***] means [***].

 

1.126      [***] License Agreement”
means that License Agreement by and between Protalix and [***]effective as of [***], as amended from time to time.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	11	 

     

    

  

1.127      “Waste” means all
wastes which arise from the Manufacture, handling or storage of Drug Substance hereunder, or which is otherwise produced through
the implementation of this Agreement, including Hazardous Materials.

 

1.128      “Work Plan” shall
have the meaning assigned to it in Section 5.2(b).

 

1.129      “[***]

 

Construction. Except where expressly
stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) “include”, “includes”
and “including” are not limiting and mean include, includes and including, without limitation; (b) definitions contained
in this Agreement are applicable to the singular as well as the plural forms of such terms; (c) references to an agreement, statute
or instrument mean such agreement, statute or instrument as from time to time amended, modified or supplemented; (d) references
to a Person are also to its permitted successors and assigns; (e) references to an “Article”, “Section”,
“Exhibit” or “Schedule” refer to an Article or Section of, or any Exhibit or Schedule to, this Agreement
unless otherwise indicated; (f) the word “will” shall be construed to have the same meaning and effect as the word
“shall”; and (g) the word “any” shall mean “any and all” unless otherwise indicated by context.

 

Section
2.             [INTENTIONALLY OMITTED]

 

Section
3.             LICENSE

 

3.1          Exclusive
License. Subject to the terms of this Agreement, including Section 3.2, Protalix hereby grants to Pfizer and Pfizer
hereby accepts an exclusive (even as to Protalix and its Affiliates, except as set forth in Section 3.2), irrevocable, perpetual,
fully-paid (upon Pfizer’s payment of the Pfizer Payment pursuant to Section 6.1 of the Agreement), royalty-free license
in the Territory and within the Field, including the right to Sublicense (subject to Section 3.4):

 

(a)          under
the Protalix Patent Rights to (i) use, sell, offer for sale, supply, cause to be supplied, and import the Licensed Product, (ii)
conduct the Fill/Finish activities and Labeling and Packaging activities, (iii) engage in Development activities with respect to
the Licensed Product, and (iv) make and have made the Drug Substance solely for incorporation in the Licensed Product; and

 

(b)          to
use Protalix Technology and Protalix Confidential Information in connection with (i) the conduct of the Fill/Finish activities
and Labeling and Packaging activities, (ii) preparing and submitting regulatory filings and communicating with Regulatory Authorities
with respect to the Licensed Product, (iii) the use, sale, offer for sale, supply and importation of the Licensed Product, (iv)
Development activities with respect to the Licensed Product, and (v) making and having made the Drug Substance solely for incorporation
in the Licensed Product.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	12	 

     

    

  

3.2          Other
License Provisions.

 

(a)          The
licenses granted to Pfizer pursuant to Section 3.1 shall be co-exclusive with Protalix only to the extent it is necessary
for Protalix to perform its obligations under this Agreement. During the Term, and without limiting the scope of the licenses granted
to Pfizer pursuant to Section 3.1, neither Protalix nor any of its Affiliates shall (i) directly or indirectly, alone or
in collaboration with any Third Party, Commercialize the Compound (other than the Oral Formulation), a drug product containing
the [***]. The parties expressly acknowledge and agree that the exclusivity grant in favor of Pfizer in Section 3.1 shall
not be construed as limiting Protalix’s right to Develop, Manufacture or Commercialize [***]. Notwithstanding anything to
the contrary herein, Protalix may conduct or have conducted Manufacturing activities and engage in or have engaged in Development
activities in Israel at any time in connection with its sale, offer for sale, supply or importation of the Licensed Product outside
the Territory; provided however, that Protalix shall not be permitted to conduct clinical studies of the [***] within Israel
without the prior written consent of Pfizer.

 

(b)          For
purposes of clarity, and without limiting the licenses granted under Section 3.1, Pfizer acknowledges that in the event
Protalix does not have exclusive rights to Protalix Patent Rights licensed by Protalix from Third Parties [***] vis à vis
the Third Party licensor, Pfizer’s rights to such Protalix Patent Rights under the sublicenses granted under Section 3.1
would not be exclusive vis à vis the Third Party licensor.

 

3.3          [***]

 

3.4          Sublicensing
and Subcontracting.

 

(a)          Pfizer
may grant Sublicenses subject to the terms and conditions set forth in this Section 3.4. Any Sublicense obligations required
by the Third Party License to be included in a sublicense shall be deemed to be included in this Agreement as obligations of Pfizer.

 

(b)          Each
Sublicense granted by Pfizer pursuant to Section 3.4(a) shall be subject and subordinate to the terms and conditions of
this Agreement and shall contain terms and conditions consistent with those in this Agreement, and shall not in any way diminish,
reduce or eliminate any of Pfizer’s obligations under this Agreement. Without limiting the foregoing, each Sublicense agreement
with Sublicensees shall contain the following provisions: (i) a requirement that such Sublicensee comply with the confidentiality
and non-use provisions of Section 9 with respect to both parties’ Confidential Information, (ii) a requirement to
comply with all other applicable terms of this Agreement, and (iii) a provision prohibiting such Sublicensee from further sublicensing
unless such further sublicense complies with the terms of this Section 3.4.

 

(c)          Right
to Subcontract. Each party may, subject to Section 9 and Section 3.4(d), subcontract its obligations under this
Agreement to an Affiliate or Third Party as it would in the normal course of its business without the prior written consent of
the other party.

 

(d)          Liability
for Affiliates, Sublicensees and Subcontractors. Each party shall ensure that each of its Affiliates, sublicensees and subcontractors
accepts and complies with all of the applicable terms and conditions of this Agreement as if such Affiliates or sublicensees or
subcontractors were parties to this Agreement and each party shall remain fully responsible for its Affiliates’ and sublicensees’
and subcontractors’ performance under this Agreement.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	13	 

     

    

  

3.5          Improvements.

 

(a)          During
the Term, Protalix shall give written notice (an “Improvement Notice”) to Pfizer within thirty (30) days of
any actual or constructive reduction to practice of any Protalix Improvement. The Improvement Notice shall set forth the nature
and details of the Protalix Improvement and any data obtained or generated by Protalix. Where such Protalix Improvements are to
an invention, Protalix shall state in the Improvement Notice whether it intends to prepare and file patent applications related
thereto. For the avoidance of doubt, the Improvement Notice and its contents shall be deemed Protalix Confidential Information
and subject to the confidentiality provisions set forth in Section 9 hereof.

 

(b)          Each
Protalix Improvement shall be deemed to be included within the Protalix Technology licensed to Pfizer pursuant to Section 3.1
of this Agreement, without the payment of any additional fees, including milestones or royalties. Any Patent Application directed
to a Protalix Improvement shall be considered to be a Protalix Patent Right licensed pursuant to Section 3.1 of this Agreement,
without the payment of any additional fees, including milestones or royalties.

 

3.6.         No
Implied License; Brazil Activities.

 

(a)          Except
for the licenses and other rights granted to Pfizer herein, all right, title and interest in and to the Protalix Patent Rights,
Protalix Technology, Protalix Confidential Information and Protalix Improvements shall remain solely with Protalix and its Third
Party licensors, as applicable. Except as expressly provided in this Section 3 or elsewhere in this Agreement, neither
party will be deemed by this Agreement to have been granted any license or other rights to the other party’s intellectual
property rights, either expressly or by implication, estoppel or otherwise.

 

(b)          Notwithstanding
anything to the contrary in this Agreement, for the avoidance of doubt, Protalix shall have the (i) sole authority and exclusive
right to determine all operating plans and strategies for the Drug Substance and Licensed Product outside the Territory and the
exclusive right to research, Develop or Commercialize the Drug Substance or Licensed Product outside the Territory and to Manufacture
(including Fill/Finish) the Drug Substance or Licensed Product for sale outside the Territory, and (ii) right to enter into, and
perform any of its obligations under, any agreements (including the Technology Transfer Agreement), including sublicenses, relating
to Protalix’s rights in clause (i) of this sentence (collectively, the “Brazil Activities”), without obtaining
any additional consents from Pfizer with respect thereto or having Pfizer participate therein. For the avoidance of doubt, as used
in this Section 3.6(b), the term “Commercialize” includes the activities referred to in Section 1.13
with respect to both Drug Substance and Licensed Product. Without limiting the foregoing, Protalix shall have the right to engage
Third Parties to perform Fill/Finish activities for, and/or supply Licensed Product to, Protalix for sale of such Licensed Product
outside the Territory.

 

    	 	14	 

     

    

  

(c)          Pfizer
acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz (or any other sublicensee of Protalix in Brazil) the
Brazil Uplyso Trademark and any other Product Marks required by applicable Laws to be included on the labeling and packaging of
the finished packaged product for use in the Brazil Activities as they exist on the labeling and packaging of finished packaged
product at the time such finished packaged product is supplied to Fiocruz (or such sublicensee), and subject to the quality control
provisions set forth in the Technology Transfer Agreement (or equivalent provisions in another agreement with the applicable sublicensee),
which shall be at least as protective as those set forth in Section 4.4(d). For the avoidance of doubt, the rights granted
pursuant to this Section 3.6(c) do not include grants to use the name or trade name of Pfizer (other than the right to sublicense
such right to Fiocruz (or any other sublicensee of Protalix in Brazil) to the extent such right is granted to Protalix pursuant
to Section 4.5 or required to be made pursuant to Section 4.4(d)(iv)(B)). Any such right to use such name or trade
name shall be governed by Section 4.5.

 

(d)          Pfizer
acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz any drug product manufacturing-related enhancements
that are specifically directed to, or new presentations of, the Licensed Product developed or otherwise owned by Pfizer or its
Affiliates (“Pfizer Improvements”), pursuant to the Technology Transfer Agreement (or another agreement with
the applicable sublicensee); provided that the Pfizer Improvements are used solely for the Licensed Product by Protalix
and Fiocruz (or the applicable sublicensee). Pfizer agrees to consider in good faith any reasonable requests for technical support
to transfer technical manufacturing information relating solely to the Pfizer Improvement in connection with such sublicense. Such
requests for technical support shall be limited to [***] person hours and should additional technical support be required, Protalix
shall provide to Pfizer a written request for such additional technical support. Protalix shall reimburse Pfizer for all actual
Pfizer costs associated with such technical support, including out-of pocket expenses and documented employee time at the FTE Rate.
For the avoidance of doubt, Pfizer shall be under no obligations to provide any technical support pursuant to this Section 3.6(d).

 

 3.7.         [***]

 

Section
4.             REGULATORY APPROVALS AND MARKETING

 

4.1          Regulatory
Affairs.

 

(a)          Regulatory
Affairs in the Territory other than Israel.

 

(i)          Copies
of Regulatory Filings. The parties acknowledge that Protalix has provided to Pfizer complete copies of all regulatory filings
in the Territory (other than Israel) relating to the Licensed Product, including INDs, filings with the FDA or other Regulatory
Authorities, supplements or amendments thereto, all written correspondence with the FDA or other Regulatory Authorities regarding
such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Protalix (including,
to the extent practicable, Protalix’s investigators) and the FDA or other Regulatory Authorities in Protalix’s possession
(or in the possession of any of Protalix’s agents and subcontractors, such as contract research organizations used by Protalix),
to the extent Protalix had the right to access and provide to Pfizer such materials.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	15	 

     

    

 

 

(ii)         Transfer
of Regulatory Filings. The parties acknowledge that Protalix assigned and transferred to Pfizer (i) Protalix’s entire
right, title and interest in and to the Regulatory Approvals for the Licensed Product in the Field in the Territory (other than
Israel) and (ii) Protalix’s entire right, title and interest in and to any other regulatory filings in the Territory (other
than Israel) with respect to the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding
any such regulatory filings with respect to the Drug Substance as a part of any Oral Formulation), or the Licensed Product, and
any related data.

 

(iii)        Regulatory
Filings. During the Term, and with respect to Israel, following the transfer of ownership of regulatory filings relating to
the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding any regulatory filings
with respect to the Drug Substance as part of any Oral Formulation), or the Licensed Product in Israel, all regulatory filings
with the FDA or other Regulatory Authorities pertaining to the Drug Substance as incorporated into the Licensed Product (and for
the avoidance of doubt, excluding any such regulatory filings with respect to the Drug Substance as part of any Oral Formulation),
or Licensed Product in the Territory shall be made in the name of Pfizer or its Affiliates in accordance with Section 4.1(g).

 

(b)          Regulatory
Affairs in Israel.

 

(i)          Transfer
of Regulatory Filings. Within the timeframe set forth by the Transition Team and to the extent permitted by applicable Law,
(A) Protalix shall assign and transfer to Pfizer, Protalix’s entire right, title and interest in and to all regulatory filings
and Regulatory Approvals in Israel with respect to the Drug Substance or Licensed Product in the Field (and for the avoidance of
doubt, excluding any such regulatory filings or Regulatory Approvals with respect to the Drug Substance as a part of any Oral Formulation),
and any related data, pursuant to instruments to such effect in form and substance reasonably satisfactory to Pfizer, and shall
perform all other actions reasonably requested by Pfizer to effect and confirm such assignment and transfer.

 

(ii)         Copies
of Regulatory Filings. Protalix shall provide to Pfizer, at Pfizer’s expense, complete copies of any regulatory filings
in Israel relating to the Licensed Product, including INDs, NDAs, filings with the Regulatory Authorities, supplements or amendments
thereto, all written correspondence with Regulatory Authorities regarding such regulatory filings, and all existing written minutes
of meetings and memoranda of conversations between Protalix (including, to the extent practicable, Protalix’s investigators)
and Regulatory Authorities in Protalix’s possession (or in the possession of any of Protalix’s agents and subcontractors,
such as contract research organizations used by Protalix), to the extent Protalix has the right to access and provide to Pfizer
such materials. To the extent available, Protalix shall provide such copies to Pfizer in electronic form.

 

(c)          Regulatory
Affairs in Brazil.

 

(i)          Transfer
of Regulatory Filings. Within the timeframe set forth by the Transition Team and to the extent permitted by applicable Laws,
Pfizer shall assign and transfer to Protalix Pfizer’s entire right, title and interest in and to all regulatory filings and
Regulatory Approvals in Brazil with respect to the Drug Substance or Licensed Product, and any related data, pursuant to instruments
to such effect in form and substance reasonably satisfactory to Protalix, and shall perform all other actions reasonably requested
by Protalix to effect and confirm such assignment and transfer.

 

    	 	16	 

     

    

  

(ii)         Copies
of Regulatory Filings. To the extent not already provided by Pfizer, Pfizer shall provide to Protalix, at Protalix’s
expense, complete copies of any regulatory filings in Brazil relating to the Licensed Product, including INDs, NDAs, filings with
the Regulatory Authorities, supplements or amendments thereto, all written correspondence with Regulatory Authorities regarding
such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Pfizer (including,
to the extent practicable, Pfizer’s investigators) and Regulatory Authorities in Pfizer’s possession (or in the possession
of any of Pfizer’s agents and subcontractors, such as contract research organizations used by Pfizer), to the extent Pfizer
has the right to access and provide to Protalix such materials. To the extent available, Pfizer shall provide such copies to Protalix
in electronic form.

 

(d)          Cooperation.
The parties shall cooperate through the Transition Team to ensure that [***]

 

(e)          Rights
of Reference and Access to Data.

 

(i)          [***]

 

(ii)         [***]

 

(iii)        [***]

 

(iv)        As
the manufacturer and supplier of Drug Substance, Protalix shall provide to Pfizer original copies of any Certificate of Pharmaceutical
Product (“CPP”) issued to Protalix as necessary to support Pfizer’s regulatory filings for the Licensed
Product in the Field in the Territory. Protalix shall use Commercially Reasonable Efforts to apply for and obtain such CPP.

 

(f)           Assignment
of Contracts. Upon Pfizer’s reasonable request and to the extent legally permissible, Protalix shall assign to Pfizer
any contract Protalix has entered into with a Third Party that solely relates to the Development of the Licensed Product in the
Territory, to the extent Pfizer requests such contract to be assigned and such contract is assignable. Protalix shall provide copies
all such contracts to Pfizer’s Transition Manager.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	17	 

     

    

  

(g)          Responsibility.

 

(i)          Pfizer
shall have the sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product in
the Field in the Territory. Without limiting the foregoing, subject to Section 4.1(b)(i), Pfizer (or, in any Country in
the Territory, one or more of its Affiliates or Sublicensees) will own and be responsible for preparing, seeking, submitting and
maintaining all regulatory filings and Regulatory Approvals for the Licensed Product in Field in the Territory, including preparing
all reports necessary as part of a regulatory filing or Regulatory Approval. Protalix shall provide (A) such assistance as Pfizer
or its Affiliates or Sublicensees reasonably requires to obtain and maintain Regulatory Approvals for the Licensed Product in the
Field in the Territory, (B) provide Pfizer with all reasonable assistance and cooperation to take all actions reasonably requested
by Pfizer that are necessary to enable Pfizer to comply with any Law applicable to the Licensed Product and (C) provide reasonable
assistance to enable Pfizer to obtain or maintain Regulatory Approvals for the Licensed Product in the Field in any Country in
the Territory, including by providing CMC, facility, bioanalytical and clinical information and data that Pfizer is required to
provide to Regulatory Authorities (to the extent such data is in Protalix’s possession and Control). Pfizer or its Affiliates
or Sublicensees shall have the sole right to apply for and secure exclusivity rights that may be available under the Law of Countries
in the Territory, including any Regulatory Exclusivity. Protalix shall use Commercially Reasonable Efforts to cooperate with Pfizer
and its Affiliates and Sublicensees, and to take such reasonable actions to assist Pfizer and its Affiliates and Sublicensees,
in obtaining such exclusivity rights in each Country, as Pfizer may reasonably request from time to time. Such requested cooperation
and assistance referred to in this Section 4.1(g)(i) (including as referenced in the foregoing sentence and the foregoing
subclauses (A), (B) and (C)) shall be provided at [***]

 

(ii)         Once
Protalix or its designee Fiocruz (or another applicable sublicensee) has successfully received Regulatory Approval for the Licensed
Product in Brazil, Protalix shall have the sole authority and exclusive right to determine all regulatory plans and strategies
for the Licensed Product in Brazil. Subject to the foregoing, Protalix or its designee Fiocruz (or another applicable sublicensee)
shall have the sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product outside
the Territory, including the right to file a marketing authorization application in Brazil. Without limiting the foregoing, subject
to Section 4.1(c)(i), Protalix (or Fiocruz or such other sublicensee) will own and be responsible for preparing, seeking,
submitting and maintaining its marketing application and all regulatory filings and Regulatory Approvals for the Licensed Product
outside the Territory, including preparing all reports necessary as part of a regulatory filing or Regulatory Approval. Pfizer
shall provide such assistance as Protalix reasonably requires to obtain Regulatory Approvals for the Presentation of the Licensed
Product Commercialized as of the Second Amendment Effective Date in Brazil. Until Protalix or its designee Fiocruz (or such other
applicable sublicensee) has successfully received Regulatory Approval for the Licensed Product in Brazil (and the corresponding
marketing authorization held by Pfizer or its Affiliate in Brazil has been cancelled), Protalix and its designee Fiocruz (or such
other applicable sublicensee) shall have express and irrevocable authorization and approval for Protalix and its designee Fiocruz
(or such other applicable sublicensee) to import the Licensed Product and Drug Substance into Brazil under Pfizer’s or its
Affiliates’ Regulatory Approvals with Regulatory Authorities in Brazil, as allowed under applicable Law, which express authorization
and approval is set forth in writing on Exhibit E. Pfizer or its relevant Affiliate shall issue one or more of such authorizations
as reasonably required by Protalix or its designee Fiocruz (or such other applicable sublicensee). Protalix, Fiocruz, or such other
sublicensee shall have the sole right to apply for and secure exclusivity rights that may be available in Brazil, including any
Regulatory Exclusivity. Pfizer shall use Commercially Reasonable Efforts to cooperate with Protalix, Fiocruz or such other sublicensee
and to take such reasonable actions to assist Protalix, Fiocruz or such other sublicensee in obtaining such exclusivity rights
in Brazil, as Protalix may reasonably request from time to time. Such requested cooperation and assistance shall be provided [***]

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	18	 

     

    

  

(h)          Pharmacovigilance.
After the Second Amendment Effective Date and prior to[***], the safety units of each of the parties shall meet and agree upon
an amendment to the written pharmacovigilance agreement that defines Pfizer’s pharmacovigilance responsibilities for the
Licensed Product in the Territory and Protalix’s pharmacovigilance responsibilities for the Licensed Product outside the
Territory and the process for exchanging adverse event reports and other safety information relating to a Licensed Product that
will permit each party to comply with applicable Laws and requirements of Regulatory Authorities.

 

(i)           Communications
with Regulatory Authorities in the Territory. For so long as[***]:

 

(i)          Protalix
shall provide Pfizer notice of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory
Authority in Israel concerning any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Israel concerning
any regulatory matters relating to the Licensed Product promptly after the scheduling of such meeting, conference, or discussion
(to the extent Protalix is made aware of them in advance). Pfizer or its designee (or such other applicable sublicensee) shall
be entitled to have one or more representatives present at all such meetings unless prohibited by applicable Law or unless reasonably
impracticable under the circumstances. Pfizer or its designee (or such other applicable sublicensee) and Protalix shall use all
reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions and on the objectives to
be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences and discussions with
such Regulatory Authority; provided that [***];

 

(ii)         Protalix
shall provide Pfizer or its designee (or such other applicable sublicensee) with copies, which copies may be in draft form, of
all material submissions to any Regulatory Authority in Israel relating to the Licensed Product, to be provided sufficiently in
advance of such planned submission to such Regulatory Authority in order to allow Pfizer or its designee (or such other applicable
sublicensee) to provide comments regarding such submission, which comments shall be considered by Protalix in good faith with respect
to such submission; provided that [***];

 

(iii)        Protalix
shall provide to Pfizer, as soon as reasonably practicable but in no event more than three (3) Business Days after its receipt,
copies of any material documents or other material correspondence received from any Regulatory Authority pertaining to the Licensed
Product; and

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	19	 

     

    

  

(iv)        Protalix
shall reasonably cooperate with Pfizer or its designee regarding (1) filings and communications with any Regulatory Authority,
(2) patient advocacy and support, and (3) pharmacovigilance activities, in each case, in Israel with respect to the Drug Substance
or the Licensed Product; provided that [***]. For purposes of clarification, Protalix is not obligated to pursue additional
indications and/or submissions in Israel other than required modifications due to those related to safety under the current, Protalix
marketing authorization.

 

(j)           Communications
with Regulatory Authorities Outside the Territory. Until any marketing authorization application for Licensed Product submitted
by Protalix or its designee Fiocruz (or such other applicable sublicensee) is approved by the National Sanitary Surveillance Agency
of the Brazilian Government (or any successor or replacement agency that has the authority to grant the necessary Regulatory Approvals)
and any other required Regulatory Approval is obtained by Protalix or its designee Fiocruz (or such other applicable sublicensee),
and with respect to any Pfizer or Pfizer Affiliate Regulatory Approvals and regulatory filings (including marketing authorizations)
in Brazil and related data:

 

(i)          Pfizer
shall provide Protalix notice of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory
Authority in Brazil concerning any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Brazil concerning
any regulatory matters relating to the Licensed Product promptly after the scheduling of such meeting, conference, or discussion
(to the extent Pfizer is made aware of them in advance). Protalix or its designee Fiocruz (or such other applicable sublicensee)
shall be entitled to have one or more representatives present at all such meetings unless prohibited by applicable Law or unless
reasonably impracticable under the circumstances. Protalix or its designee Fiocruz (or such other applicable sublicensee) and Pfizer
shall use all reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions and on the
objectives to be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences and discussions
with such Regulatory Authority; provided that [***];

 

(ii)         Pfizer
shall provide Protalix or its designee Fiocruz (or such other applicable sublicensee) with copies, which copies may be in draft
form, of all material submissions to any Regulatory Authority in Brazil relating to the Licensed Product, to be provided sufficiently
in advance of such planned submission to such Regulatory Authority in order to allow Protalix or its designee Fiocruz (or such
other applicable sublicensee) to provide comments regarding such submission, which comments shall be considered by Pfizer in good
faith with respect to such submission; provided that [***];

 

(iii)        Pfizer
and Protalix (or Protalix’s designee Fiocruz (or such other applicable sublicensee)) shall provide to the other, as soon
as reasonably practicable but in no event more than three (3) Business Days after its receipt, copies of any material documents
or other material correspondence received from any Regulatory Authority in Brazil; and

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	20	 

     

    

  

(iv)        Pfizer
shall reasonably cooperate with Protalix and its Affiliates or its designee Fiocruz (or such other applicable sublicensee) regarding
(1) filings and communications with any Regulatory Authority, (2) patient advocacy and support, and (3) pharmacovigilance activities,
in each case, in Brazil with respect to the Drug Substance or the Licensed Product; provided that [***]. For purposes of
clarification, Pfizer is not obligated to pursue additional indications and/or submissions in Brazil other than required modifications
due to those related to safety under the current, Pfizer marketing authorization. 

 

(k)          [Reserved].

 

(l)           Recalls
or Other Corrective Action.

 

(i)          Pfizer
shall promptly notify Protalix of any material actions to be taken by Pfizer in the Territory with respect to any recall or market
withdrawal or other corrective action related to the Licensed Product prior to such action, if reasonably practicable under the
circumstances, to permit Protalix a reasonable opportunity to consult with Pfizer with respect thereto. [***]

 

(ii)         Protalix
shall promptly notify Pfizer of any material actions to be taken by Protalix outside the Territory with respect to any recall or
market withdrawal or other corrective action related to the Licensed Product prior to such action, if reasonably practicable under
the circumstances, to permit Pfizer a reasonable opportunity to consult with Protalix with respect thereto.

 

4.2          Commercialization
and Pricing.

 

(a)          Pfizer
shall have the sole authority and exclusive right to Commercialize, and shall be responsible for paying all costs and expenses
(except as otherwise expressly set forth in this Agreement) associated with the Commercialization of, the Licensed Product in the
Field in the Territory, including marketing, promoting, selling, distributing and [***] for the Licensed Product and obtaining
any necessary Price Approvals. Protalix hereby agrees to refrain from selling Licensed Product outside the Territory to any Person
if Protalix has knowledge or reason to believe that such Licensed Product is intended for transshipment or delivery by such Person
in the Territory. Pfizer hereby agrees to refrain from selling the Licensed Product in the Territory to any Person if Pfizer has
knowledge or reason to believe that such Licensed Product is intended for transshipment or delivery by such Person outside the
Territory.

 

(b)          Notwithstanding
anything to the contrary in Section 4.2(a), Protalix shall continue to Commercialize the Licensed Product in the Field in
Israel following the Second Amendment Effective Date until such time that Pfizer has received the necessary Regulatory Approvals
for Pfizer to commence Commercialization of the Licensed Product in the Field in Israel, but in no event extending longer than
[***] after the Second Amendment Effective Date (the “Israel Transition Period”), and during the Israel Transition
Period, (i) Protalix shall not materially alter its usual activities and practices with respect to inventory levels (including
samples) of the Licensed Product maintained at the wholesale, pharmacy or institutional levels in Israel, without the consent of
the Transition Team, (ii) Protalix shall not take any non-routine action that deviates from the ordinary course of business with
respect to the Commercialization of the Licensed Product in the Field in Israel without consulting with the Transition Team, and
(iii) Protalix shall inform the Transition Team of any allegations, inquiries, or investigations of violations of Protalix’s
policies or Laws related to commercialization of the Licensed Product in Israel. Pfizer shall provide Protalix written notice immediately
upon becoming aware that Pfizer has received the necessary Regulatory Approvals for Pfizer to commence Commercialization of the
Licensed Product in the Field in Israel. Pfizer shall consider in good faith whether to continue to participate in any[***] at
the end of the Israel Transition Period.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	21	 

     

    

  

(c)          Following
the Second Amendment Effective Date, Pfizer shall purchase all remaining finished goods inventories of Licensed Product relating
to Israel [***]. Such shipment shall be accompanied by a Manufacturing Certificate of Analysis and shall be subject to Sections
5.10(a) through (d), and such invoice shall be payable to Protalix within forty-five (45) days of receipt of the invoice.
Any disputes with respect to such invoice shall be escalated to the Transition Team for resolution. If the Transition Team is unable
to resolve such dispute, then such dispute shall be escalated to the Supply Chain Committee to resolve pursuant to Section 5.1.

 

4.3          Protalix
Trademarks. Protalix hereby grants to Pfizer a license to use any trademarks (including Protalix’s name or trade names)
Controlled by Protalix solely for the purposes of selling, and solely to the extent reasonably necessary to sell, the Inventories
in Israel pursuant to Section 4.2(c), subject to quality control provisions substantially equivalent to those set forth
in Section 4.4(d), which shall apply mutatis mutandis hereto.

 

4.4          Pfizer
Trademarks.

 

(a)          Assignment.
The parties acknowledge that Protalix transferred and assigned to Pfizer all of its worldwide rights, title and interest to the
Uplyso Trademarks, including any goodwill associated with such Uplyso Trademarks. Pfizer shall be responsible for paying all costs
and expenses associated with recording the trademark assignment instrument with the appropriate governmental authorities throughout
the world.

 

(b)          Choice
of Trademarks. Pfizer may choose, in its sole discretion, to use the Uplyso Trademarks or any other trademarks to Commercialize
the Licensed Product in the Field in the Territory and Pfizer shall own all such trademarks (collectively, the “Product
Marks”).

 

(c)          License
to Protalix. Pfizer hereby grants to Protalix an exclusive license, free of charge, to use the Brazil Uplyso Trademark and
any other Product Marks required by applicable Laws to be included on the labeling and packaging of the finished packaged product
outside the Territory solely in connection with the packaging, sale, marketing, promotion, advertising, disposition and distribution
of the Licensed Product in the Field outside the Territory. Pfizer acknowledges and agrees that Protalix is permitted to sublicense
to Fiocruz (or any other sublicensee of Protalix in Brazil) the Brazil Uplyso Trademark and any other Product Marks required by
applicable Laws to be included on the labeling and packaging of the finished packaged product outside the Territory as set forth
in Section 3.6(c). For the avoidance of doubt, the rights granted pursuant to this Section 4.4(c) do not include
grants to use the name or trade name of Pfizer (other than to the extent such right is granted to Protalix pursuant to Section
4.5 or required to be made pursuant to Section 4.4(d)(iv)(B)). Any such right to use such name or trade name shall be
governed by Section 4.5.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	22	 

     

    

  

(d)          Quality
Control.

 

(i)          The
quality of the Licensed Product sold by Protalix outside the Territory under or in connection with the Brazil Uplyso Trademark
(and any Product Marks licensed to Protalix pursuant to Section 3.6(c) and Section 4.4(c)) must be of a sufficiently
high quality to be generally comparable to the quality of the Licensed Product sold by Pfizer in the Territory under or in connection
with the Product Marks.

 

(ii)         Protalix
shall comply with all applicable Laws pertaining to the proper use and designation of the Brazil Uplyso Trademark (and any Product
Marks licensed to Protalix pursuant to Section 3.6(c) and Section 4.4(c)).

 

(iii)        Protalix
agrees to use the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to Section 3.6(c) and Section
4.4(c)) only in the form and manner and with appropriate legends as prescribed from time to time by Pfizer. 

 

(iv)        Additionally,
Protalix shall:

 

(A)         display
the proper form of trademark notice associated with the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant
to Section 3.6(c) and Section 4.4(c));

 

(B)         on
any item which bears the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to Section 3.6(c)
and Section 4.4(c)), include where practicable a statement identifying Pfizer or its Affiliate, as applicable, as the owner
of the Brazil Uplyso Trademark or Product Mark and where possible indicating that Protalix or its Affiliate, as applicable, is
an authorized user of the Brazil Uplyso Trademark or Product Mark;

 

(C)         not
use any Product Mark as a corporate name, business name, or trade name;

 

(D)         not
use any Product Mark in a manner that would reasonably be expected to materially impair the validity, reputation, or distinctiveness
of any Product Mark; and

 

(E)         not
use any Product Mark in a manner that would reasonably be expected to materially impair the reputation of Pfizer or any of its
Affiliates.

 

(e)          Prosecution
and Maintenance of Product Marks. Pfizer shall have the sole right, but not the obligation, through counsel of its choosing,
to prosecute and maintain the Product Marks in the Territory and the first right, but not the obligation, through counsel of its
choosing, to prosecute and maintain the Product Marks outside the Territory. In the event Pfizer elects not to prosecute or maintain
the Brazil Uplyso Trademark outside the Territory, Pfizer shall provide reasonable prior written notice to Protalix of its intention
not to prosecute or maintain any such Product Mark outside the Territory, and Protalix shall have the right to prosecute or maintain
the Brazil Uplyso Trademark on behalf of Pfizer. All costs and expenses incurred by Pfizer in the filing, prosecution and maintenance
of Product Marks in the Territory shall be [***]. All costs and expenses incurred by either party in the filing, prosecution and
maintenance of Product Marks (in the case of Pfizer) or the Brazil Uplyso Trademark outside the Territory as provided in this Section
4.4(e) shall be [***].

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	23	 

     

    

  

(f)           Enforcement
of Product Marks.

 

(i)          Pfizer
will promptly notify Protalix in the event of any actual, potential or suspected infringement of the Brazil Uplyso Trademark by
any Third Party and Protalix will promptly notify Pfizer in the event of any actual, potential or suspected infringement of the
Brazil Uplyso Trademark or a Product Mark by any Third Party. Pfizer shall have the sole right, but not the obligation, to institute
litigation or take other remedial measures in connection with Third Party infringement of Product Marks in the Territory and the
first right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party infringement
of Product Marks outside the Territory. If Pfizer fails to initiate litigation or take other remedial measures against a Third
Party who is infringing the Brazil Uplyso Trademark outside the Territory within ninety (90) days after becoming aware of the basis
for such litigation or action, then Protalix may, in its discretion, provide Pfizer with written notice of Protalix’s intent
to initiate a suit or take other appropriate action. If Protalix provides such notice and Pfizer fails to initiate litigation or
take such other appropriate action within thirty (30) days after receipt of such notice from Protalix, then Protalix shall have
the right to initiate litigation or take other appropriate action that it believes is reasonably required to protect its right
to use the Brazil Uplyso Trademark outside the Territory. Upon request of Protalix, Pfizer agrees to timely join as party-plaintiff
in any such litigation, and in any event to cooperate with Protalix in connection with such infringement action. All costs and
expenses incurred by Pfizer in enforcing the Product Marks in the Territory shall be borne by Pfizer and any recoveries resulting
from such litigation or other appropriate action, in pursuing such litigation or other appropriate action, shall be retained by
Pfizer. All costs and expenses incurred by Protalix in enforcing the Brazil Uplyso Trademark outside the Territory shall be [***]
and Protalix shall reimburse Pfizer for any and all costs or expenses incurred by Pfizer in connection with such enforcement by
Protalix outside the Territory. Protalix shall retain all recoveries received by Protalix as a result of its enforcement of the
Brazil Uplyso Trademark outside the Territory.

 

4.5          Use
of Names. No right, expressed or implied, is granted by this Agreement to a party to use in any manner the name or any other
trade name of the other party or its Affiliates in connection with this Agreement. Notwithstanding the foregoing, Protalix shall
have the right to use the Pfizer corporate name, subject to Pfizer’s trademark usage guidelines provided to Protalix from
time to time, including at least sixty (60) days prior to the date of Protalix’s first use of the Pfizer corporate name,
on package inserts, packaging or trade packaging associated with the Licensed Product outside the Territory solely as required
by applicable Laws outside the Territory. Protalix will submit for Pfizer’s approval (which approval shall not be unreasonably
withheld or delayed) a sample of each such proposed use of the Pfizer corporate name within sixty (60) days before the first use
permitted pursuant to this Section 4.5. Notwithstanding anything to the contrary in this Section 4.5, Pfizer shall
have the right to use the name of Protalix or its Affiliates or any other trade name of Protalix pursuant to and in accordance
with Section 4.3.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	24	 

     

    

  

4.6          Access
to Information. At Pfizer’s reasonable request during the Term, Protalix shall provide Pfizer, its designated Affiliate
or its agents and representatives with reasonable access [***], during regular business hours to (a) information concerning the
Drug Substance, Licensed Product, Protalix Patent Rights and/or Protalix Technology that may be reasonably necessary for Pfizer
to seek Regulatory Approval for Licensed Product, Manufacture (including performing Fill/Finish activities on) the Drug Substance
or the Licensed Product or Commercialize the Licensed Product, in each case, in the Field in the Territory and (b) Protalix-designated
employees who possess the information described in clause (a) of this Section 4.6, in each case, solely for the purpose
of enabling Pfizer to exercise the licenses granted to Pfizer hereunder. Such requested cooperation and assistance shall be provided
at no cost to Pfizer, except that [***]

 

4.7          Transition
Assistance. During the Transition Period, each party shall use Commercially Reasonable Efforts to cooperate with the other
party and to take such reasonable actions to assist the other party, as the other party may reasonably request, (i) to ensure the
smooth transition of the Commercialization of the Drug Substance or Licensed Product from Protalix to Pfizer (or a Third Party
designated by Pfizer) in Israel and from Pfizer to Protalix (or a Third Party designated by Protalix) in Brazil, and (ii) to ensure
the continuity of patient care in Brazil and Israel. Except as set forth in this Agreement, the parties shall no longer have any
obligations under the Agreement to Commercialize or Develop the Licensed Product, conduct any pre-clinical or clinical studies
or participate in any committees with the other party other than the Supply Chain Committee and the Transition Team.

 

(a)          Transition
Team. Within five (5) days following the Second Amendment Effective Date, Pfizer and Protalix shall each appoint a person (each
a “Transition Manager” and together, the “Transition Team”) to facilitate a smooth transition
of the Commercialization of the Drug Substance or Licensed Product from Protalix to Pfizer (or a Third Party designated by Pfizer)
in Israel and from Pfizer to Protalix (or a Third Party designated by Protalix) in Brazil, and to implement the Transition Plan
(as defined below). Each party shall notify the other party in writing of the identity and contact information for their respective
Transition Manager, which shall be the primary contact for each party with respect to the transition and the Transition Plan and
all activities thereunder. For [***] following the Second Amendment Effective Date (the “Transition Period”),
the Transition Managers shall meet (in person, by teleconference, video-conference or other reasonable means, in each case as mutually
agreed upon by the Transition Managers) as reasonably necessary, but not less frequently than a weekly basis, as mutually agreed
upon by the Transition Managers to facilitate the implementation of the Transition Plan. In the event that the Transition Plan
has not been implemented within [***] following the Second Amendment Effective Date, the parties shall mutually agree in good faith
on a new Transition Period, and following such agreement the term Transition Period shall refer to such new period as so agreed
upon by the parties.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	25	 

     

    

  

(b)          Transition
Plan. In connection with the transition of Israel and Brazil, during the Transition Period, the parties shall use Commercially
Reasonable Efforts to accomplish all of the transition activities described in Exhibit F to effect a reasonably smooth and
orderly transition (the “Transition Plan”). Pfizer and Protalix will commence delivery of the items specified
in the Transition Plan as soon as reasonably practicable and shall use Commercially Reasonable Efforts to meet the timelines specified
in the Transition Plan.

 

4.8          Records.
Each party will maintain accurate records and books relating to its activities in relation to the Development of the Drug Substance
and the Licensed Product, including any activities conducted under the Development plans between the parties pursuant to the Amended
Agreement.

 

Section
5.             MANUFACTURE AND SUPPLY.

 

5.1          Supply
Chain Committee.

 

(a)          Formation
and Membership. The parties shall continue to maintain a Supply Chain Committee (the “Supply Chain Committee”)
during the Supply Term. The Supply Chain Committee shall consist of representatives appointed by each party. The Supply Chain Committee
will provide a forum for the discussion of matters related to the Manufacture of and supply chain for the Drug Substance and Licensed
Product.

 

(b)          Meetings.
During the Supply Term, the Supply Chain Committee shall meet monthly or as otherwise determined by the parties (each such meeting,
a “Supply Chain Committee Meeting”). Upon the request of the Supply Chain Committee, each party will provide
written materials relating to its Manufacturing and related activities in advance of a Supply Chain Committee Meeting. All Supply
Chain Committee Meetings may be conducted in person, by videoconference or by teleconference at such times and such Pfizer or Protalix
locations as shall be determined by the Supply Chain Committee. In-person meetings of the Supply Chain Committee will alternate
between appropriate offices of each party. The parties shall each bear all expenses of their respective representatives relating
to their participation on the Supply Chain Committee. The members of the Supply Chain Committee also may convene or be polled or
consulted from time to time by means of telecommunications, video conferences, electronic mail or correspondence, as deemed necessary
or appropriate.

 

(c)          Responsibilities.
The Supply Chain Committee will have the following roles and responsibilities:

 

(i)          Discuss
each party’s requirements for Drug Substance and Licensed Product for Development activities in accordance with Section
5.3;

 

(ii)         Act
as a forum pursuant to which the parties may discuss Manufacturing issues, and any issues that may affect patient access to the
Licensed Product in the Territory;

 

(iii)        Be
informed of requests for and results of regulatory inspections related to Drug Substance and Licensed Product and review steps
to be taken by Protalix to address any deficiencies noted;

 

    	 	26	 

     

    

  

(iv)        Monitor
logistical strategies, Protalix’s capacity for Manufacturing Drug Substance and inventory levels for Drug Substance and Licensed
Product for consistency with the Forecasts and Long Range Forecasts and address any Failure to Supply and Persistent Failure to
Supply;

 

(v)         Be
informed of and discuss proposed changes in Manufacturing sites, testing sites, and responsibilities in the supply chain for Drug
Substance and Licensed Product;

 

(vi)        Be
informed of and address any quality-related issues concerning the Drug Substance and Licensed Product including non-conformance;

 

(vii)       Provide
updates on the Supply Chain Committee’s activities and achievements to the parties, as applicable, no less frequently than
once each quarter after the Second Amendment Effective Date; and

 

(viii)      Such
other roles and responsibilities provided for in this Agreement or as may be assigned to the Supply Chain Committee in writing
by mutual agreement of the parties.

 

(d)          Decision-Making.
Except for a decision to create a Technical Subcommittee as described in Section 5.1(e), the Supply Chain Committee will
have no decision-making authority, but instead will act in an advisory capacity to the parties, unless otherwise agreed by the
parties in writing.

 

(e)          Technical
Subcommittee. The Supply Chain Committee may, from time to time, create a subcommittee (a “Technical Subcommittee”)
to advise the Supply Chain Committee and the parties on and analyze any technical issues relating to Manufacturing Drug Substance
or Licensed Product, including issues relating to quality or process, identified by either party or by the Supply Chain Committee.
Any Technical Subcommittee shall consist of representatives from each party with the appropriate technical expertise to analyze
and provide advice with respect to any such technical issues, and such representatives may or may not also be representatives on
the Supply Chain Committee. Each Technical Subcommittee will continue to operate until resolution of the identified problem, as
determined by the Supply Chain Committee. If the Supply Chain Committee is unable to reach agreement with respect to the issue
identified by the Supply Chain Committee, Pfizer’s Vice President of Global External Supply and Protalix’s Chief Operating
Officer will meet promptly to attempt to resolve the dispute by good faith negotiations.

 

5.2          Capacity.

 

(a)          Protalix
shall [***].

 

(b)          [***]
Along with such request, Pfizer shall [*** ]If Protalix determines [***] Protalix shall [***] Pfizer and Protalix shall agree [***]
Pfizer shall [***] Notwithstanding the foregoing, in no case shall Protalix [***] Pfizer shall [***] Protalix shall [***]

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	27	 

     

    

  

(c)          Protalix
shall dedicate at least [***] of its Drug Substance Manufacturing capacity in order to Manufacture Drug Substance for Pfizer’s
clinical and commercial use in the Field in the Territory and may dedicate all remaining capacity to Manufacture Drug Substance
for Protalix’s clinical and commercial use in the Field outside the Territory (such allocation between the Territory and
outside the Territory, the “Allocation Percentage”). Subject to the Current Capacity Cap or, after achieving
the Increased Capacity Goal, the Increased Capacity Cap (collectively, the “Capacity Cap”), subject to the Allocation
Percentage, and subject to and in accordance with the terms of this Section 5 and the Quality Agreement, Protalix shall
supply all quantities of the Drug Substance ordered by Pfizer under this Agreement for clinical and commercial use in the Field
in the Territory.

 

(d)          In
the event either party reasonably believes that capacity for the Manufacture of Drug Substance in excess of the Increased Capacity
Cap is necessary to meet projected future clinical and commercial need for Licensed Product in the Territory, the parties shall
discuss such matter in good faith, including the funding of any capital expenditures necessary to increase such Manufacturing capacity
beyond the Increased Capacity Cap.

 

5.3          Development
Supply of Drug Substance. Subject to the Capacity Cap and the Allocation Percentage, Protalix shall Manufacture and supply
Pfizer’s requirements of the Drug Substance for incorporation into Licensed Product for Development activities to be performed
by Pfizer in the Field in the Territory, which supply shall be subject to and in accordance with the terms of this Section 5.
For the avoidance of doubt, in no event shall Protalix be obligated to Manufacture or supply quantities of Drug Substance in excess
of the Capacity Cap unless otherwise agreed by the parties.

 

5.4          Commercial
Supply of Drug Substance. Subject to the Capacity Cap and the Allocation Percentage, Protalix shall Manufacture and supply
Pfizer’s requirements of the Drug Substance for incorporation into Licensed Product and commercial sale in the Field in the
Territory pursuant to this Agreement, which supply shall be subject to and in accordance with the terms of this Section 5
and the Quality Agreement. For the avoidance of doubt, in no event shall Protalix be obligated to Manufacture or supply quantities
of Drug Substance in excess of the Capacity Cap unless otherwise agreed by the parties.

 

5.5          Supply
Term. The terms of this Section 5 shall be effective as of the Second Amendment Effective Date and, unless this Agreement
is earlier terminated pursuant to Section 14, shall remain in effect only until terminated in accordance with this Section
5 (the “Supply Term”).  The initial term for the supply of Drug Substance under this Section 5
shall be for ten (10) years after the Second Amendment Effective Date (the “Initial Supply Term”).  If
Protalix determines not to extend the supply of Drug Substance to Pfizer hereunder beyond such Initial Supply Term, Protalix shall
have the right to provide written notice of termination of the Supply Term, at least three (3) years prior to the effective date
of termination of the Supply Term set forth in such notice (which shall in no event be prior to the end of the Initial Supply Term)
(the “Supply Termination Notice”); provided that notwithstanding the timely issuance of a Supply Termination
Notice by Protalix in accordance with the foregoing sentence Pfizer shall have the right to extend the Supply Term for up to two
additional periods of thirty (30) months each (each, a “Renewal Supply Term”) by providing to Protalix a written
extension notice at least one (1) year prior to the end of the Initial Supply Term or the first Renewal Supply Term, as applicable
(with the first Renewal Supply Term commencing at the end of the Initial Supply Term and the second Renewal Supply Term commencing
at the end of the first Renewal Supply Term).  For the avoidance of doubt, (i) in the event Pfizer does not provide a written
extension notice at least one (1) year prior to the end of the Initial Supply Term in accordance with the foregoing sentence, the
Supply Term shall terminate upon the stated effective date of termination in the Supply Termination Notice, (ii) in the event Pfizer
provides a written extension notice for the first Renewal Supply Term in accordance with the foregoing sentence, but does not provide
a written extension notice for the second Renewal Supply Term at least one (1) year prior to the end of the first Renewal Supply
Term in accordance with the foregoing sentence, the Supply Term shall terminate upon the end of the first Renewal Supply Term,
and (iii) in the event Pfizer provides a written extension notice for the first and second Renewal Supply Terms in accordance with
the foregoing sentence, the Supply Term shall terminate fifteen (15) years after the Second Amendment Effective Date.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	28	 

     

    

  

5.6          Forecasting
and Ordering.

 

(a)          Forecasts;
Purchase Orders. [***], Pfizer shall deliver to Protalix Pfizer’s quarterly projection of the quantities of Drug Substance
that Pfizer anticipates ordering from Protalix pursuant to this Agreement for the four (4) calendar quarters commencing with the
first quarter that includes the first requested delivery date (the “Initial Forecast”), together with a firm
purchase order (a “Purchase Order”) for Drug Substance for the first calendar quarter covered by such Initial
Forecast. The quantities of Drug Substance specified for the following quarter of such Initial Forecast shall be binding as provided
in this Section 5.6 and the remaining two (2) quarters of such Initial Forecast shall be non-binding. Thereafter, ninety
(90) days prior to the first business day of each subsequent calendar quarter during the Term, Pfizer shall deliver to Protalix
a rolling four (4) calendar quarter forecast updating the prior forecast (together with the Initial Forecast, each a “Forecast”),
together with a Purchase Order for the first calendar quarter of such Forecast. The quantities of Drug Substance specified for
the following quarter of such Forecast shall be binding as provided in this Section 5.6 and the remaining two (2) quarters
of such Forecast shall be non-binding. Unless agreed separately between the parties, each Purchase Order shall specify no more
than three (3) delivery dates for the Drug Substance in each calendar quarter. Purchase Orders shall be in writing, and no verbal
communications or e-mail shall be construed to mean a commitment to purchase or sell. Each Purchase Order delivered by Pfizer to
Protalix pursuant to this Section 5.6(a) shall be binding on Protalix to the extent provided by Section 5.6(c). Protalix
shall confirm receipt of any [***].

 

(b)          Long
Range Capacity Planning. Concurrent with the Initial Forecast, for the purposes of discussion and planning of Manufacturing
capacity, Pfizer shall provide a non-binding forecast of its projected Drug Substance needs for the eight (8) calendar quarters
following that specified in the Initial Forecast as described in Section 5.6(a) (a “Long Range Forecast”).
Each Long Range Forecast shall be deemed to be revised by any subsequent Forecast. In the event Protalix anticipates that it will
be unable to supply the quantities of Drug Substance reflected in a Long Range Forecast, Protalix shall promptly notify Pfizer
and the Supply Chain Committee shall work to remedy the shortfall in accordance with and subject to the terms of this Section
5 in an effort to assure that the necessary capacity exists. Unless otherwise agreed to by the parties during the Term, the
Long Range Forecast shall be updated by Pfizer annually by July 1 of each calendar year during the Term.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	29	 

     

    

  

(c)          Maximum
Quantities. Unless otherwise agreed in writing by Protalix, in no event shall Protalix be obligated to deliver quantities of
Drug Substance [***] The foregoing limitation shall be in addition to the Capacity Cap. Protalix shall, however, use Commercially
Reasonable Efforts, but will be under no obligation, to supply Drug Substance [***].

 

(d)          Minimum
Quantities. If the quantities of Drug Substance specified in a Purchase Order for a quarter are less than [***] of the quantities
specified by Pfizer for the same period in the Forecast delivered [***], then, at the election of Pfizer set forth in a notice
which Pfizer shall deliver to Protalix within [***], (i) Protalix shall, [***]

 

(e)          Receipt
and Acceptance. Subject to Sections 5.6(c) and 5.6(d), Pfizer shall purchase all Drug Substance ordered and specified
in a Purchase Order. Purchase Orders may be delivered electronically or by other means to such location as Protalix shall designate.
Nothing in any such Purchase Order or written acceptance shall supersede the terms and conditions of this Agreement or the Quality
Agreement. All Purchase Orders, confirmations of receipt of Purchase Orders and other notices contemplated under this Section
5.6(e) shall be sent to the attention of such persons as each party may identify to the other in writing from time to time
in accordance with Section 18.9.

 

5.7          Pricing
and Invoicing.

 

(a)          Supply
Delivery Price. [***]

 

(b)          Invoices.
Following the release of the Drug Substance subject to the Purchase Order hereunder and the submission to Pfizer of the Manufacturing
Certificate of Acceptance and the Certificate of Compliance (as defined in the Quality Agreement) relating to such released Drug
Substance, each delivery of Drug Substance under a Purchase Order hereunder shall be accompanied by an invoice. Protalix shall
invoice Drug Substance at [***] Protalix shall include the following information, where applicable, on all invoices: the type,
description, and quantity of the product delivered; the date of shipment; the prices; any applicable taxes, transportation charges
or other charges provided for in the applicable Purchase Order; and the applicable Purchase Order number. [***]

 

(c)          Taxes.
All sales and use taxes which Protalix is required by law to collect from Pfizer with respect to the Manufacture and supply of
Drug Substance to Pfizer shall be separately stated in Protalix’s invoice and shall be paid by Pfizer to Protalix unless
Pfizer provides an exemption to Protalix. Protalix shall be solely responsible for the timely payment of all such taxes to the
applicable taxing authority, and Protalix shall pay (without reimbursement by Pfizer), and shall hold Pfizer harmless against,
any penalties, interest or additional taxes that may be levied or assessed as a result of the failure or delay of Protalix to pay
any such taxes.

 

5.8          Shipping
and Delivery.

 

(a)          Storage.
Protalix shall maintain dedicated freezer storage (i.e., freezers that is used only to store Drug Substance manufactured for Pfizer)
for Drug Substance manufactured but not yet delivered to Pfizer pursuant to a Purchase Order. Such dedicated freezers shall be
maintained in compliance with cGMP requirements and shall be stored in a secure area to prevent unauthorized access and/or manipulation.
Procedures shall be in place for reporting and neutralizing unauthorized entry into such dedicated freezers.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	30	 

     

    

  

(b)          Delivery.
Subject to Section 5.5, Protalix shall deliver (or have delivered) to Pfizer in accordance with this Section 5.8
the quantities of the Drug Substance specified for a given delivery date in each Purchase Order with, in the case of Drug Substance,
no less than: [***] Such decision by the Supply Chain Committee shall be intended to ensure sufficient supply of Drug Substance
meeting the requirements of the applicable Regulatory Authorities and Regulatory Approvals throughout the Territory. If the Supply
Chain Committee determines to increase the Minimum Shelf Life, then the Minimum Shelf Life shall be increased by [***] of such
approved increase in shelf life. All dates for delivery of Drug Substance are [***]

 

(c)          Delivery
Terms. The Drug Substance shall be supplied to Pfizer [***]. The Drug Substance shall be shipped [***]. Pfizer shall be responsible
for[***] For the avoidance of doubt, title and risk of loss shall not transfer to Pfizer until the Drug Substance is delivered
to Pfizer or its designee in accordance with this Section 5.8(c).

 

(d)          Retention.
Unless the parties agree otherwise, Protalix shall maintain analytical samples of each batch of Drug Substance in storage for a
time period based upon Protalix’s sample retention policy.

 

5.9          Compliance;
Quality Control Obligations.

 

(a)          The
parties shall determine if the Quality Agreement needs to be updated, and if necessary, shall update the Quality Agreement within
sixty (60) days following the Second Amendment Effective Date. The Quality Agreement shall set forth the parties’ compliance
obligations with respect to the Drug Substance Manufactured by Protalix for clinical and commercial requirements in the Territory.
To the extent there are any inconsistencies or conflicts between this Agreement and the Quality Agreement with respect to quality
issues, the terms and conditions of the Quality Agreement shall control.

 

5.10        Certificate
of Analysis; Acceptance and Returns.

 

(a)          Manufacturing
Certificate of Analysis; Notice of Non-Conformance.

 

(i)          Following
Manufacture. Following the release of the Drug Substance subject to an applicable Purchase Order by Protalix and before issuing
an invoice for such Drug Substance pursuant to Section 5.7(b), Protalix shall supply to Pfizer the applicable batch number
for the Drug Substance, and such other information as the parties may set forth in the Quality Agreement with respect to the Manufacture
(a “Manufacturing Certificate of Analysis”) for such Drug Substance.

 

(ii)         Following
Delivery. Pfizer shall (within the time period specified in Section 5.10(b)) inspect, or cause to have inspected, each
shipment of the Drug Substance for any damage, defect or shortage and give Protalix written notice of any such damaged, defective
or short shipment (a “Notice of Non-Conformance”) within the time periods specified in Sections 5.10(a)(iii)
and 5.10(b), as applicable.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	31	 

     

    

  

(iii)        Latent
defects shall be communicated to Protalix, together with appropriate detail, within fifteen (15) Business Days of the date on which
such latent defect was first discovered by Pfizer or was notified to Pfizer by the relevant party discovering the defect.

 

(b)          Rejection.
Pfizer shall have [***] following its receipt of each shipment of the Drug Substance to inspect such shipment. If Pfizer determines
that any shipment of the Drug Substance does not conform to the Product Specifications (or is otherwise a short shipment), it shall
promptly notify Protalix within [***] following such determination in compliance with the procedures set forth in the Quality Agreement.

 

(c)          Disputes.
If Pfizer delivers a Notice of Non-Conformance in respect of all or any part of a shipment of the Drug Substance, and Protalix
does not agree with Pfizer’s determination that such shipment fails to meet the Product Specifications (or is otherwise a
short shipment), the parties shall in good faith attempt to resolve such dispute at the Supply Chain Committee. Protalix and Pfizer
shall have thirty (30) days, unless otherwise agreed in writing by the parties, from the date of Protalix’s receipt of a
Notice of Non-Conformance to resolve such dispute regarding whether all or any part of such shipment was Manufactured in conformance
with the Product Specifications (or was otherwise a short shipment). If the dispute regarding whether all or any part of a shipment
rejected by Pfizer was Manufactured in conformance with the Product Specifications (or was otherwise a short shipment) is not resolved
in such thirty (30) day period, then [***]

 

(d)          Destruction.
In the event any shipment of Drug Substance is rejected pursuant to this Section 5.10 as a result of any act or omission
of Protalix, then Pfizer shall, at the direction of Protalix, either (x) destroy such rejected Drug Substance or Licensed Product
at Protalix’s expense (in accordance with applicable Law) or (y) return such rejected Drug Substance or Licensed Product
to Protalix, at a location designated by Protalix and at Protalix’s expense; provided that if Protalix requests
the return of such rejected Drug Substance or Licensed Product, Protalix shall not use such Drug Substance or Licensed Product
for any purpose, shall destroy such rejected Drug Substance or Licensed Product and certify to Pfizer that it has destroyed such
rejected Drug Substance or Licensed Product.

 

(e)          Refund,
Replacement of Non-Conforming Product. Pfizer may return to Protalix at Protalix’s expense any Drug Substance rejected
pursuant to this Section 5.10 as a result of any act or omission of Protalix, its Affiliates or their respective agents,
vendors, suppliers or subcontractors. In addition to any other rights or remedies of Pfizer hereunder, Protalix shall at Pfizer’s
sole discretion (i) replace any Drug Substance rejected by Pfizer, at no additional cost to Pfizer, as soon as reasonably practicable
on an expedited basis; or (ii) provide a credit or refund to Pfizer for the full amount invoiced to and paid by Pfizer for such
Drug Substance.

 

(f)           Shortages.
In the event that the materials and/or Manufacturing capacity required by Protalix to Manufacture and to deliver to Pfizer the
Drug Substance required as specified in Purchase Orders are in short supply, Protalix shall notify Pfizer of such shortage and
the Supply Chain Committee shall promptly meet to discuss the shortage. Protalix shall provide to the Supply Chain Committee a
written plan of action stating in reasonable detail the proposed measures to address such shortage and the date such shortage is
expected to end. Protalix shall use its Commercially Reasonable Efforts to minimize the duration of any shortage, including using
all capacity at its Facility to Manufacture Drug Substance (including stopping the manufacture of all other products at the Facility
for sales by Protalix or Third Parties). During any such shortage, Protalix shall allocate the materials and resources used in
the supply of the Drug Substance such that Pfizer receives [***] of the Drug Substance for the Territory and Protalix receives
[***] of the Drug Substance for outside the Territory.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	32	 

     

    

  

5.11        Product
Specification and Manufacturing Changes. Product Specification and Manufacturing changes, including those resulting from a
request received by a party from a Governmental Authority, shall be dealt with pursuant to the Quality Agreement; provided
that all applicable Regulatory Approvals shall be prepared and filed by the parties in accordance with the provisions of Section
4.

 

5.12        Change
Control. Protalix shall not make any changes to its process, raw materials, supply sources, manufacturing locations or facilities
(including Drug Substance storage facilities and equipment) used to make Drug Substance for Pfizer under this agreement, including
any such changes that may require Pfizer to provide notification to Regulatory Authorities, except to the extent permitted under
the Quality Agreement.

 

5.13        Practices.
Protalix shall comply with current Good Manufacturing Practices (cGMP) as it applies to receipt, storage, handling and control
of materials and the Drug Substance.

 

5.14        Pest
Control. Protalix shall manufacture and store Drug Substance, and shall store all ingredients, raw materials and components
used to manufacture Drug Substance, in a clean, dry area, free from insects and rodents, in a manner to prevent entry of foreign
materials and contamination of Drug Substance. Protalix’s pest control measures shall include adequate cleaning of the facility,
control of food and drink, protection of Drug Substance from the environment, monitoring of flying and crawling pests, and logs
detailing findings and actions taken. Protalix’s pest control program shall be described in a written procedure subject to
review and approval of Pfizer. Failure of Protalix to comply with this Section 5.14 shall be deemed a material breach of
this Agreement.

 

5.15        Records
and Audits. Protalix shall maintain complete and accurate records of all matters relating to the Manufacturing of Drug Substance
that enable Protalix to demonstrate compliance with its obligations under this Agreement, including Protalix’s compliance
with applicable Laws, in accordance with the terms of the Quality Agreement. As used in this Section 5.15, records include
all books, documents, and other data specified in the Quality Agreement regardless of type or form. Protalix shall maintain such
records for the period of time set forth in the Quality Agreement. Pfizer or its representatives may (at Pfizer’s sole cost
and expense), subject to the confidentiality provisions in Section 9, audit such records of Protalix in accordance with
the terms of the Quality Agreement at any time during the Supply Term and for the [***] period following the expiration or termination
of (x) the Supply Term or (y) the last Purchase Order in effect, whichever occurs later, during normal business hours and upon
reasonable advance written notice to Protalix. Protalix shall make such records readily available for such audit, and Pfizer or
its representatives may copy any and all such records in connection with any such audit.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	33	 

     

    

  

5.16        Quality
Assurance. Protalix shall have a formal quality assurance program and appropriate written quality control procedures covering
its operations.

 

5.17        Technical
Support. Protalix shall provide means for Pfizer to contact Protalix’s service representative twenty-four (24) hours
a day, seven (7) days a week during the Supply Term.

 

5.18        Technical
Assistance; Facility Access.

 

(A)         Pfizer
shall have the right to provide technical assistance and advice to Protalix on an ongoing basis, including in-person at Protalix’s
Facility;

 

(B)         Pfizer
may physically inspect Protalix’s Facility, including being present during Manufacturing operations, quality control, quality
assurance, pack out and shipping;

 

(C)         Protalix
shall provide Pfizer with reasonable ongoing access to its Facility and all relevant Manufacturing records and personnel (wherever
located) of Protalix and will use Commercially Reasonable Efforts to facilitate access to any Third Party suppliers of materials
for the Drug Substance; and

 

(D)         Protalix
shall reasonably cooperate with Pfizer and its representatives in connection with the activities described above and, upon mutual
agreement of the parties as to any deficiencies, Protalix shall use its Commercially Reasonable Efforts to promptly correct any
such deficiencies if and to the extent mutually agreed by the parties.

 

Pfizer and its representatives shall carry out
the activities described in this Section 5.18 during Protalix’s regular business hours at times reasonably agreed
upon by Pfizer and Protalix, with as minimal disruption to Protalix’s operations as reasonably practicable [***]. Such requested
cooperation and assistance pursuant to Sections 5.18(C) and 5.18(D), shall be provided [***]

 

5.19        Other
Assistance by Pfizer. Protalix acknowledges that Pfizer has expertise with respect to manufacturing and pharmaceutical sciences
and is able to provide assistance to Protalix in the following areas: (a) registering with the FDA and EMEA a manufacturing technology
for commercial supply of Drug Substance, including the preparation of a complete, approvable chemistry, manufacturing, and controls
section of an NDA and other regulatory filings packages, (b) the regulatory review process, (c) addressing regulatory review feedback
or post-approval requirements by any Regulatory Authority, (d) bioprocess, analytical or formulation development, (e) validation,
(f) characterization and stability studies, (g) preparing for and supporting pre-approval inspections; and (h) preparing Protalix’s
Facility to make it suitable for Regulatory Approval, including finalizing any required changes to the facility or equipment train,
IQ/OQ/PQ, and equipment cleaning and cleaning validation (collectively, the “Advisory Services”). At any time
during the Term, Pfizer shall have the right to provide Advisory Services to Protalix and upon reasonable advance written notice
from Pfizer, Protalix shall reasonably consider in good faith the recommendations of Pfizer with respect to such Advisory Services.
Pfizer shall be responsible for and bear [***] of the costs and expenses it incurs in providing Advisory Services to Protalix.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	34	 

     

    

  

5.20        Master
Cell Bank. During the Term, Protalix shall, as the supplier of Drug Substance, maintain half of the master cell bank relating
to the Drug Substance in a location selected by Protalix and the other half of the master cell bank relating to the Drug Substance
at a different location selected by Protalix and approved by Pfizer (such approval not to be unreasonably withheld or delayed),
which may include the Facility where Pfizer performs Fill/Finish activities (provided that Pfizer obtains all required
approvals from the applicable Regulatory Authority necessary to store the master cell bank in such Facility).

 

5.21        [***]

 

5.22        [***]

 

5.23        Manufacturing
Transition Assistance. Upon Pfizer’s request, in order to ensure continuity of supply of the Drug Substance following
expiration or termination of this Agreement or Pfizer’s election to exercise its right to Manufacture or have a Third Party
Manufacture the Drug Substance, Protalix shall provide reasonable assistance to Pfizer in arranging for the Manufacture of the
Drug Substance by Pfizer or by an alternative supplier chosen by Pfizer, including providing technical consulting services to Pfizer
or such alternative supplier and transferring know-how and other information relating to the Manufacture of the Drug Substance
to Pfizer or such alternative supplier. [***] Protalix shall provide such assistance in accordance with a written transition plan
(the “Manufacturing Transition Plan”) that details the actions and timelines for transitioning the Manufacture
of the Drug Substance to Pfizer or such alternative supplier in a timely and efficient manner without material risk or disruption
to either Protalix or Pfizer and no later than the end of the Term (if in connection with the expiration or termination of the
Agreement) or no later than the time agreed to by the parties (if in connection with Pfizer’s exercise of its right to Manufacture
or have a Third Party Manufacture the Drug Substance). Protalix shall provide the proposed Manufacturing Transition Plan to Pfizer
for Pfizer’s written approval, which shall not be unreasonably withheld, within [***] following Pfizer’s request. In
addition, upon Pfizer’s request, Protalix shall use Commercially Reasonable Efforts to cause the counterparty to any contract
relating to the Manufacture of the Drug Substance (a) to consent to the partial assignment to Pfizer or such alternative supplier
of those rights necessary for such manufacture by Pfizer or such alternative supplier or (b) to otherwise reasonably cooperate
with Pfizer in Pfizer’s efforts to establish a new contractual relationship with such counterparty on substantially the same
terms as the terms of its contract with Protalix.

 

Section
6.             FINANCIAL PROVISIONS

 

6.1          Second
Amendment Effective Date Payment. Within thirty (30) days following the Second Amendment Effective Date, Pfizer shall pay to
Protalix the amount of thirty-six million dollars (US $36,000,000) (the “Pfizer Payment”) in accordance with
Section 7.2(a).

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	35	 

     

    

  

6.2          Deferred
Payment. Within thirty (30) days of the fifth (5th) anniversary of the Second Amendment Effective Date, Protalix
shall pay to Pfizer the non-refundable, non-creditable amount of four million three hundred thousand seven hundred sixteen dollars
and forty-six cents (US $4,300,716.46) (the “Protalix Payment”) in accordance with Section 7.2(b) and
as set forth in the promissory note delivered by Protalix to Pfizer. Protalix shall have delivered a promissory note in the form
of Exhibit H on the Second Amendment Effective Date (the “Promissory Note”).

 

6.3          Payments
With Respect to Commercialization in Israel. During the Israel Transition Period, [***]

 

6.4          Payments
With Respect to Commercialization in Brazil. Until such time that Protalix has provided written notice to Pfizer permitting
Pfizer to cancel its Brazilian marketing authorization with respect to the Licensed Product, [***]

 

6.5          Release
of Payment Obligations. Upon (i) the payment by Pfizer to Protalix of the Pfizer Payment, Pfizer shall be deemed to have fully
satisfied and discharged, and Protalix hereby fully and forever releases Pfizer and its Affiliates from, all payment obligations
under Section 6 of the Amended Agreement that have accrued as of the Second Amendment Effective Date, including milestone payments
and profit sharing payments, and (ii) the later to occur of (A) the delivery of the promissory note for the Protalix Payment by
Protalix to Pfizer as required under Section 6.2 and (B) Protalix providing Pfizer with written notice permitting Pfizer
to cancel its Brazilian marketing authorization with respect to the Licensed Product, Protalix shall be deemed to have fully satisfied
and discharged, and Pfizer hereby fully and forever releases Protalix and its Affiliates from, all payment obligations under Section
2 of the First Amendment (which, for the avoidance of doubt, shall no longer be in effect as of the Second Amendment Effective
Date) and Section 6 of the Amended Agreement that have accrued as of the Second Amendment Effective Date (except to the extent
such payments under Section 2 of the First Amendment are payable pursuant to Section 6.4 of this Agreement) (collectively,
the “Released Obligations”), other than payment of the Protalix Payment in accordance herewith. In addition,
the Released Obligations include all associated reporting obligations, reconciliation payments and procedures and payments in respect
of reimbursable expenses that may have accrued under Section 7 of the Amended Agreement. In connection with the foregoing release,
each party hereby waives any and all rights to inspect or audit the books and records of the other party and its Affiliates and
sublicensees relating to the Released Obligations and to seek any adjustment or modification of any amounts paid or payable in
connection with any such audit or inspection.

 

Section
7.             ACCOUNTING AND PROCEDURES FOR PAYMENT

 

7.1          Currency.
All payments to be made hereunder by one party to the other party shall be computed and paid in United States dollars.

 

7.2          Method
of Payments.

 

(a)          Each
payment to be made hereunder by Pfizer to Protalix shall be made by electronic transfer in immediately available funds via either
a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Protalix’s
election, to the account designated on Appendix 7.2(a). With respect to any payment invoiced by Protalix to Pfizer, Protalix
may designate a different bank account on such invoice. With respect to any other payment, Protalix may designate a different bank
account at least forty-five (45) days before such payment is due.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	36	 

     

    

  

(b)          Each
payment to be made hereunder by Protalix to Pfizer shall be made by electronic transfer in immediately available funds via either
a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Pfizer’s
election, to the account designated on Appendix 7.2(b), or to such other bank account as Pfizer shall designate in a notice
at least fifteen (15) Business Days before the payment is due.

 

7.3          Tax
Matters.

 

(a)          VAT.
It is understood and agreed between the parties that any payments made by Pfizer under this Agreement are inclusive of any value
added or similar tax imposed upon such payments. It is understood and agreed between the parties that any payments made by Protalix
to Pfizer under this Agreement are exclusive of any value added or similar tax (VAT), which shall be added thereon as applicable.

 

(b)          Tax
Cooperation.

 

(i)          Subject
to Section 7.3(c) to the extent Pfizer is required to deduct and withhold taxes on any payments to Protalix, Pfizer shall
pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Protalix an official
tax certificate or other evidence of such withholding sufficient to enable Protalix to claim credits for such payments of taxes.
 Protalix shall provide to Pfizer any tax forms that may be reasonably necessary in order for Pfizer not to withhold tax or
to withhold tax at a reduced rate under an applicable bilateral income tax treaty.  Protalix shall use reasonable efforts
to provide any such tax forms to Pfizer at least thirty (30) days prior to the due date for any payments for which Protalix desires
that Pfizer apply a reduced withholding rate.  Each party shall provide the other with reasonable assistance to enable the
recovery, as permitted by law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement,
such recovery to be for the benefit of the party bearing such withholding tax or VAT. Each party further agrees to provide reasonable
cooperation to the other party, at the other party’s expense, in connection with any official or unofficial tax audit or
contest relating to payments made by Pfizer to Protalix under this Agreement.

 

(ii)         Subject
to Section 7.3(c), to the extent Protalix is required to deduct and withhold taxes on any payments to Pfizer, Protalix shall
pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Pfizer an official
tax certificate or other evidence of such withholding sufficient to enable Pfizer to claim credits for such payments of taxes.
Pfizer shall provide to Protalix any tax forms that may be reasonably necessary in order for Protalix not to withhold tax or to
withhold tax at a reduced rate under an applicable bilateral income tax treaty. Pfizer shall use reasonable efforts to provide
any such tax forms to Protalix at least thirty (30) days prior to the due date for any payments for which Pfizer desires that Protalix
apply a reduced withholding rate. Each party shall provide the other with reasonable assistance to enable the recovery, as permitted
by Law, of withholding taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for
the benefit of the party bearing such withholding tax. Each party further agrees to provide reasonable cooperation to the other
party, at the other party’s expense, in connection with any official or unofficial tax audit or contest relating to payments
made by Protalix to Pfizer under this Agreement.

 

    	 	37	 

     

    

  

(c)          [***]

 

Section
8.             PATENTS AND INFRINGEMENT

 

8.1          Filing
and Prosecution. Protalix shall have the exclusive right, subject to Sections 8.2 through 8.5, to:

 

(a)          file
Patent Applications on any invention included in the Protalix Patent Rights;

 

(b)          take
all reasonable steps to prosecute all pending and new Patent Applications included within the Protalix Patent Rights;

 

(c)          respond
to oppositions, interferences, nullity actions, re-examinations, revocation actions and similar proceedings filed by Third Parties
against the grant of Patents for such Patent Applications; and

 

(d)          maintain
in force any patents in the Territory included within the Protalix Patent Rights by duly filing all necessary papers and paying
any fees required by the relevant patent laws and regulations of the particular Country in which the patent was granted.

 

(e)          [***]
shall be responsible for bearing [***] of the expenses and costs incurred by [***] in connection with the exercise of its rights
under this Section 8.1.

 

8.2          Correspondence.
[***] will keep [***] fully-informed of the status of the [***] Patent Rights to the extent the Protalix Patent Rights [***], and
will provide [***] with copies of all substantive documentation submitted to, or received from, the patent offices in connection
therewith. With respect to any substantive submissions that [***] is required to or otherwise intends to submit to a patent office
regarding such Protalix Patent Rights, [***] shall use Commercially Reasonable Efforts to provide a draft of such submission to
[***] at least thirty (30) days prior to the deadline or intended filing date, whichever is earlier, for submission of such documentation.
[***] shall have the right to review and comment upon any such submission by [***] to a patent office that could affect the scope
of coverage or validity of any claim of the Protalix Patent Rights to the extent covering the Compound or Licensed Product, or
the Development, Manufacture, or Commercialization of [***], and will provide such comments, if any, no later than ten (10) days
prior to the applicable deadline or intended filing date. Notwithstanding the foregoing, when such substantive documentation submitted
to or received from the patent offices is solely related to [***], [***] shall have the right, but no obligation, to fully inform
[***] of the status of these Protalix Patent Rights.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	38	 

     

    

  

(a)          Upon
[***] written request, provided that [***] submits such written request reasonably in advance of any relevant filing deadline
or intended filing date, [***] will file Patent Applications directed to the rights licensed to [***] under this Agreement [***]

 

(b)          With
respect to Protalix Patent Rights that are [***][***] shall consider in good faith all comments provided by [***] with respect
to a Protalix Patent Right to the extent relating to [***], and incorporate all such comments that [***] deems reasonable and appropriate.
If [***] disagrees with any such comment provided by [***] after giving such comments due consideration, [***] shall provide
[***] with an explanation of the basis for such disagreement. If a failure to incorporate [***]’s comment would reasonably
be expected to impair the Licensed Product in the Field in the Territory, [***] shall have final-decision making authority with
respect to filings and prosecution of such Protalix Patent Rights (other than the Protalix System Patent Rights). [***] shall have
final-decision making authority with respect to filings and prosecution of Protalix Patent Rights relating solely to an [***] and
with respect to filings and prosecution of Protalix Patent Rights that [***]

 

(c)          Notwithstanding
the foregoing, [***]’s obligation to keep [***] informed of the status of the Protalix System Patent Rights will be limited
to situations where changes to the status of the Protalix System Patent Rights would reasonably be expected to impair the Licensed
Product in the Field in the Territory. With respect to the Protalix System Patent Rights, [***] shall reasonably consider all comments
provided by [***], but [***] shall have final-decision making authority with respect to filings and prosecution of the Protalix
System Patent Rights.

 

8.3          Maintenance.
Protalix will maintain for the full life thereof all Patent Rights under the Protalix Patent Rights where the abandonment for non-payment
would [***]. Protalix will notify Pfizer of any decision (a) not to file applications for, or (b) not to enter the national phase
for a PCT patent application (or not to validate a patent in a particular Country) for, or (c) to cease prosecution and/or maintenance
of, or (d) not to pursue, or (e) to cease to pay the expenses of prosecution or maintenance of, any Protalix Patent Rights in any
Country in the Territory. Protalix will provide such notice upon the earlier of (i) its decision with respect to any of the foregoing,
or (ii) ninety (90) days prior to any filing or payment due date, or any other due date that requires action, in connection with
such Protalix Patent Rights. In such event, Pfizer shall have the right to make the filing, or to continue the prosecution and
maintenance of such Patent Rights (other than Protalix System Patent Rights) in its own name and at its sole expense, and such
Patent Rights shall be assigned to Pfizer and shall no longer be part of the Protalix Patent Rights. Notwithstanding the foregoing,
Protalix shall have no obligation to provide such notice where the subject Protalix Patent Rights are directed solely to an [***].

 

8.4          Notices
and Encumbrances. Protalix agrees that it will, and will cause its Affiliates to, (a) execute and file those notices and other
filings as Pfizer shall request be made, from time to time with the United States Patent and Trademark Office (or any successor
agency) or any analogous patent office in the Territory with respect to the rights granted under this Agreement and, (b) maintain
(subject to Section 8.3) at all times during the Term sole ownership of the Patents and Patent Applications under the Protalix
Patent Rights (other than Protalix Patent Rights directed solely to [***]), free and clear of any and all mortgages, liens, pledges,
security interests, charges or encumbrances. Protalix shall also keep the Protalix Technology (other than Protalix Technology directed
solely to or solely embodied in [***]), free and clear of any and all mortgages, liens, pledges, security interests, charges or
encumbrances during the Term. For the sake of clarity, encumbrances as contemplated in this Section 8.4 specifically exclude
licenses to Protalix Patent Rights and Protalix Technology, wherein such licenses are [***] [***] [***].

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	39	 

     

    

  

8.5          Patent
Term Extensions. Pfizer shall have the first right, but not the obligation, to seek, in Protalix’s name if so required,
patent term extensions, and supplemental protection certificates and the like available under Law, including 35 U.S.C. § 156
and applicable foreign counterparts, in any Country in the Territory in relation to the Protalix Patent Rights covering the Compound
(other than Protalix Patent Rights directed solely to the Compound [***]) or Licensed Products. In the event that Pfizer decides
not to seek such patent term extension or supplemental patent protection in any Country in the Territory, Protalix shall have the
right to seek such patent term extension or supplemental patent protection in any such Country. Protalix and Pfizer shall cooperate
in connection with all such activities, and Pfizer, its agents and attorneys will give due consideration to all suggestions and
comments of Protalix regarding any such activities, but in the event of a disagreement between the parties, as it relates to the
Compound ([***]) or Licensed Product, Pfizer will have the final decision-making authority. Any costs incurred by Pfizer in connection
with this Section 8.5 shall be borne [***]. Any costs incurred by Protalix in connection with this Section 8.5 shall
be borne [***].

 

8.6          Third
Party Infringement. Each party will promptly notify the other in the event of any actual, potential or suspected infringement
of a Patent under the Protalix Patent Rights by any Third Party.

 

(a)          Infringement
of Protalix Patent Rights in the Field.

 

(i)          Pfizer
shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third
Party infringement of the Protalix Patent Rights occurring in the Field within the Territory (other than Protalix Patent Rights
directly solely to [***]), where such Third Party infringement would reasonably be expected [***]. In order to establish standing,
Protalix, upon request of Pfizer, agrees to timely commence or to join in any such litigation, at [***] and in any event to cooperate
with Pfizer at [***]. Any costs and expenses incurred by Pfizer with respect to any such litigation or remedial measures shall
be [***] and any recoveries resulting from such litigation or measures relating to a claim of a Third Party infringement in pursuing
such claim, will be [***].

 

(ii)         Protalix
shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third
Party infringement of any Protalix Patent Rights occurring [***] and with respect to Third Party infringement of any Protalix Patent
Rights directed solely to [***] and any such litigation or remedial measures shall be [***]. Protalix shall retain [***] received
by Protalix as a result of its enforcement of Protalix Patent Rights under this Section 8.6(a)(ii).

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	40	 

     

    

  

(b)          Infringement
of Protalix Patent Rights [***]. Protalix shall have the sole right, but not the obligation, to institute litigation
or take other remedial measures in connection with Third Party infringement occurring [***] and any such litigation or remedial
measures shall be [***]. Protalix shall either (i) provide Pfizer with prior written notice of Protalix’s intent to initiate
a suit, take other appropriate action, or to not file suit or seek other redress or (ii) convene a meeting of the parties to discuss
what would be in the parties’ best interest with respect to the Third Party infringement occurring [***]. Protalix shall
retain [***] received by Protalix as a result of its enforcement of Protalix Patent Rights under this Section 8.6(b).

 

8.7          Paragraph
IV Notices.

 

(a)          If
either party receives a notice under 21 U.S.C. §355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) directed to a Compound ([***]) or
Licensed Product, concerning any Protalix Patent Right (“Paragraph IV Notice”), then it shall provide a copy
of such notice to the other party promptly and in any event no later than two (2) Business Days after its receipt thereof. Pfizer
shall have the exclusive right, but not the obligation, to initiate patent infringement litigation based on a Paragraph IV Notice
directed to a Compound ([***]) or Licensed Product, concerning a Protalix Patent Right, and any expenses incurred by Pfizer with
respect to such infringement litigation shall be [***]. Upon request of Pfizer, Protalix agrees to timely join as party−plaintiff
in any such litigation, and in any event to cooperate with Pfizer in connection with such infringement action, including timely
filing such action in Protalix’s name if required. Pfizer shall promptly notify Protalix of its intention not to initiate
patent infringement litigation based on such Paragraph IV Notice. The amount of any recovery from any such infringement suit with
respect to activities in the Field in the Territory will be [***].

 

(b)          Protalix
and Pfizer are aware of currently proposed legislation in the United States that may create or affect the regulatory pathway for
a follow-on biologic product to the Licensed Product. [***] To the extent required to establish standing, and possibly to comply
with heretofore unknown regulations accompanying this regulatory pathway, [***], shall reasonably cooperate with [***] in any litigation
or administrative action at [***] expense and shall commence or join in any such litigation or administrative action at [***] request
and expense. The amount of any recovery from any such proceedings shall first be used to pay reasonable costs, including attorneys’
fees and the remaining amount of the recovery will be [***].

 

8.8          Other
Actions by a Third Party. Each party shall promptly notify the other in the event of any (a) claims by a Third Party of alleged
patent infringement by Pfizer or Protalix or any of their respective Affiliates with respect to [***] of a Compound ([***]) or
Licensed Product or (b) legal or administrative action by any Third Party involving a Protalix Patent Right (other than Protalix
Patent Rights directed solely to [***]) of which it becomes aware, including any nullity, revocation, reexamination or compulsory
license proceeding. Pfizer shall have the first right, but no obligation, to defend against any such action involving such Protalix
Patent Right in the Territory when the alleged patent infringement would reasonably be expected to [***], and any such defense
shall be [***]. Protalix, upon request of Pfizer, agrees to join in any such action [***] and in any event to cooperate with Pfizer
[***] If Pfizer fails to defend Protalix against any such action involving a Protalix Patent Right, then Protalix shall have the
right to defend such action, and any such defense shall be[***]. Pfizer, upon request of Protalix, shall reasonably cooperate with
Protalix in any such action [***].

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	41	 

     

    

  

8.9          Compensation
to Inventors. [***]

 

8.10        Patent
Marking. Each party shall comply with the patent marking statutes in each Country in which a Licensed Product in the Field
is made, offered for sale, sold or imported by such party, its Affiliates and sublicensees.

 

8.11        In-Licensed
Patents. With respect to this Section 8, “Protalix Patent Rights” shall include Patent Rights that
are Controlled by Protalix or any of its Affiliates pursuant to a Third Party License (i.e., such Patent Rights are not
owned by Protalix or any of its Affiliates) only if [***]

 

Section
9.             CONFIDENTIALITY; PUBLICATION

 

9.1          Confidential
Information.

 

(a)          Pfizer
and Protalix each agree that during the Term and for five (5) years after the Term, it will keep confidential, and will cause its
Affiliates to keep confidential, all of the other party’s Confidential Information that is disclosed to it, or to any of
its Affiliates. Pfizer and Protalix each agree to take such action, and to cause its Affiliates to take such action, to preserve
the confidentiality of Protalix Confidential Information and Pfizer Confidential Information, respectively, as it would customarily
take to preserve the confidentiality of its own similar types of confidential information.

 

(b)          Each
of Pfizer, Protalix and their respective Affiliates agree (i) to use Protalix Confidential Information and Pfizer Confidential
Information, respectively, only as expressly permitted in this Agreement and (ii) not to disclose Protalix Confidential Information
and Pfizer Confidential Information, respectively, to any Third Parties under any circumstance without the prior consent of the
other party, except as expressly permitted in this Agreement.

 

9.2          Permitted
Disclosure of Confidential Information.

 

(a)          Disclosure
of Protalix Confidential Information.

 

(i)          Notwithstanding
anything to the contrary in this Section 9, Pfizer may disclose Protalix Confidential Information: (A) to Governmental Authorities
(x) to the extent desirable to obtain or maintain Regulatory Approvals for the Compound or Licensed Product within the Territory,
and (y) in order to respond to inquiries, requests or investigations relating to this Agreement; (B) to Sublicensees, outside consultants,
contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent
desirable to Develop, register or Commercialize the Compound or Licensed Product; provided that Pfizer shall obtain the
same confidentiality obligations and degree of care from such Third Parties as it obtains with respect to its own similar types
of confidential information; provided further that no Protalix Confidential Information consisting of non-public information
relating to Protalix’s manufacturing know-how may be disclosed (and, notwithstanding anything to the contrary herein, Protalix
shall not have any obligation under this Agreement to disclose any such manufacturing know-how) to any Sublicensee that is a direct
competitor of Protalix in the field of plant cell expressed biologics manufacturing, except to the extent such disclosure is necessary
for Pfizer to identify and establish an alternative source of supply of Drug Substance pursuant to Section 5.21(d); (C)
in connection with filing or prosecuting Patent Rights or trademark rights as permitted by this Agreement; (D) in connection with
prosecuting or defending litigation as permitted by this Agreement; (E) in connection with or included in scientific presentations
and publications relating to the Compound or Licensed Product, including abstracts, posters, journal articles and the like, and
posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites; and (F) to the extent necessary
or desirable in order to enforce its rights under this Agreement.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	42	 

     

    

  

(ii)         If
Pfizer is required or requested to disclose Protalix Confidential Information (x) as required by Law or legal proceedings or (y)
as required to be contained in Pfizer’s financial statements prepared in accordance with GAAP, as applied on a consistent
basis, Pfizer shall (1) with respect to disclosures described in clause (x), use Commercially Reasonable Efforts to obtain confidential
treatment of financial and trade secret information, and (2) with respect to disclosures described in clauses (x) and (y), if reasonably
practicable under the circumstances, give Protalix sufficient advance notice of the text so that Protalix will have the opportunity
to seek, at its own cost, an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement.
If Protalix seeks a protective order, Pfizer will cooperate. If Protalix fails to obtain a protective order or waive compliance
with the relevant portions of this Agreement, Pfizer will disclose only that portion of information concerning the Compound or
Licensed Product which its legal counsel determines it is required to disclose.

 

(b)          Disclosure
of Pfizer Confidential Information.

 

(i)          Notwithstanding
anything to the contrary in this Section 9, Protalix may disclose Pfizer Confidential Information to: (x) Governmental Authorities
in order to respond to inquiries, requests or investigations relating to this Agreement or to comply with applicable Laws and (y)
to the extent necessary or desirable in order to enforce its rights under this Agreement.

 

(ii)         If
Protalix is required or requested to disclose Pfizer Confidential Information (x) as required by Law or legal proceedings or in
connection with Section 9.2(b)(i) above or (y) as required to be contained in Protalix financial statements prepared in
accordance with GAAP, as applied on a consistent basis, Protalix shall (1) with respect to disclosures described in clause (x),
use Commercially Reasonable Efforts to obtain confidential treatment of financial and trade secret information, and (2) with respect
to disclosures described in clauses (x) and (y), if reasonably practicable under the circumstances, give Pfizer sufficient advance
notice of the text so that Pfizer will have the opportunity to seek, at its own cost, an appropriate protective order or other
remedy or waive compliance with the provisions of this Agreement. If Pfizer seeks a protective order, Protalix will cooperate.
If Pfizer fails to obtain a protective order or waive compliance with the relevant portions of this Agreement, Protalix will disclose
only that portion of information concerning the Compound or Licensed Product which its legal counsel determines it is required
to disclose.

 

    	 	43	 

     

    

  

(iii)        If
Protalix desires to disclose Pfizer Confidential Information that (x) has been announced previously in accordance with Section
9.4 (Publicity), or (y) has been announced previously by Pfizer, such disclosure is permitted so long as (1) it is consistent
with such previously announced statement and (2) Pfizer is permitted a review and comment period of no fewer than sixty (60) days
prior to the planned disclosure to redact any Pfizer Confidential Information and ensure the disclosure is within the scope of
previous disclosures as set forth in this Section 9.2(b)(iii).

 

9.3          Publication.

 

(a)          Subject
to Section 9.3(d), neither Pfizer nor any of its Affiliates or their respective employees, consultants, contractors and
agents shall publish or present any information, including the results of any preclinical or clinical studies, with respect to
the Compound or Licensed Product unless Pfizer has used Commercially Reasonable Efforts to provide Protalix with thirty (30) days’
notice prior to any such publication or presentation.

 

(b)          Subject
to Section 9.3(c) and Section 9.3(d), neither Protalix nor any of its Affiliates or their respective employees, consultants,
contractors, licensees and agents shall publish or present any information, including the results of any preclinical or clinical
studies, with respect to the Compound ([***]) or Licensed Product without the prior written approval of Pfizer ([***]), except
as may be required by Law or legal proceedings.

 

(c)          Section
9.3(a) does not prohibit: (i) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees
and agents) from publishing or presenting information relating to the development or use of the System that does not contain information
with respect to the Compound (other than the Oral Formulation) or Licensed Product; (ii) Protalix and its Affiliates (and their
respective employees, consultants, contractors, licensees and agents) from publishing or presenting information relating to the
Oral Formulation; or (iii) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees and
agents) from publishing or presenting information that has been either previously published or presented by Protalix in accordance
with Section 9.3(a) or by Pfizer. Protalix will use Commercially Reasonable Efforts to provide Pfizer a copy of any such
proposed publication or presentation described in clauses (i) or (ii) of this Section 9.3(c) at least thirty (30) days prior
to any such publication or presentation.

 

(d)          Nothing
in this Section 9.3 shall be construed to (a) limit the rights of either party’s Third Party clinical investigators
to publish the results of their studies or (b) prevent either party from complying with applicable Law with respect to the disclosure
of clinical study data and results or of any other material matter or information.

 

9.4          Publicity.

 

(a)          The
public announcement of the execution of this Agreement is set forth on Exhibit I attached hereto and shall be promptly disseminated
as a press release following the execution of this Agreement by Protalix.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	44	 

     

    

  

(b)          Except
as set forth in Sections 9.3, 9.4(a) or 9.4(c) or with respect to any activities or contemplated activities
by Protalix outside of the Territory, Protalix shall not make (and shall cause its Affiliates not to make) any public statement
(written or oral), including in analyst meetings, concerning the terms of, or events related to, this Agreement or concerning the
Licensed Product in the Territory without the prior written approval of Pfizer (which may be withheld in its sole and final discretion)
except where such statement: (i) is required by Law or legal proceedings (or to respond to a specific request of the securities
exchange upon which Protalix’s securities are listed); (ii) is required to be contained in Protalix financial statements
prepared in accordance with GAAP; (iii) has been announced previously in accordance with this Section 9.4; or (iv) has been
announced previously by Pfizer; so long as, in the case of (iii) or (iv), such public statement is consistent with such previously
announced statement. In the case of any public statement (written or oral) that is required by Law or legal proceedings, Protalix
shall (and shall cause its Affiliates to) (x) use Commercially Reasonable Efforts to obtain confidential treatment of financial
and trade secret information (except in connection with press releases) and (y) if reasonably practicable under the circumstances,
give Pfizer sufficient advance notice of the text so that Pfizer will have the opportunity to comment upon the statement, and give
due consideration to any specific reasonable comments of Pfizer on such text timely received from Pfizer.

 

(c)          Section
9.4(b) does not prohibit Protalix from making public announcements that any of the following has commenced or has been completed:
any [***]; provided that such public announcement complies with all applicable Laws. Protalix will provide Pfizer a copy
of any such proposed public announcement at least ten (10) Business Days prior to such announcement so that Pfizer will have the
opportunity to comment upon the announcement, and give due consideration to any specific reasonable comments of Pfizer on such
text timely received from Pfizer. For the avoidance of doubt, this Section 9.4(c) shall be subject to Section 9.3(b).

 

9.5          Filing,
Registration or Notification of the Agreement. If a party determines that it is required by Law to publicly file, register
or notify this Agreement with a Governmental Authority, such party shall provide to the other party a redacted version of this
Agreement indicating the sections of the Agreement to be redacted in such filing and both parties shall agree in good faith upon
a final redacted version of the Agreement for such filing (the “Redacted Agreement”). The disclosing party shall
(a) initially file the Redacted Agreement, (b) request, and use Commercially Reasonable Efforts to obtain, confidential treatment
of all terms redacted from this Agreement, as reflected in the Redacted Agreement, for a period of at least ten (10) years, (c)
permit the other party to review and approve such request for confidential treatment and any subsequent correspondence with respect
thereto at least five (5) Business Days prior to its submission to such Governmental Authority, (d) promptly deliver to the other
party any written correspondence received by it or its representatives from such Governmental Authority with respect to such confidential
treatment request and promptly advise the other party of any other communications between it or its representatives with such Governmental
Authority with respect to such confidential treatment request, (e) upon the written request of the other party, request an appropriate
extension of the term of the confidential treatment period for this Agreement, the Original Agreement and the First Amendment,
and (vi) if such Governmental Authority requests any changes to the redactions set forth in the Redacted Agreement, use Commercially
Reasonable Efforts to support the redactions in the Redacted Agreement as originally filed and shall not agree to any changes to
the Redacted Agreement without first discussing such changes with the other party and taking the other party’s comments into
consideration when deciding whether to agree to such changes. Each party shall be responsible for its own legal and other external
costs in connection with any such filing, registration or notification. Notwithstanding the foregoing or anything to the contrary
herein, Pfizer acknowledges and agrees that Protalix BioTherapeutics, Inc. shall have the right to describe (and, as reasonably
necessary, include) this Agreement in its U.S. Securities and Exchange Commission (“SEC”) filings; provided,
however, that Protalix shall give Pfizer sufficient advance notice of the text describing this Agreement in its filings
with the SEC so that Pfizer will have the opportunity to comment upon such description, and Protalix shall give due consideration
to any specific reasonable comments of Pfizer on such description timely received from Pfizer.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	45	 

     

    

 

 

Section
10.           REPRESENTATIONS, WARRANTIES AND COVENANTS

 

10.1        Protalix
Representations, Warranties and Covenants. Protalix hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise indicated) and covenants to Pfizer as follows:

 

(a)          Protalix
has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and the
execution, delivery and performance of this Agreement by Protalix have been duly and validly authorized and approved by proper
corporate action on the part of Protalix, and Protalix has taken all other action required by Law, its certificate of incorporation,
by-laws or other organizational documents or any agreement to which it is a party or to which it may be subject, required to authorize
such execution, delivery and performance. Assuming due authorization, execution and delivery on the part of Pfizer, this Agreement
constitutes a legal, valid and binding obligation of Protalix, enforceable against Protalix in accordance with its terms.

 

(b)          The
execution and delivery of this Agreement by Protalix and the performance by Protalix contemplated hereunder does not and will
not violate any Laws (as in effect on the Second Amendment Effective Date), except for such violations that would not have an
adverse effect on the ability of Protalix to perform its obligations under this Agreement, or any order of any court or Governmental
Authority in effect on the Second Amendment Effective Date.

 

(c)          To
the knowledge of Protalix, the Protalix Patent Rights owned by Protalix or its Affiliates are valid and enforceable and no Third
Party (i) is infringing any such Protalix Patent Rights or (ii) has challenged the validity or enforceability of the Protalix
Patent Rights owned by Protalix or its Affiliates (including by way of example through the institution or written threat of institution
of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous
foreign entity).

 

(d)          To
the knowledge of Protalix, neither (i) the Manufacture, use or Development (including the use or provision of Licensed Product
in Early Access Programs) by Protalix (or its Affiliates) of the Drug Substance or Licensed Product on or prior to the Second
Amendment Effective Date has infringed nor (ii) the Manufacture, use, Development, sale, offer for sale, supply or importation
by Protalix or Pfizer (or their respective Affiliates) of the Drug Substance or Licensed Product (as currently constituted) on
or prior to the Second Amendment Effective Date or as contemplated by this Agreement has infringed or would infringe any issued
Patent of any Third Party that exists on the Second Amendment Effective Date or, if and when issued, any valid claim within any
Third Party Patent Application published before the Second Amendment Effective Date.

 

    	 	46	 

     

    

 

(e)          Exhibit
B contains a complete and correct list as of the Second Amendment Effective Date of all Patents and Patent Applications owned
by or otherwise Controlled by Protalix (and indicating which entity owns or Controls each Patent and Patent Application and which
are owned and which are Controlled) covering the Compound, any Licensed Product and the System.

 

(f)           Protalix
is the sole and exclusive owner of all the Protalix Patent Rights and Protalix Technology (other than Patent Rights licensed to
Protalix as described in Exhibit B), free of any lien, encumbrance, charge, security interest, mortgage or other similar
restriction, and no Person (including any Affiliate of Protalix) has any right, interest or claim in or to, and neither Protalix
nor any of its Affiliates has entered into any agreement granting any right, interest or claim in or to any Protalix Patent Rights
owned by Protalix or its Affiliates or Protalix Technology to any Third Party, including any academic organization or agency.

 

(g)          Protalix
has complied in all material respects with all applicable Laws, including any disclosure requirements, in connection with the
filing, prosecution and maintenance of the Protalix Patent Rights (other than Patent Rights licensed to Protalix) in the Territory.

 

(h)          Prior
to the Second Amendment Effective Date, to the extent such activities have been conducted by Protalix, its Affiliates or Third
Parties acting on behalf of Protalix, the Compound, Drug Substance and Licensed Product have been Developed, Manufactured, stored,
labeled, distributed and tested by Protalix and its Affiliates and, to the knowledge of Protalix, by any Third Parties acting
on behalf of Protalix, in compliance in all material respects with all applicable Laws.

 

(i)           Other
than Patent Rights licensed to Protalix as described in Exhibit B, none of the rights of Protalix or its Affiliates under
the Protalix Patent Rights were developed with federal funding from the United States government or any other Governmental Authority,
other than grants received by Protalix from the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor
(the “Israel Grant”), a copy of which Protalix has provided to Pfizer prior to the Second Amendment Effective
Date. No obligations, restrictions or covenants have been imposed upon Protalix or its licensees, the Drug Substance or the Licensed
Product in connection with the Israel Grant.

 

(j)           Protalix
has obtained assignments from the inventors of all inventorship rights relating to the Protalix Patent Rights (other than Patent
Rights licensed to Protalix), and all such assignments of inventorship rights covering the Protalix Patent Rights (other than
Patent Rights licensed to Protalix) are valid and enforceable.

 

    	 	47	 

     

    

 

(k)          Each
Third Party License as heretofore delivered by Protalix to Pfizer represents the complete agreement and understanding between
the Third Party licensor(s) under such Third Party License and Protalix relating to the Protalix Patent Rights and Protalix Technology
which are the subject of such Third Party License. No Third Party License has been modified, supplemented or amended, other than
by amendments thereto provided to Pfizer prior to the Second Amendment Effective Date. Except for the Third Party Licenses
listed on Exhibit C, there are no agreements to which Protalix or any of its Affiliates is a party pursuant to which Protalix
or any of its Affiliates has a license, or an option to obtain a license, or holds an immunity from suit, with respect to patents
which (i) are pending, applied for, granted or registered, and (ii) but for Protalix’s rights under such agreements, could
be asserted by Third Parties to be infringed by the Manufacture, distribution, use, marketing or sale of the Drug Substance or
Licensed Product. Each Third Party License is in full force and effect, all payments to date required to be made thereunder by
Protalix have been made, and Protalix is in compliance in all respects with its respective obligations thereunder. [***]

 

(l)           Protalix
has previously delivered to Pfizer all of its material agreements with any Third Parties regarding the Development, supply and
Manufacture of all goods and services relating to the Drug Substance and Licensed Product to the extent requested by Pfizer, none
of which have been modified, supplemented or amended in any material respect, other than by amendments thereto provided to
Pfizer prior to the Second Amendment Effective Date. Each such agreement is in full force and effect, all payments to date required
to be made thereunder by Protalix have been made, and Protalix is in compliance in all respects with its respective obligations
thereunder.

 

(m)         Protalix
has heretofore disclosed to Pfizer all material scientific and technical information and all material information relating to
safety and efficacy known to it or its Affiliates with respect to the Drug Substance and Licensed Product.

 

(n)          Protalix
has heretofore disclosed to Pfizer all material correspondence and contact information between Protalix and the FDA and any other
Governmental Authorities regarding the Drug Substance or Licensed Product.

 

(o)          Neither
the execution and delivery of this Agreement nor the performance hereof by Protalix requires Protalix to obtain any permits, authorizations
or consents from any Governmental Authority or from any other Person, and such execution, delivery and performance will not result
in the breach of or give rise to any right of termination, rescission, renegotiation or acceleration under, or trigger any other
rights under, any agreement or contract to which Protalix is a party or to which it may be subject that relates to the Protalix
Patent Rights, Protalix Technology, Drug Substance or Licensed Product.

 

(p)          There
is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of
any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Protalix, threatened
against Protalix, any of its Affiliates or any Third Party, in each case in connection with the Protalix Patent Rights owned by
Protalix, Protalix Technology owned by Protalix, the Drug Substance, the Licensed Product, the System, Protalix’s business
practices relating to the Drug Substance or the Licensed Product, Protalix’s compliance with the Foreign Corrupt Practices
Act of 1977, as amended and the U.K. Bribery Act, or relating to the transactions contemplated by this Agreement.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	48	 

     

    

 

(q)          To
the knowledge of Protalix, information provided by Protalix in response to any of Pfizer’s due diligence requests prior
to the Second Amendment Effective Date was in all material respects complete, truthful and accurate.

 

(r)           Protalix
and, to Protalix’s knowledge, any agent or subcontractor of Protalix engaged in activities related to this Agreement has
not and will not directly or indirectly offer or pay, or authorize such offer or payment, of any money or anything of value or
improperly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted,
and will not accept in the future such payment in connection with this Agreement. For purposes of this Section 10.1, a
“Government Official” is defined as and includes: (i) any elected or appointed government official (e.g., a
member of a ministry of health); (ii) any employee or person acting for or on behalf of a Government Official, agency, or enterprise
performing a governmental function; (iii) any political party, officer, employee, or person acting for or on behalf of a political
party or candidate for public office; (iv) an employee or person acting for or on behalf of a public international organization;
or (v) any person otherwise categorized as a Government Official under local Law where “Government” includes all levels
and subdivisions of non-U.S. governments (i.e., local, regional, or national and administrative, legislative, or executive).

 

(s)          To
the knowledge of Protalix, all information provided by Protalix or its Affiliate to Pfizer during pre-contractual due diligence,
including the information provided in the compliance questionnaire (the “Compliance Questionnaire”), is in
all material respects complete, truthful and accurate. Further, Protalix undertakes to promptly update this representation and
warranty if (during the Term) Protalix, or any of its employees, or individuals, or subcontractors who will be primarily responsible
for performing under this Agreement, or a relative of such an employee or individual or subcontractor, becomes a Government Official
or, if a government or Government Official becomes an owner of five percent (5%) or more of Protalix.

 

(t)           Protalix
will comply in all material respects with Pfizer’s Anti-Bribery and Anti-Corruption Principles set forth on Appendix
10.1(t).

 

(u)          Protalix
will complete and submit to Pfizer an executed copy of the compliance certification attached hereto as Exhibit K on the
Second Amendment Effective Date.

 

(v)         [***]

 

(w)          Protalix
has implemented, and will maintain, a system of internal accounting controls designed to ensure the making and keeping of fair
and accurate books, records, and accounts with respect to Protalix’s business or any services provided under the Agreement,
as and to the extent required under Section 4.8 and Section 5.15 hereof.

 

(x)          Protalix
undertakes to promptly inform Pfizer if it becomes aware of any compliance issues related to any allegations of improper payments
to healthcare professionals or Government Officials that have not been previously reported and related to any discussions, notices
or changes with respect to any investigation by Governmental Authorities or Regulatory Authorities or prosecution involving allegations
of corruption or serious criminal misconduct involving its business.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	49	 

     

    

 

(y)          Protalix
will, subject to and in accordance with Section 5.15 hereof, permit, during the Supply Term and for [***] after final payment
has been made under the Agreement, Pfizer’s internal and external auditors access to any relevant books, documents, papers,
and records of Protalix involving transactions related to the Agreement.

 

(z)          With
respect to the Commercialization of the Licensed Product in Israel, since January 1, 2015, Protalix has not (i) materially altered
its activities and practices with respect to inventory levels of the Licensed Product maintained at the wholesale, pharmacy or
institutional levels, including its practices with respect to product samples, or (ii) sold, transferred or given any supplies
or samples of the Licensed Product to any Third Party in or for use in Israel, in each case, except in the ordinary course of
business that is consistent with past practice.

 

(aa)        [***]

 

10.2        Manufacturing
Representations, Warranties and Covenants. Each party hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise stated) and covenants to the other party as follows:

 

(a)          All
Drug Substance and Licensed Product Manufactured and supplied hereunder by, or under authority of, such party shall be Manufactured
and supplied such that:

 

(i)          Any
Facility and all equipment, tooling and molds utilized in the Manufacture and supply of Drug Substance and Licensed Product hereunder
by such party shall, during the Term, be maintained in good operating condition and shall be maintained and operated in accordance
with all applicable Laws. The Manufacturing and storage operations, procedures and processes utilized by such party in Manufacture
and supply of Drug Substance and Licensed Product hereunder (including any Facility) shall be in full compliance with all applicable
Laws, including GMP and health and safety Laws.

 

(ii)         Such
party shall perform all of its Manufacturing and supply obligations under this Agreement in full compliance with all applicable
Laws. Such party shall hold during the Term all licenses, permits and similar authorizations required by any Governmental Authority
for such party to perform its Manufacturing and supply obligations under this Agreement.

 

(b)          The
Drug Substance and Licensed Product, as applicable, furnished by such party [***]:

 

(i)          shall
be Manufactured, packaged, labeled, handled, stored and shipped in accordance with, shall be of the quality specified in, and
shall conform to, the Product Specifications;

 

(ii)         shall
be Manufactured, packaged, labeled, handled, stored and shipped in compliance with all applicable Laws including GMP, and in accordance
with the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this
Agreement) and any other quality assurance requirements provided in writing to such party by the other party, and this Agreement;

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	50	 

     

    

 

(iii)        shall
not contain any material that has not been used, handled or stored in accordance with the Product Specifications, all applicable
Laws, the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this
Agreement) and any other quality assurance requirements of the other party or the supplier of such material, and this Agreement;

 

(iv)        shall
not contain any material that would cause the Drug Substance or Licensed Product to be adulterated or misbranded within the meaning
of any Laws;

 

(v)         shall
be free from defects in material and workmanship; and

 

(vi)        shall,
at the time delivered, have a remaining shelf-life as specified in the Quality Agreement (with respect to Drug Substance and/or
Licensed Product furnished by Protalix to Pfizer under this Agreement) and Section 5.8(a).

 

(c)          Such
party does not currently employ and will not employ during the Term, and such party does not use as a subcontractor and will not
use during the Term, and such party’s subcontractors do not currently employ and will not employ or engage during the Term,
any Person that has been debarred or is subject to debarment or has otherwise been disqualified or suspended from performing scientific
or clinical investigations or otherwise subjected to any restrictions or sanctions by the FDA or any other Governmental Authority
or Regulatory Authority or professional body with respect to the performance of scientific or clinical investigations; any other
Person who by virtue of any Laws is or may be disqualified, restricted or prevented in any way from performing the services to
be provided under this Agreement; or any Person convicted of a criminal offense in relation to:

 

(i)          In
respect of a company, partnership or association, the development or approval, including the process for development or approval
of an abbreviated drug application;

 

(ii)         In
respect of an individual:

 

(A)         the
development or approval of any drug product or otherwise relating to the regulation of any drug product; or

 

(B)         bribery,
payment of illegal gratuities, fraud, perjury, false statement, racketeering, blackmail, extortion, falsification or destruction
of records or interference with, obstruction of an investigation into a prosecution of any criminal offense.

 

    	 	51	 

     

    

 

(d)          Notwithstanding
the foregoing in this Section 10.2, Pfizer shall not be responsible for any failure to conform to the representations and
warranties under Sections 10.2(a) and 10.2(b), and shall have no liability to Protalix with respect thereto to the
extent that Pfizer’s failure to conform to such representations and warranties is as a result of an act or omission of Protalix,
Protalix’s Affiliates or their respective agents, consultants or contractors in respect of the Manufacture of Drug Substance.
Notwithstanding the foregoing in this Section 10.2, Protalix shall not be responsible for any failure to conform to the
representations and warranties under Sections 10.2(a) and 10.2(b), and shall have no liability to Pfizer with respect
thereto to the extent that Protalix’s failure to conform to such representations and warranties is as a result of an act
or omission of Pfizer, Pfizer’s Affiliates or their respective agents, consultants or contractors in respect of their Fill/Finish
activities or supply of Licensed Product to Protalix for Commercialization in Israel or in respect of the Drug Substance after
acceptance by Pfizer of the Drug Substance supplied to Pfizer, such as a failure to properly store the Drug Substance.

 

10.3        Environmental
Representations, Warranties and Covenants. Each party hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise indicated) and covenants to the other party as follows:

 

(a)          Compliance
With Environmental Laws.

 

(i)          To
the knowledge of such party, there is no pending or threatened governmental enforcement action or private claim against such party
pursuant to applicable Environmental Law, no Release or threatened Release of Hazardous Materials, nor any other existing environmental
conditions, events or circumstances that are reasonably likely to limit, impede or otherwise jeopardize such party’s ability
to meet its Manufacturing obligations under this Agreement.

 

(ii)         Such
party shall perform all of the Manufacturing services to be provided by it hereunder in compliance with all Environmental
Laws and all licenses, registrations, notifications, certificates, approvals, authorizations or permits required under applicable
Environmental Laws (“Environmental Permits”), except where such non-compliance would not be reasonably likely
to limit, impede or otherwise jeopardize such party’s ability to meet its Manufacturing obligations under this Agreement.
Such party shall abate any condition or practice, regardless of whether such condition or practice constitutes non-compliance
with Environmental Laws, with respect to its usage, handling, storage or disposal of Hazardous Materials, that would be reasonably
likely to limit, impede or otherwise jeopardize such party’s ability to fulfill its Manufacturing obligations under this
Agreement.

 

(b)          Notice
to Other Party. Such party shall provide the other party with reasonably prompt notice in the event of any significant event,
occurrence or circumstance, including any governmental or private action in connection with such party’s compliance with
applicable Environmental Laws or with respect to such party’s usage, handling, storage or disposal of Hazardous Materials,
which would be reasonably likely to limit, impede or otherwise jeopardize such party’s ability to fulfill its Manufacturing
obligations under this Agreement. These could include, but are not limited to: (i) material revocation or modification of any
of such party’s Environmental Permits, (ii) any action by Governmental Authorities that may reasonably lead to the material
revocation or modification of such party’s Environmental Permits, (iii) any Third Party claim against the management or
ownership of any Facility pursuant to applicable Environmental Law that could reasonably and materially impact such party’s
obligations under this Agreement, (iv) any fire, explosion, significant accident (one causing serious injury or fatality), or
catastrophic Release of Hazardous Materials, (v) any significant non-compliance with Environmental Laws, and (vi) any environmental
condition or operating practice that may reasonably be believed to present a significant threat to human health, safety or the
environment.

 

    	 	52	 

     

    

 

(c)          Equipment.
Such party shall be solely responsible for the safe operation and maintenance of all equipment used to fulfill its Manufacturing
obligations under this Agreement, and all associated employee training, regardless of whether the equipment is owned by such party,
the other party or a Third Party.

 

(d)          Environmental,
Health and Safety Reviews. Each party shall permit the other party reasonable access to conduct periodic reviews during regular
business hours of the environmental and health and safety practices and performance of the Facility(ies) where such party’s
performance is occurring. In connection with such audit or evaluation, such party shall assist in the other party’s completion
of an Environmental Health & Safety survey of such party or the scheduling of an Environmental Health & Safety audit of
any Facility, as applicable. Such party will provide copies of all Environmental Permits to the other party upon request in connection
with such review. The other party shall share its findings with such party as soon as practicable and such party shall correct,
at no expense to the other party, such deficiencies in its environmental and health and safety management practices that materially
jeopardize its ability to fulfill its Manufacturing obligations under this Agreement. Such party acknowledges that such reviews
and evaluations conducted by the other party are for the benefit of the other party only; they are not a substitute for such party’s
own environmental and health and safety management obligations under this Agreement and accordingly, such party may not rely upon
them.

 

10.4        Pfizer
Representations, Warranties and Covenants. Pfizer hereby represents and warrants as of the Second Amendment Effective
Date (unless otherwise indicated) and covenants to Protalix as follows:

 

(a)          Pfizer
has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and the
execution, delivery and performance of this Agreement by Pfizer have been duly and validly authorized and approved by proper corporate
action on the part of Pfizer, and Pfizer has taken all other action required by Law, its certificate of incorporation or by-laws,
or any agreement to which it is a party or to which it may be subject, required to authorize such execution, delivery and performance.
Assuming due authorization, execution and delivery on the part of Protalix, this Agreement constitutes a legal, valid and binding
obligation of Pfizer, enforceable against Pfizer in accordance with its terms.

 

(b)          The
execution and delivery of this Agreement by Pfizer and the performance by Pfizer contemplated hereunder does not and will not
violate any Laws, except for such violations that would not have an adverse effect on the ability of Pfizer to perform its obligation
under this Agreement, or any order of any court or Governmental Authority.

 

    	 	53	 

     

    

 

(c)          Neither
the execution and delivery of this Agreement nor the performance hereof by Pfizer requires Pfizer to obtain any permits, authorizations
or consents from any Governmental Authority (other than any Regulatory Approvals relating to the Manufacture, use, importation
or sale of the Compound or Licensed Product) or from any other Person, and such execution, delivery and performance will not result
in the breach of or give rise to any right of termination under any agreement or contract to which Pfizer is a party or to which
it may be subject, except for those breaches or rights that would not adversely affect the ability of Pfizer to perform its obligations
under this Agreement.

 

(d)          There
is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of
any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Pfizer, threatened
against Pfizer or any of its Affiliates or any Third Party relating to the transactions contemplated by this Agreement.

 

10.5        Disclaimer
of Warranty. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY
OF ANY KIND WITH RESPECT TO THE COMPOUND, DRUG SUBSTANCE, ANY LICENSED PRODUCT, PROTALIX IMPROVEMENT, PROTALIX PATENT RIGHTS,
PROTALIX TECHNOLOGY OR CONFIDENTIAL INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, EACH PARTY EXPRESSLY
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.

 

Section
11.           ADDITIONAL COVENANTS

 

11.1        Restrictions
on Transfers and Liens. Protalix shall not (and shall cause its Affiliates not to) sell, assign or otherwise transfer
to any Person any Protalix Patent Rights or any Protalix Technology (or agree to do any of the foregoing), except to the extent
permitted by, and in compliance with, Section 18.6 (including, for the avoidance of doubt, to any permitted assignee of
the Agreement permitted by and in compliance with Section 18.6). In addition, Protalix hereby covenants and agrees that
Protalix shall not incur or permit to exist (and shall cause each of its Affiliates not to incur or permit to exist), with respect
to any Protalix Patent Rights owned by Protalix and/or Protalix Technology owned by Protalix, any lien, encumbrance, charge, security
interest, mortgage, liability, grant of license to Third Parties in the Field in the Territory or other restriction (including
in connection with any indebtedness). For purposes of clarity, this Section 11.1 is not intended to prohibit Protalix from
(i) licensing to an Affiliate of Protalix or a Third Party rights under any Protalix Patent Rights or any Protalix Technology
to the extent such rights have not been licensed to Pfizer pursuant to this Agreement and to the extent such license by Protalix
does not otherwise conflict with the terms of this Agreement, or (ii) otherwise entering into any collaboration, license, assignment
or other commercial agreement with a Third Party with respect to the Protalix Patents or Protalix Technology in relation to any
products (excluding the Licensed Product) outside of the Field.

 

    	 	54	 

     

    

 

11.2        Third
Party Licenses and Agreements. Protalix (a) shall not execute or otherwise permit, and shall cause its Affiliates to
refrain from executing or otherwise permitting, any amendment, modification or waiver to any of the Third Party Licenses without
the prior written consent of Pfizer, (b) shall not make any election or exercise any right or option (or omit to take any action)
which would, and shall cause its Affiliates to refrain from making any election or exercising any right or option (or omitting
to take any action) which would, terminate or relinquish in whole or in part any right under a Third Party License, (c) shall
comply, and shall cause its Affiliates to comply in all respects, with all of its, and its Affiliates’, obligations under
the Third Party Licenses, (d) shall take, and shall cause its Affiliates to take, such actions as shall be necessary to keep in
full force and effect the Third Party Licenses, and (e) shall give prompt notice to Pfizer, together with a detailed summary of
outstanding issues if Pfizer so requests, of any notice received from the Third Party, of any actual or alleged defaults, breaches,
violations, proposed amendments or proposed modifications of, or any proposed waivers under, any of the Third Party Licenses by
any of the parties thereto. Protalix shall not assign or otherwise transfer any Third Party License or any of its rights or obligations
thereunder to any Person (or agree to do any of the foregoing) except to the extent permitted by, and in compliance with, Section
18.6. This Section 11.2 shall apply to the [***] to the same extent it applies to a Third Party License.

 

11.3        Compliance
with Laws. Each of Protalix and Pfizer shall conduct, and shall use reasonable efforts to cause its Affiliates to conduct,
all its activities contemplated under this Agreement in accordance with all applicable Laws of the Country in which such activities
are conducted.

 

11.4        Coordination
outside the Territory. Protalix and its Affiliates shall not, unless required by applicable Law, (a) conduct, or consent
to or support any activities by a Third Party, with respect to the Licensed Product in the Field outside the Territory (including
investigator-initiated research) if, in the good faith and reasonable judgment of Protalix, such activities would reasonably be
expected to adversely impact the market for the Licensed Product in the Field in the Territory in any material respect, or (b)
make any revisions to the labeling for the Licensed Product in the Field outside the Territory without first discussing such activities
with Pfizer.

 

11.5        Protalix
Non-Compete. From the Second Amendment Effective Date until the earlier of (a) the effective date of termination of
this Agreement or (b) the [***] anniversary of the Second Amendment Effective Date, neither Protalix nor any of its Affiliates
shall, directly or indirectly, alone or in collaboration with any Third Party, Commercialize in any Country in the Territory any
Competing Product.

 

11.6        Limitation
on Non-Compete Restrictions. Notwithstanding anything to the contrary herein, neither Protalix nor any of its Affiliates
will be deemed to be in breach of the restrictions set forth in Section 11.5, if Protalix or any of its Affiliates undergoes
[***] (and such Commercialization shall not be deemed to be a breach of Section 11.5).

 

11.7        [***]

 

11.8        [***]

 

11.9        [***]

 

Section
12.           [Reserved.]

 

Section
13.           TERM

 

This Agreement shall be effective as of
the Second Amendment Effective Date and shall remain in effect until the later of (i) the end of the term of the last to expire
of the Protalix Patent Rights and (ii) the expiration of the Supply Term, unless earlier terminated pursuant to Section 14
(the “Term”).

 

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	55	 

     

    

 

Section
14.           TERMINATION

 

14.1        Pfizer
Termination Right for Convenience. At any time and for any reason, Pfizer shall have the right, at Pfizer’s sole
discretion, to terminate this Agreement in its entirety, or with respect to a particular Country or Countries within the Territory,
such termination to be effective upon thirty (30) days prior written notice to Protalix.

 

14.2        Pfizer
Termination Right for Breach. If Protalix materially breaches or materially defaults in the performance or observance
of any of its obligations under this Agreement related to the Manufacture of the Drug Substance (including a Failure to Supply)
or a violation of any applicable anti-corruption law, and such breach or default is not cured within ninety (90) days after Pfizer
provides Protalix with written notice specifying such breach or default, then, in addition to all other remedies available at
law or in equity, Pfizer shall have the right to terminate this Agreement by providing Protalix written notice within ten (10)
days following the expiration of such ninety (90)-day period (such termination to be effective upon receipt of such notice). For
the avoidance of doubt, and notwithstanding the foregoing, a breach of Section 10.1(r) shall be considered a material breach
for purposes of this Section 14.2.

 

14.3         Protalix
Right of Termination. Protalix shall have no right to terminate this Agreement for any reason other than as set forth in this
Section 14.3. If Pfizer materially breaches or materially defaults in the performance or observance of any of its obligations
under this Agreement, and such breach or default is not cured within ninety (90) days after Protalix provides Pfizer with written
notice specifying such breach or default, then Protalix shall have the right to terminate this Agreement by providing Protalix
written notice within ten (10) days following the expiration of such ninety (90)-day period (such termination to be effective upon
receipt). For purposes of this Section 14.3, material breaches or material defaults in the performance or observance of
any of Pfizer’s obligations under this Agreement (for which a termination right may be triggered if such breach is not cured
as set forth above) shall be limited to: (i) Pfizer’s failure to pay the Price for the Drug Substance in accordance with
the terms of this Agreement and such failure to pay is not being disputed in good faith; and (ii) Pfizer’s breach of Section
3.7.

 

14.4        Continuing
and Accrued Obligations and Surviving Provisions. Termination of this Agreement for any reason (i) shall be without
prejudice to and shall not impair or limit in any manner (A) Protalix’s right to receive any payment from Pfizer that accrued
in accordance with this Agreement prior to the effective date of such termination, including for any Drug Substance ordered by
Pfizer pursuant to this Agreement prior to the effective date of such termination, whether or not the due date for such payment
is after such effective date of termination, (B) Pfizer’s right to receive the Protalix Payment from Protalix, which such
payment to be made in accordance with Section 14.5(b), and any payment from Protalix that accrued pursuant to this Agreement
prior to the effective date of such termination (subject to the last two sentences of Section 5.21(b)(i)) and (C) any remedies
that either party may have and (ii) shall not release a party hereto from any indebtedness, liability, payment or other obligation
incurred hereunder (including liability for breach of this Agreement) by such party prior to the effective date of termination.

 

    	 	56	 

     

    

 

14.5        Effects
of Termination or Expiration.

 

(a)          License
Grants. The licenses granted to Pfizer under Section 3.1 shall be perpetual and irrevocable such that the expiration
or termination of this Agreement for any reason shall not affect or limit any of the rights granted thereunder. Upon the effective
date of termination of this Agreement in accordance with this Section 14, except as otherwise provided in Section 14.4,
this Section 14.5, and Section 18.4, all other licenses and rights provided for herein, and all obligations of the
parties hereunder, shall terminate and this Agreement shall cease to be of further force or effect.

 

(b)          Deferred
Payment. If the Agreement is terminated by Pfizer pursuant to Section 14.1 or by Protalix pursuant to Section 14.3
before Protalix has made the Protalix Payment, Protalix shall pay to Pfizer the Protalix Payment in accordance with Section
6.2. If the Agreement is terminated by Pfizer pursuant to Section 14.2, Protalix shall pay to Pfizer the Protalix Payment
within thirty (30) days following the effective date of termination of this Agreement as provided in the Promissory Note.

 

(c)          Confidential
Information. Following any termination of this Agreement, each of Pfizer and Protalix shall, upon request of the other party,
return or destroy all Protalix Confidential Information and Pfizer Confidential Information, respectively, disclosed to it pursuant
to this Agreement, including all copies and extracts of documents, as promptly as practicable following receipt of such request,
except (i) that one (1) copy may be kept for the purpose of complying with continuing obligations under this Agreement and (ii)
to the extent and for so long as necessary to perform its obligations or exercise its rights under this Section 14.5.

 

14.6        Bankruptcy.
All rights and licenses granted under or pursuant to this Agreement by Protalix are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The parties agree that Pfizer, as the licensee of intellectual property under this Agreement,
shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. Without limiting the foregoing,
Section 365(n) shall apply to any case commenced under Chapter 15 of the U.S. Bankruptcy Code and, if the foreign representative
in such a case rejects or repudiates rights of licenses granted under or pursuant to this Agreement, Pfizer shall be entitled
to make the election and exercise the rights described in Section 365(n). The parties further agree that, in the event of a rejection
of this Agreement by Protalix in any bankruptcy proceeding by or against Protalix under the U.S. Bankruptcy Code or rejection
or repudiation by a foreign representative in a foreign bankruptcy proceeding, (a) Pfizer shall be entitled to a complete duplicate
of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which,
if not already in the possession of the licensee, shall be promptly delivered to it upon Pfizer’s written request therefor,
and (b) Protalix shall not interfere with Pfizer’s rights to intellectual property and all embodiments of intellectual property,
and shall assist and not interfere with Pfizer in obtaining intellectual property and all embodiments of intellectual property
from another entity. The term “embodiments” of intellectual property includes all tangible, intangible, electronic
or other embodiments of rights and licenses hereunder, including all compounds and products embodying intellectual property, Licensed
Products, regulatory filings, clinical studies and related rights, and Technology.

 

    	 	57	 

     

    

 

Section
15.           INDEMNIFICATION AND INSURANCE

 

15.1        Indemnification.

 

(a)          Protalix
will indemnify, defend and hold Pfizer and Pfizer’s Affiliates, and their respective directors, officers and employees harmless
from and against all Third Party Claims (defined in Section 15.3 below) and associated Losses, in each case to the extent
arising out of:

 

(i)          the
breach of any covenant, warranty or representation made by Protalix under this Agreement;

 

(ii)         the
negligence, recklessness, or willful misconduct of, or violation of law by, Protalix or any of its Affiliates;

 

(iii)        any
acts or omissions of Protalix or any of its Affiliates, agents, consultants or contractors (A) in connection with the research,
Development, Manufacture or Commercialization of the Drug Substance or Licensed Product prior to the Effective Date, (B) in connection
with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Products
in Brazil following the Amendment Effective Date, (C) in connection with the research, Development, Manufacture (including Fill/Finish)
or Commercialization of the Drug Substance or Licensed Product prior to the Second Amendment Effective Date and during the Israel
Transition Period or (D) in connection with the Manufacture of the Drug Substance for supply to Pfizer pursuant to
Section 5;

 

(iv)        (A)
any claim made by an [***] against Pfizer for any consideration allegedly owed to an [***] in connection with Commercialization
of the Licensed Product in Brazil, or the Technology Transfer Agreement, or (B) any inquiry, investigation, litigation or proceeding
by a governmental authority or Third Party regarding any ATME Person in connection with the Commercialization of the Licensed
Product in Brazil by Protalix, the Technology Transfer Agreement, or any other actions of an ATME Person on behalf of Protalix;
or

 

(v)         any
and all claims asserted by [***] against any Pfizer Indemnified Party with respect to the Drug Substance, the Licensed Product
[***], including any claims of infringement or misappropriation or for royalties, milestone payments, license fees or other payments
due thereunder, in relation to Pfizer’s exercise (in accordance with this Agreement) of the license granted hereunder to
Pfizer under the Protalix Patent Rights licensed by Protalix from VTIP [***]; provided however, Protalix shall not indemnify,
defend and hold Pfizer harmless to extent any such claim asserted by [***] relates to [***] intellectual property that has not
been licensed to Protalix under the [***]. For the avoidance of doubt, (a) in no event shall Pfizer be responsible for any royalties,
milestone payments, license fees or other payments payable to VTIP under the [***], and (b) Protalix shall be solely responsible
to [***] for any amounts owed to [***] under the [***].

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	58	 

     

    

 

Protalix shall be obligated to so indemnify, defend and hold
Pfizer harmless only to the extent that such Losses (i) do not arise from the negligence, recklessness or willful misconduct of
Pfizer and (ii) are not Losses as to which Protalix is entitled to indemnification pursuant to Section 15.1(b).

 

(b)          Pfizer
will indemnify, defend and hold Protalix, its Affiliates, and their respective directors, officers and employees harmless from
and against all Third Party Claims and associated Losses, to the extent arising out of:

 

(i)          the
breach of any covenant, warranty or representation made by Pfizer under this Agreement;

 

(ii)         the
negligence, recklessness, or willful misconduct of, or violation of law by, Pfizer or any of its Affiliates; or

 

(iii)        (A)
any acts or omissions of Pfizer or any of its Affiliates, agents, consultants or contractors in connection with the research,
Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field inside
the Territory (other than Israel or Brazil) after the Effective Date, (B) any acts or omissions of Pfizer or any of its Affiliates,
agents consultants or contractors in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization
of the Drug Substance or Licensed Product in the Field in Brazil prior to the Amendment Effective Date, or (C) any acts or omissions
of Pfizer or any of its Affiliates, agents, consultants or contractors in connection with the research, Development, Manufacture
(including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field in Israel after the Israel
Transition Period.

 

Pfizer shall be obligated to so indemnify, defend and hold
Protalix harmless only to the extent that such Losses (i) do not arise from the negligence, recklessness or willful misconduct
of Protalix and (ii) are not Losses as to which Pfizer is entitled to indemnification pursuant to Section 15.1(a).

 

15.2        Losses.
For purposes of this Agreement, “Losses” means any and all damages (including all incidental, consequential,
statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs,
fees, liabilities, obligations, taxes, liens, losses and expenses incurred by or awarded to Third Parties with respect to a Third
Party Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into, and all other
documented costs and expenses incurred in investigating, preparing or defending any Third Party Claim litigation or proceeding,
commenced or threatened, or in complying with any judgments, orders, decrees, stipulations and injunctions (including court costs,
interest and reasonable fees of attorneys, accountants and other experts).

 

    	 	59	 

     

    

 

15.3        Defense
Procedures; Procedures for Third Party Claims.

 

(a)          For
purposes of this Agreement, “Third Party Claim” means a claim asserted by a Third Party (in no event to include
any Affiliate of either party) against a party or any of its Affiliates, or any of their respective directors, officers and employees.
In the event a Third Party Claim is asserted with respect to any matter for which a party or any of its Affiliates, or any of
their respective directors, officers and employees (the “Indemnified Party”) is entitled to indemnification
hereunder, then the Indemnified Party shall promptly notify in writing the party obligated to indemnify the Indemnified Party
(the “Indemnifying Party”) thereof; provided, however, that no delay on the part of the Indemnified
Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then
only to the extent that) the Indemnifying Party is prejudiced thereby.

 

(b)          The
Indemnifying Party shall assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying
Party and reasonably acceptable to the Indemnified Party. The Indemnified Party shall have the right to join in (including the
right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at
its own expense, the defense of any Third Party Claim that the Indemnifying Party is defending as provided in this
Agreement. Notwithstanding anything to the contrary contained herein, an Indemnified Party shall be entitled to assume the defense
of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party, in which case the
Indemnifying Party shall be relieved of liability under Section 15.1, as applicable, solely for such Third Party Claim
and related Losses.

 

(c)          Neither
party will enter into any settlement of any suit involving Licensed Products that materially affects the other party’s rights
or obligations with respect to the Licensed Product without the other party’s prior written consent. Without limiting the
foregoing, the Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be
unreasonably withheld), effect any settlement of any pending or threatened litigation in which the Indemnified Party has sought
indemnification hereunder by the Indemnifying Party, unless such settlement involves solely monetary damages and includes an unconditional
release of the Indemnified Party from all liability on claims that are the subject matter of such litigation.

 

15.4         Disclaimer
of Liability for Consequential Damages. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER
THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT
LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE, SUFFERED BY PFIZER, PROTALIX OR ANY OF THEIR RESPECTIVE AFFILIATES,
EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM A PARTY’S WILLFUL MISCONDUCT OR INTENTIONAL BREACH OF ITS OBLIGATIONS UNDER
THIS AGREEMENT AND EXCEPT FOR ANY PERSISTENT FAILURE TO SUPPLY PAYMENTS AS EXPRESSLY PROVIDED IN SECTION 5.21. THE FOREGOING
SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER
Section 15 OR LIABILITIES RESULTING FROM A BREACH OF THE CONFIDENTIALITY
OBLIGATIONS UNDER Section 9 ABOVE AND PROVIDED THAT THIS SECTION
15.4 SHALL NOT RELIEVE EITHER PARTY FROM ITS PAYMENT OBLIGATIONS UNDER THIS AGREEMENT.

 

    	 	60	 

     

    

 

15.5        Sole
Remedy. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT AND EXCEPT FOR ANY EQUITABLE REMEDIES THAT MAY BE AVAILABLE
TO A PARTY, INDEMNIFICATION PURSUANT TO Section 15 SHALL BE THE SOLE AND
EXCLUSIVE REMEDY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY) AVAILABLE TO PROTALIX OR PFIZER FOR THE MATTERS COVERED
THEREIN.

 

15.6        Insurance
Requirements. As of the Second Amendment Effective Date, Protalix shall provide and maintain such insurance coverage,
in minimum types and amounts as described in subsection (b) below. As of the Second Amendment Effective Date, Pfizer shall
self insure or provide and maintain such insurance coverage, in minimum types and amounts as described in subsection (d)
below.

 

(a)          Protalix
Insurance Generally.

 

(i)          Any
and all deductibles for Protalix’s insurance policies (the “Protalix Insurance Policies”) shall be assumed
by, for the account of, and at Protalix’s sole risk. All deductibles and self-insured retention amounts shall be assumed
by Protalix.

 

(ii)         Such
Protalix Insurance Policies shall be primary and non-contributing with respect to any other similar insurance policies available
to Pfizer or its Affiliates. Except for employers’ liability and property insurance policies, Protalix will add Pfizer and
its Affiliates on all such Protalix Insurance Policies as additional insureds with respect to liability incurred by Pfizer or
its Affiliates arising from any acts or omissions of Protalix, and Protalix will require that the property insurance policy included
in the Protalix Insurance Policies include a waiver of subrogation in favor of Pfizer and its Affiliates.

 

(iii)        Prior
to the Second Amendment Effective Date, Protalix has provided Pfizer with original certificates and additional insurance endorsements
evidencing the specified insurance coverage, and at each renewal thereof or expiration of any one coverage, whichever occurs first,
Protalix shall furnish to Pfizer original certificates and additional insurance endorsements evidencing the specified insurance
coverage. Such certificates shall provide that not less than thirty (30) days prior written notice of any policy cancellation
or detrimental change shall be given to Pfizer. The certificate(s) of insurance shall be signed by a person authorized by the
insurer(s) to bind coverage on its (their) behalf. Protalix shall provide, pay for, and maintain in effect, the Protalix Insurance
Policies with a minimum “A-” A.M. Bests rating or S&P minimum of BBB or their substantial equivalent (in the case
of such policies in Israel, to the extent such ratings or substantial equivalents are available).

 

    	 	61	 

     

    

 

(b)          Protalix
Insurance Requirements. The insurance required under subsection (a) shall be written for not less than any limits of
liability specified herein or as required by law, whichever is greater; Protalix has the right to provide the total limits required
by any combination of primary and excess/umbrella coverage; said Protalix insurance to include, without limitation, the following:

 

(i)          Insurance
for liability applicable with respect to persons performing the work hereunder and employer’s liability insurance covering
all claims by or in respect to the employees of Protalix and all subcontractors, providing:

 

(ii)         Employer’s
liability insurance with a limit of the greater of the equivalent of [***] for each occurrence and in the aggregate in the Protalix
Insurance Policies.

 

(iii)        Commercial
General/Public Liability insurance with the following limits and forms/endorsements:

 

(A)         Each
occurrence and in the aggregate: [***]

 

(B)         Clinical
Trials Coverage or Products & Completed Operations Aggregate once products are marketed: $[***].

 

(C)         Pfizer
and its Affiliates as additional insureds with respect to any legal liability of Pfizer or its Affiliates, arising out of Protalix’s
performance hereunder.

 

If Protalix has care, custody or control of Pfizer property
or inventory, Protalix shall be responsible for any loss or damage to it, and provide all risk property coverage included within
the Protalix Insurance Policies at full replacement cost for same.

 

(c)          Pfizer
Insurance Generally.

 

(i)          Any
and all deductibles for Pfizer’s insurance policies (the “Pfizer Insurance Policies”) shall be assumed
by, for the account of, and at Pfizer’s sole risk.

 

(ii)         To
the extent of its negligence, such Pfizer Insurance Policies shall be primary and non-contributing with respect to any other similar
insurance policies available to Protalix or its Affiliates. Except for workers compensation/employers’ liability, Pfizer
will add Protalix and its Affiliates, as additional insureds, and Pfizer will require that the Pfizer Insurance Policies provide
a waiver of subrogation in favor of Protalix and its Affiliates.

 

(iii)        Prior
to the Second Amendment Effective Date of the Agreement and, at Protalix’s request, at each renewal thereof or expiration
of any one coverage, whichever occurs first, Pfizer shall furnish to Protalix original certificates evidencing the specified insurance
coverage. Such certificates shall provide that not less than thirty (30) days prior written notice of any policy cancellation
or detrimental change shall be given to Protalix. The certificate(s) of insurance shall be signed by a person authorized by the
insurer(s) to bind coverage on its (their) behalf. Pfizer shall provide, pay for, and maintain in effect the Pfizer Insurance
Policies with minimum “A-” A.M. Bests rated insurance carriers.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	62	 

     

    

 

(d)          Pfizer
Insurance Requirements. The insurance required under subsection (c) shall be written for not less than any limits of
liability specified herein or as required by law, whichever is greater; Pfizer has the right to provide the total limits required
by any combination of self insurance, primary and excess/umbrella coverage; said Pfizer Insurance to include, without limitation,
the following:

 

(i)          Insurance
for liability under the workers’ compensation or occupational disease laws of any state or other jurisdiction in which Pfizer
performs activities pursuant to this Agreement (or be a qualified self-insurer in those states and jurisdictions) or otherwise
applicable with respect to persons performing hereunder and employer’s liability insurance covering all claims by or in
respect to the employees of Pfizer, providing:

 

Employer’s liability insurance with a limit of
[***]

(ii)         Commercial
General Liability insurance with the following limits and forms/endorsements:

 

(A)         Each
occurrence: [***]

 

(B)         Products
& Completed Operations Aggregate: [***]

 

(C)         Protalix
and its Affiliates as additional insureds with respect to any legal liability of Protalix or its Affiliates, arising out of Pfizer’s
performance hereunder.

 

(iii)        Umbrella
(Excess) Liability Coverage (follow form) in an amount not less than [***] per occurrence.

 

Section
16.           [RESERVED.]

 

Section
17.           GOVERNING LAW AND JURISDICTION

 

17.1        Governing
Law. This Agreement shall be governed by and construed in accordance with the substantive laws of the State of New
York, without regard to conflicts of law rules.

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	63	 

     

    

 

17.2        Jurisdiction.
In the event of any controversy, claim or counterclaim arising out of or relating to this Agreement, the parties shall first attempt
to resolve such controversy or claim through good faith negotiations for a period of not less than thirty (30) days following
notification of such controversy or claim to the other party. If such controversy or claim cannot be resolved by means of such
negotiations during such period, then such controversy or claim shall be resolved by the United States District Court for the
Southern District of New York or, in the event federal subject matter jurisdiction is lacking, a New York State court sitting
in New York, New York (the “Court”). Each party (a) irrevocably submits to the exclusive jurisdiction of the
Court for purposes of any action, suit or other proceeding relating to or arising out of this Agreement and (b) agrees not to
raise any objection at any time to the laying or maintaining of the venue of any such action, suit or proceeding in the Court,
irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further
irrevocably waives the right to object, with respect to such action, suit or other proceeding, that the Court does not have any
jurisdiction over such party. The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall not
apply to this Agreement. Protalix hereby irrevocably designates, appoints and empowers CT Corporation System, 111 Eighth Avenue,
New York, NY  10011, as its true and lawful agent and attorney-in-fact in its name, place and stead to receive and accept
on its behalf service of process in any action, suit or proceeding in the Court with respect to any matters as to which it has
submitted to jurisdiction as set forth in the immediately preceding sentence.

 

Section
18.           MISCELLANEOUS

 

18.1        Force
Majeure. Neither party hereto shall be liable to the other party for any losses or damages attributable to a default
under or breach of this Agreement that is the result of war (whether declared or undeclared), acts of God, revolution, acts of
terror, fire, earthquake, flood, pestilence, riot, enactment or change of Law (following the Second Amendment Effective Date),
accident(s), labor trouble, shortage of or inability to obtain material equipment or transport or any other cause beyond the reasonable
control of such party (each, a “Force Majeure Event”); provided that if such a cause occurs, then
the party affected will promptly notify the other party of the nature and likely result and duration (if known) of such cause
and use its Commercially Reasonable Efforts to avoid or remove such causes of nonperformance as soon as is reasonably practicable.
Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence. If
the event lasts for a period of longer than one (1) month, the parties shall meet and work diligently to implement appropriate
remedial measures.

 

18.2        Severability.
If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render this entire
Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the enforceability
or validity of the remainder of this Agreement or any of its provisions; provided, however, the parties shall
use their respective reasonable efforts to mutually agree to replace the invalid provisions in a manner that best accomplishes
the original intentions of the parties.

 

18.3        Waivers.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition. Neither the waiver by any party of any term or condition of this Agreement nor the failure on the part of any
party, in one or more instances, to enforce any of the provisions of this Agreement or to exercise any right or privilege, shall
be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach
hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none
of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.

 

    	 	64	 

     

    

 

18.4        Entire
Agreements; Amendments. This Agreement, together with the Quality Agreement(s), sets forth the entire agreement and
understanding between the parties as to the subject matter hereof and supersedes all agreements or understandings, verbal or written,
made between Protalix and Pfizer before the Second Amendment Effective Date with respect to the subject matter hereof, including
the Confidential Disclosure Agreement between the parties, dated June 11, 2009 and the Amended Agreement, except as otherwise
provided in Section 6.4.  All Confidential Information disclosed by either party to the other party prior
to the Second Amendment Effective Date will be deemed to have been disclosed pursuant to this Agreement. None of the terms of
this Agreement shall be amended, supplemented or modified except in writing signed by the parties.

18.5         Survival.
The provisions of Section 3.1 (Exclusive License), Section 3.3 (Non-Assertion of Rights), Section 3.4 (Sublicensing
and Subcontracting), Section 3.6(a) (No Implied License; Brazil Activities), Section 4.1(f) (Assignment of Contracts),
Section 4.1(g)(i) (Responsibility), Section 4.1(l) (Recalls or Other Corrective Action), Section 4.2(a) (Commercialization
and Pricing), Section 4.4 (Pfizer Trademarks), Section 4.5 (Use of Names), Section 5.15 (Records and Audits),
Section 5.21(f) (Damages), Section 5.23 (Manufacturing Transition Assistance), Section 6.2 (Deferred Payment),
Section 8 (Patents and Infringement), Sections 9.1 and 9.2 (Confidentiality), Section 9.3 (Publication),
Section 9.4 (Publicity), Section 10.5 (Disclaimer of Warranty), Section 11.1 (Restrictions on Transfers and
Liens), Section 11.2 (Third Party Licenses and Agreements), Section 11.4 (Coordinating outside the Territory), Section
14.4 (Continuing and Accrued Obligations and Surviving Provisions), Section 14.5 (Effect of Termination or Expiration),
Section 14.6 (Bankruptcy), Section 15 (Indemnification) other than Section 15.6 (Insurance Requirements), Section
17 (Governing Law and Jurisdiction) and this Section 18 (Miscellaneous), as well as (x) any other Sections or defined
terms referred to in such Sections or necessary to give them effect and (y) any other provision that by its terms expressly survives
termination of this Agreement, shall survive termination of this Agreement and remain in force until discharged in full. Furthermore,
any other provisions required to interpret and enforce the parties’ rights and obligations or to wind up their outstanding
obligations under this Agreement shall survive to the extent required.

 

18.6        Assignment;
Binding Effect.

 

(a)          Neither
this Agreement nor any rights or obligations of either party to this Agreement may be assigned or otherwise transferred by either
party without the consent of the other party; provided, however, either party may, without such consent, assign
this Agreement, in whole or in part: (i) to any of its respective Affiliates, provided that such assigning party
shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned; (ii) to a Third Party
where a party or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Licensed
Product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition; or (iii)
to a Third Party successor to all or substantially all of the assets of such party whether by merger, sale of stock, all or substantially
all of a party’s assets or other similar transaction, so long as such Third Party agrees in writing to be bound by the terms
of this Agreement.

 

    	 	65	 

     

    

 

(b)          Any
purported assignment in violation of this Section 18.6 shall be void. Any permitted assignee shall assume all obligations
of its assignor under this Agreement.

 

(c)          Pfizer
may assume this Agreement in any proceeding under the U.S. Bankruptcy Code upon satisfaction of the conditions set forth in U.S.
Bankruptcy Code Section 365(b)(1).

 

18.7        Divestiture.
For the avoidance of doubt, nothing in this Section 18.7 shall prevent Pfizer from assigning its rights and obligations
under this Agreement pursuant to Section 18.6.

 

(a)          Notwithstanding
anything to the contrary contained in this Agreement, to the extent related to or arising in connection with a divestiture (whether
by sale, spin-off, or similar transaction) by Pfizer of all or any portion of a Pfizer business or business unit (a “Divestiture”),
Pfizer may, without prior written notice to or consent of Protalix, without any penalty, and at no additional cost to Pfizer or
to any affiliate of Pfizer or to the company or the group of companies resulting from such Divestiture (collectively, such companies,
the “Resulting Companies”): (1) assign its rights and obligations under this Agreement, in whole or in part
to one or more of the Resulting Companies, or (2) split and assign, in whole or in part, its rights and obligations under this
Agreement to one or more of the Resulting Companies so as to retain the benefits of this Agreement for both Pfizer and the applicable
Resulting Companies following such Divestiture; provided that [***]

 

(b)          From
and after any partial assignment or split the rights and obligations of Pfizer hereunder shall be divided between Pfizer and the
Resulting Companies to whom such rights and obligations are transferred as specified by Pfizer, such that all such rights and
obligations related to the business of the applicable Resulting Companies shall be enforceable only by and against the applicable
Resulting Companies, and all other such rights and obligations shall be enforceable only by and against Pfizer.  Protalix
will, [***], work cooperatively with Pfizer and the applicable Resulting Companies to ensure a smooth and orderly transition,
including, to the extent requested by Pfizer, entering into separate agreements with Pfizer and the applicable Resulting Companies
on substantially the same terms and conditions (as adjusted to take into account the nature of the separate contracts while maintaining
the economic, business and other purposes of the Agreement).

 

18.8        Independent
Contractor. The relationship between Protalix and Pfizer is that of independent contractors. Protalix and Pfizer are
not joint venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent
contracting parties.

 

18.9        Notices.
Each communication and document made or delivered by one party to another under this Agreement shall be made in the English language.
All notices, consents, approvals, requests or other communications required hereunder given by one party to the other hereunder
shall be in writing and made by registered or certified air mail, express overnight courier or delivered personally to the following
addresses of the respective parties:

 

 

 

[***] Redacted pursuant to confidential treatment request.

 

    	 	66	 

     

    

 

	If to Protalix:	Protalix Ltd.
	 	2 Snunit Street
	 	Science Park
	 	P.O.B. 455
	 	Carmiel 20100, Israel
	 	Attention:  Chief Executive Officer
	 	 
	If to Pfizer:	Pfizer Inc.
	 	235 East 42nd Street
	 	New York, New York, 10017-5755
	 	U.S.A.
	 	Attention:      President of the Global Innovative Products Business Unit
	 	 
	with a copy to:	 
	 	Pfizer Inc.
	 	235 East 42nd Street
	 	New York, New York, 10017-5755
	 	U.S.A.
	 	Attention:     Chief Counsel, Global Innovative Products Business Unit
	 	 
	 	Pfizer Inc.
	 	235 East 42nd Street
	 	New York, New York, 10017-5755
	 	U.S.A.
	 	Attention:     Senior Vice President, Business Development

 

Notices hereunder shall be deemed to be effective (a) upon
receipt if personally delivered, (b) on the tenth (10th) Business Day following the date of mailing if sent by registered or certified
air mail and (c) on the second (2nd) Business Day following the date of delivery to the overnight courier if sent by overnight
courier. A party may change its address listed above by sending notice to the other party in accordance with this Section 18.9.

 

18.10      Third
Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third
Party, including any creditor of either party. No Third Party shall obtain any right under any provision of this Agreement or
shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either
party.

 

18.11      Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs,
successors and permitted assigns.

 

18.12      Performance
by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a party, such party agrees to
cause its Affiliates to perform such obligations. Pfizer may use one or more of its Affiliates to exercise its rights or perform
its obligations and duties hereunder, provided that Pfizer shall remain liable hereunder for the prompt payment and
performance of all of its obligations hereunder.

 

    	 	67	 

     

    

 

18.13      Corporate
Integrity Agreement. Protalix acknowledges that (a) Pfizer develops and promotes its products in compliance with the
statutes, regulations and written directives of Medicare, Medicaid and all other federal health care programs (as defined in 42
U.S.C. § 1320a-7b(f)) and with the statutes, regulations, and written directives of the Food and Drug Administration, and
(b) Pfizer shall not be obligated to take any action pursuant to this Agreement that it believes, in its sole discretion, constitutes
a violation of any of Pfizer’s obligations set forth in subsection (a) above or such Corporate Integrity Agreement.

 

18.14      Counterparts.
This Agreement may be executed in any counterparts, each of which, when executed, shall be deemed to be an original and which
together shall constitute one and the same document.

 

18.15      Headings.
Headings in this Agreement are included herein for ease of reference only and shall have no legal effect. References to the parties,
Sections, Schedules, and Exhibits are to the parties, Sections, Schedules and Exhibits to and of this Agreement unless otherwise
specified.

 

18.16      Equitable
Remedies. The parties agree that irreparable damage may occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms or were otherwise breached.  It is accordingly agreed that, without
limitation of other remedies which may be available to a party for breach of this Agreement by the other party, the parties shall
be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement.

 

    	 	68	 

     

    

 

IN WITNESS WHEREOF the parties hereto have
caused this Agreement to be executed by their duly authorized officers upon the date set out below.

 

	Protalix Ltd.	 	Pfizer Inc.
	 	 	 	 	 
	By:	 	 	By:	 
	 	 	 	 	 
	Name: 	Moshe Manor	 	Name: 	Michael Goettler
	Title:	President and Chief Executive Officer	 	Title:	Global Commercial Officer, Senior Vice President

 

     

     

    

 

[***]

 

	Protalix Biotherapeutics, Inc.	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	Date:	 	 

 

 

 

 

[***] Redacted pursuant to confidential treatment request.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]